0001140361-12-002690.txt : 20120117 0001140361-12-002690.hdr.sgml : 20120116 20120117155537 ACCESSION NUMBER: 0001140361-12-002690 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20111130 FILED AS OF DATE: 20120117 DATE AS OF CHANGE: 20120117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 12529638 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5169974600 MAIL ADDRESS: STREET 1: 150 MOTOR PARKWAY STREET 2: SUITE 408 CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10q-nov2011.htm FORM 10-Q vaso10q-nov2011.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 10-Q


[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended November 30, 2011

[   ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from _______________ to ______________

Commission File Number: 0-18105

VASOMEDICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware
11-2871434
(State or other jurisdiction of
(IRS Employer Identification Number)
incorporation or organization)
  

180 Linden Ave., Westbury, New York 11590
(Address of principal executive offices)

Registrant’s Telephone Number
(516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes [X]  No  [   ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
Large Accelerated Filer [  ] Accelerated Filer [  ] Non-Accelerated Filer [  ] Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes [   ] No  [X]

Number of Shares Outstanding of Common Stock, $.001 Par Value, at January 9, 2011 – 153,186,296



 
 
Page 1
 

Vasomedical, Inc. and Subsidiaries

 
INDEX




 
 
Page 2
 
ITEM 1 - FINANCIAL STATEMENTS
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED BALANCE SHEETS
   
November 30, 2011
    
May 31, 2011
  
ASSETS
  
(unaudited)
    
(audited)
  
CURRENT ASSETS
            
Cash and cash equivalents
   $ 3,684,854     $ 8,130,031  
Short-term investments
     110,148       109,709  
Accounts and other receivables, net of an allowance for doubtful
                
accounts and commission adjustments of $1,617,193 at November 30, 2011,
          
and $1,296,947 at May 31, 2011
     12,982,119       4,018,572  
Inventories, net
     2,683,265       1,786,057  
Financing receivables, net
     19,225       18,425  
Deferred commission expense
     2,823,456       2,532,048  
Deferred related party consulting expense - current portion
     510,000       510,000  
Other current assets
     176,009       267,235  
 Total current assets
     22,989,076       17,372,077  
                 
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
                
$1,789,204 at November 30, 2011, and $1,633,290 at May 31, 2011
     418,683       366,199  
GOODWILL
     3,175,152       -  
DEFERRED DISTRIBUTOR COSTS, net of accumulated amortization of
                
 $588,876 at November 30, 2011, and $464,402 at May 31, 2011
     -       124,474  
FINANCING RECEIVABLES, net
     17,316       27,133  
DEFERRED RELATED PARTY CONSULTING EXPENSE
     127,500       382,500  
OTHER ASSETS
     350,542       282,162  
    $ 27,078,269     $ 18,554,545  
LIABILITIES AND STOCKHOLDERS' EQUITY
                
CURRENT LIABILITIES
                
Accounts payable
   $ 541,238     $ 480,661  
Accrued commissions
     2,645,081       1,963,826  
Accrued expenses and other liabilities
     1,440,094       632,374  
Sales tax payable
     374,369       160,321  
Deferred revenue - current portion
     12,610,574       10,917,732  
Deferred gain on sale-leaseback of building - current portion
     35,497       53,245  
Accrued professional fees
     30,000       61,550  
Trade payable due to related party
     3,359       265,863  
Total current liabilities
     17,680,212       14,535,572  
                 
LONG-TERM LIABILITIES
                
Deferred revenue
     2,091,992       1,004,483  
Accrued rent expense
     -       3,001  
Deferred gain on sale-leaseback of building
     -       8,874  
Notes payable due to related party
     284,550       -  
Other long-term liabilities
     76,267       94,835  
Total long-term liabilities
     2,452,809       1,111,193  
COMMITMENTS AND CONTINGENCIES (NOTE P)
                
STOCKHOLDERS' EQUITY
                
Preferred stock, $.01 par value; 1,000,000 shares authorized;
                
0 shares at November 30, 2011 and 299,024 shares at
                
May 31, 2011 issued and outstanding
     -       2,990  
Common stock, $.001 par value; 250,000,000 shares authorized;
                
153,103,796 shares at November 30, 2011 and 117,078,704 at
                
May 31, 2011 issued and outstanding
     153,103       117,079  
Additional paid-in capital
     60,152,117       55,743,295  
Accumulated deficit
     (53,363,971 )     (52,955,584 )
Accumulated other comprehensive income
     3,999       -  
Total stockholders’ equity
     6,945,248       2,907,780  
    $ 27,078,269     $ 18,554,545  
The accompanying notes are an integral part of these consolidated condensed financial statements.
Page 3

 
Vasomedical, Inc. and Subsidiaries

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
 
     Six Months Ended November 30,    Three Months Ended November 30,
   
2011
    
2010
    
2011
    
2010
  
Revenues
                        
Equipment sales
   $ 1,151,711     $ 1,913,275     $ 876,751     $ 1,188,756  
Equipment rentals and services
     943,198       1,144,690       456,210       600,798  
Commissions
     12,186,855       2,018,624       8,620,367       2,011,188  
Total revenues
     14,281,764       5,076,589       9,953,328       3,800,742  
                                 
Cost of revenues
                                
Cost of sales, equipment
     700,251       1,191,184       539,297       791,855  
Cost of equipment rentals and services
     460,878       461,709       222,031       225,016  
Cost of commissions
     2,902,041       423,913       1,799,933       421,963  
Total cost of revenues
     4,063,170       2,076,806       2,561,261       1,438,834  
Gross profit
     10,218,594       2,999,783       7,392,067       2,361,908  
                                 
Operating expenses
                                
Selling, general and administrative
     9,165,913       6,513,547       4,791,028       3,408,868  
Research and development
     273,555       216,468       138,426       106,079  
Total operating expenses
     9,439,468       6,730,015       4,929,454       3,514,947  
Operating income (loss)
     779,126       (3,730,232 )     2,462,613       (1,153,039 )
                                 
Other income (expenses)
                                
Interest and financing costs
     (6,872 )     (6,496 )     (4,612 )     (2,853 )
Interest and other income, net
     42,851       16,144       21,666       12,612  
Amortization of deferred gain on
                                
sale-leaseback of building
     26,623       26,623       13,312       13,312  
Total other income, net
     62,602       36,271       30,366       23,071  
                                 
Income (loss) before income taxes
     841,728       (3,693,961 )     2,492,979       (1,129,968 )
Income tax expense, net
     (26,129 )     (7,330 )     (24,329 )     (1,500 )
Net income (loss)
     815,599       (3,701,291 )     2,468,650       (1,131,468 )
                                 
Preferred stock dividends
   $ (1,221,362 )     (152,111 )   $ (1,135,869 )     (124,403 )
Net (loss) income applicable to common stockholders
   $ (405,763 )   $ (3,853,402 )   $ 1,332,781     $ (1,255,871 )
                                 
Other comprehensive (loss) income
                                
Foreign currency adjustments
     3,999       -       3,999       -  
Comprehensive (loss) income
   $ (401,764 )   $ (3,853,402 )   $ 1,336,780     $ (1,255,871 )
                                 
Earnings (loss) per common share
                                
- basic
   $ (0.00 )   $ (0.03 )   $ 0.01     $ (0.01 )
- diluted
   $ (0.00 )   $ (0.03 )   $ 0.01     $ (0.01 )
                                 
Weighted average common shares outstanding
                                
- basic
     145,387,954       110,775,966       153,310,322       111,123,353  
- diluted
     145,387,954       110,775,966       160,078,677       111,123,353  
                                 
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 4
 
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
    Six months ended November 30,  
   
2011
    
2010
  
Cash flows from operating activities
            
Net  income (loss)
   $ 815,599     $ (3,701,291 )
Adjustments to reconcile net income (loss) to net cash used in operating activities
          
Depreciation and amortization of property and equipment
     83,949       72,707  
Amortization of deferred gain on sale-leaseback of building
     (26,623 )     (26,623 )
(Gain) on disposal of fixed assets
     (3,673 )     -  
Provision for doubtful accounts
     320,426       623,535  
Amortization of deferred distributor costs
     124,474       62,792  
Share-based compensation
     185,114       208,615  
Amortization of deferred consulting expense
     317,079       -  
Changes in operating assets and liabilities:
                
Accounts and other receivables
     (9,204,258 )     (7,010,909 )
Inventories, net
     (254,716 )     490,885  
Finance receivables
     9,017       (54,200 )
Deferred commission expense
     (291,408 )     (894,833 )
Other current assets
     69,358       (18,869 )
Other assets
     (85,892 )     (93,696 )
Accounts payable
     (94,174 )     203,947  
Accrued commissions
     681,255       1,078,125  
Accrued expenses and other  liabilities
     785,865       612,702  
Sales tax payable
     70,522       4,924  
Deferred revenue
     2,780,351       5,570,045  
Accrued rent expense
     (3,001 )     (1,327 )
Accrued professional fees
     (31,550 )     (57,822 )
Trade payable due to related party
     (62,356 )     1,590  
Other long-term liabilities
     (18,568 )     49,320  
Net cash used in operating activities
     (3,833,210 )     (2,880,383 )
                 
Cash flows from investing activities
                
Purchases of property and equipment
     (57,852 )     (132,270 )
Acquisition of Fast Growth Enterprises
     (1,000,000 )     -  
Cash acquired through purchase of Fast Growth Enterprises
     441,886       -  
Net cash used in investing activities
     (615,966 )     (132,270 )
                 
Cash flows from financing activities
                
Issuance of note payable
     -       250,000  
Proceeds from preferred stock
     -       3,333,608  
Net cash (used) provided by financing activities
     -       3,583,608  
                 
Effect of exchange rate differences on cash
     3,999       -  
                 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
     (4,445,177 )     570,955  
Cash and cash equivalents - beginning of period
     8,130,031       481,679  
Cash and cash equivalents - end of period
   $ 3,684,854     $ 1,052,634  
                 
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
                
Interest paid
   $ 6,026     $ 722  
Income taxes paid
   $ 16,287     $ 2,200  
                 
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
          
Inventories transferred to property and equipment, attributable to operating leases, net
   $ 27,433     $ 30,477  
Issuance of note payable for purchase of insurance policy
   $ -     $ 58,360  
Conversion of notes payable to preferred stock
   $ -     $ 1,250,000  
Fair value of assets acquired
   $ 4,469,125     $ -  
Liabilities assumed through acquisition
   $ (931,611 )   $ -  
Accrued preferred stock dividends
   $ (1,221,362 )   $ (152,111 )
                 
The accompanying notes are an integral part of these consolidated condensed financial statements.
 
Page 5
 

Vasomedical, Inc. and Subsidiaries

Notes to Consolidated Condensed Financial Statements (unaudited)

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In April 2010, the Company, through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, organized a group of medical device sales professionals in anticipation of entering into the sales and representation business for other equipment manufacturers.  On May 19, 2010, VasoHealthcare signed a sales representative agreement with GE Healthcare (the “GEHC Agreement”), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products.  Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.

In September 2011, the Company acquired two Chinese operating companies, Life Enhancement Technologies Limited and Biox Instruments Co. Ltd (see Note J).  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and will operate through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare will continue as an operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. will operate the Company’s newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note D).

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended May 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.
 
Page 6
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
Significant Accounting Policies
 
Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended May 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.  Policies newly adopted for the quarter ended November 30, 2011 are set forth below:
 
Goodwill
 
Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350 – “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment, at least annually, in accordance with this guidance.
 
Comprehensive Income (Loss)
 
In countries in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date.  Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive income.  As of November 30, 2011, accumulated other comprehensive income includes income of $3,999, which is entirely from foreign currency translation.
 
Reclassifications
 
Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C - LIQUIDITY

                While the Company has achieved substantial profitability for the six months ended November 30, 2011, it has historically incurred operating losses. We have achieved profitability by launching the VasoHealthcare business. The Company will seek to achieve greater profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio to include ambulatory monitoring devices (the BIOX series ECG Holter recorders, ambulatory blood pressure monitors and analysis software) and patient management devices (the EZ ECG and EZ O2 products).
 
In fiscal 2011, the Company issued Series E convertible preferred stock (see Note O) to finance the initial operation of its Sales Representation segment and generated in excess of $4.1 million in operating cash flow by fiscal year end.  While we expect to continue to generate significant operating cash flows in fiscal 2012, the progressive nature of the GEHC Agreement can cause related cash inflows to vary widely during the fiscal year.
 
In addition, under the terms of our agreement with GEHC, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of $3.3 million from October 2010 to November 2011, and $1.0 million for the six months ended November 30, 2011, and are expected to generate additional commission revenues estimated to range from $1.3 million to $1.5 million over approximately one or more years.
 
Page 7
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
 
Based on our current operations through November 30, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will continue to be sufficient for the Company to fund its operations through at least November 30, 2012.

NOTE D – SEGMENT REPORTING AND CONCENTRATIONS
 
The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company’s responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:
 
 
Page 8
 
 
    As of or for the three months ended November 30, 2011  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                         
Revenues from external customers
   $ 1,332,961     $ 8,620,367     $ -     $ 9,953,328  
Operating income/(loss)
   $ (733,789 )   $ 3,463,347     $ (266,945 )   $ 2,462,613  
Total assets
   $ 8,179,790     $ 15,175,375     $ 3,723,104     $ 27,078,269  
Accounts and other receivables, net
   $ 1,099,955     $ 11,882,164     $ -     $ 12,982,119  
Deferred commission expense
   $ -     $ 3,097,173     $ -     $ 3,097,173  
                                 
        As of or for the three months ended November 30, 2010  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 1,789,554     $ 2,011,188     $ -     $ 3,800,742  
Operating income/(loss)
   $ 177,330     $ (1,270,512 )   $ (59,857 )   $ (1,153,039 )
Total assets
   $ 3,374,898     $ 7,055,400     $ 1,075,134     $ 11,505,432  
Accounts and other receivables, net
   $ 867,837     $ 5,993,415     $ -     $ 6,861,252  
Deferred commission expense
   $ -     $ 984,574     $ -     $ 984,574  
                                 
        As of or for the six months ended November 30, 2011  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 2,094,909     $ 12,186,855     $ -     $ 14,281,764  
Operating income/(loss)
   $ (1,402,345 )   $ 2,739,578     $ (558,107 )   $ 779,126  
Total assets
   $ 8,179,790     $ 15,175,375     $ 3,723,104     $ 27,078,269  
Accounts and other receivables, net
   $ 1,099,955     $ 11,882,164     $ -     $ 12,982,119  
Deferred commission expense
   $ -     $ 3,097,173     $ -     $ 3,097,173  
                                 
        As of or for the six months ended November 30, 2010  
   
Equipment Segment
  
Sales Representation Segment
  
Corporate
    
Consolidated
  
                                 
Revenues from external customers
   $ 3,057,965     $ 2,018,624     $ -     $ 5,076,589  
Operating income/(loss)
   $ 18,821     $ (3,632,752 )   $ (116,301 )   $ (3,730,232 )
Total assets
   $ 3,374,898     $ 7,055,400     $ 1,075,134     $ 11,505,432  
Accounts and other receivables, net
   $ 867,837     $ 5,993,415     $ -     $ 6,861,252  
Deferred commission expense
   $ -     $ 984,574     $ -     $ 984,574  
                                 
 
For the six months ended November 30, 2011 and 2010, GE Healthcare accounted for 85% and 40% of revenue, respectively.  For the three months ended November 30, 2011 and 2010, GE Healthcare accounted for 87% and 53% of revenue, respectively.  Also, GE Healthcare accounted for $11,760,974, or 91%, and $2,990,978, or 74%, of accounts and other receivables at November 30, 2011 and May 31, 2011, respectively.
 
NOTE E – SHARE-BASED COMPENSATION
 
The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.
 
 
Page 9
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
During the six-month period ended November 30, 2011, the Company’s Board of Directors granted 525,000 restricted shares of common stock, valued at $189,750 to an officer and an outside director. During the six-month period ended November 30, 2010, the Company’s Board of Directors granted, under the 2010 Stock Plan (see Note O), 3,750,000 restricted shares of common stock valued at $712,500 to non-officer employees and consultants.  Shares valued at $65,550 vested immediately with the remainder vesting over three years.  During the six-month period ended November 30, 2010, 1,200,000 shares of common stock valued at $252,000 were issued to officers and outside directors, of which 650,000 shares valued at $136,500 will vest over three years.
 
During the six-month period ended November 30, 2011 and 2010, the Company’s Board of Directors did not grant any stock options.
 
Share-based compensation expense recognized for the six months ended November 30, 2011 and 2010 was $185,114 and $208,615, respectively, and was $103,776 and $116,109 for the three months ended November 30, 2011 and 2010, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $317,079 and $5,225 for the six months ended November 30, 2011 and 2010, respectively, and was $158,539 and $950 for the three months ended November 31, 2011 and 2010, respectively.  Unrecognized expense related to existing share-based arrangements is approximately $1.2 million at November 30, 2011 and will be recognized ratably through July 2013.
 
NOTE F – EARNINGS (LOSS) PER COMMON SHARE
 
 Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.
 
Basic and diluted loss per common share was $0.00 and $0.03 for the six months ended November 30, 2011 and 2010, respectively, and earnings of $0.01 and a loss of $0.01 for the three months ended November 30, 2011 and 2010, respectively.
 
Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:
 
    Six months ended November 30,     Three months ended November 30,  
   
2011
    
2010
    
2011
    
2010
  
Basic weighted average shares outstanding
     145,387,954       110,775,966       153,310,322       111,123,353  
Dilutive effect of share-based compensation and warrants
     -       -       4,790,333       -  
Dilutive effect of contingently issuable shares
     -       -       1,978,022       -  
Dilutive weighted average shares outstanding
     145,387,954       110,775,966       160,078,677       111,123,353  
                                 
 
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended November 30, 2011 and 2010, because the effect of their inclusion would be anti-dilutive.

 
 
Page 10
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
    Six months ended November 30,     Three months ended November 30,  
   
2011
    
2010
    
2011
    
2010
  
Stock options
     1,809,776       1,888,776       259,776       1,888,776  
Warrants
     5,785,714       4,285,714       1,500,000       4,285,714  
Convertible preferred stock
     -       29,156,312       -       29,156,312  
Common stock grants
     2,903,333       4,340,000       375,000       4,340,000  
      10,498,823       39,670,802       2,134,776       39,670,802  

NOTE G – FAIR VALUE MEASUREMENTS
 
The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
 
The following tables present information about the Company’s assets and liabilities measured at fair value as of November 30, 2011 and May 31, 2011:
 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
    
Significant
Other
Observable
Inputs
(Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
    
Balance
as of
November 30,
2011
  
Assets
                        
Cash equivalents invested in money market funds
   (included in cash and cash equivalents)
   $ 2,811,214     $ -     $ -     $ 2,811,214  
Investment in certificates of deposit
   (included in short-term investments)
     110,148       -       -       110,148  
    $ 2,921,362     $ -     $ -     $ 2,921,362  
                                 
   
Quoted Prices
in Active
Markets for
Identical Assets
(Level 1)
    
Significant
Other
Observable
Inputs
 (Level 2)
    
Significant
Unobservable
Inputs
(Level 3)
      
Balance
as of
May 31,
2011
  
Assets
                                
Cash equivalents invested in money market funds
   (included in cash and cash equivalents)
   $ 7,029,886     $ -     $ -     $ 7,029,886  
Investment in certificates of deposit
    (included in short-term investments)
     109,709       -       -       109,709  
    $ 7,139,595     $ -     $ -     $ 7,139,595  
                                 
 
The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
 
NOTE H – ACCOUNTS AND OTHER RECEIVABLES, NET
 
The following table presents information regarding the Company’s accounts and other receivables as of November 30, 2011 and May 31, 2011:
 
 
Page 11
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)

 
   
November 30, 2011
    
May 31, 2011
  
Trade receivables
   $ 14,461,811     $ 5,194,953  
Due from employees
     137,501       120,566  
Allowance for doubtful accounts and
                
commission adjustments
     (1,617,193 )     (1,296,947 )
    $ 12,982,119     $ 4,018,572  
 
Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
 
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees primarily reflects commission advances made to sales personnel.

NOTE I – INVENTORIES, NET
 
Inventories, net of reserves, consist of the following:
   
November 30, 2011
    
May 31, 2011
  
             
Raw materials
   $ 875,786     $ 514,387  
Work in process
     814,138       484,798  
Finished goods
     993,341       786,872  
    $ 2,683,265     $ 1,786,057  
 
At November 30, 2011 and May 31, 2011, the Company had reserves for excess and obsolete inventory of $407,154 and $409,490, respectively.

NOTE J– BUSINESS COMBINATION
 
On August 19, 2011, the Company, through its newly formed subsidiary, Vasomedical Global, signed an agreement to purchase Life Enhancement Technology Limited and Biox Instruments Co., Ltd., both of which are based in the People’s Republic of China.
 
On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company that owns Life Enhancement Technology Limited (“LET”) and Biox Instruments Co. Ltd. (“Biox”), as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company’s common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.
 
LET, based in Foshan, Guangdong, China, has been Vasomedical’s supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a leading developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical’s partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.
 

 
 
Page 12
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
The operating results of FGE from September 2, 2011 to November 30, 2011 are included in the accompanying Consolidated Condensed Statement of Operations.  The Consolidated Condensed Balance Sheet as of November 30, 2011 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:

Vasomedical, Inc. common stock
   $ 2,100,000  
Vasomedical, Inc. warrants to purchase common stock
     304,000  
Contingent issuance of Vasomedical, Inc. common stock
     575,400  
Cash
     1,000,000  
Total purchase price
   $ 3,979,400  

In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
 

Cash and cash equivalents
   $ 441,886  
Accounts receivable and other current assets
     591,460  
Inventories
     669,926  
Property and equipment
     32,587  
Goodwill
     3,175,152  
Accounts payable and other current liabilites
     (931,611 )
Net assets acquired
   $ 3,979,400  

During the three month period ending November 30, 2011, the Company expensed $122,224 of acquisition-related costs.  These costs are included in the line item Selling, General & Administrative costs in the accompanying Consolidated Condensed Statement of Operations and are comprised of accounting and legal fees.
 
After elimination of intercompany transactions, the amounts of revenue and  net loss  of FGE included in the Company’s Consolidated Condensed Statement of Operations for the three months ended November 30, 2011 was $227,200 and $61,290, respectively.  Loss per share was $0.00.  Prior to elimination of the intercompany transactions, the amounts of revenue and net income recognized by FGE from the acquisition date to November 30, 2011 was $453,011 and $114,494, respectively.
 
The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2010 (amounts in thousands, except per share amounts):
 
 
Page 13
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 

    Six Months Ended November 30,     Three Months Ended November 30,  
   
2011
    
2010
    
2011
    
2010
  
Revenue
   $ 14,655     $ 5,527     $ 9,953     $ 3,918  
                                 
Net income (loss)
     977       (3,589 )     2,591       (1,047 )
                                 
Basic and diluted earnings (loss) per share
   $ (0.00 )   $ (0.03 )   $ 0.01     $ (0.01 )
 
An adjustment was made to the pro forma financial information to reflect the acquisition-related costs in the six month period ending November 30, 2010.
 
NOTE K – FINANCING RECEIVABLES, NET
 
At November 30, 2011, the Company had financing receivables of $36,541, net of unearned interest of $3,059.  These financing receivables were generated by a sales-type lease of our EECP® equipment in our Equipment Segment for a term of three years ending September 1, 2013.  At November 30, 2011, there were no past due amounts on these financing receivables and the Company has consequently made no provision for credit loss.  At May 31, 2011, the Company had financing receivables of $45,558, net of unearned interest of $4,842.
 
NOTE L – GOODWILL AND OTHER INTANGIBLES

              The change in the carrying amount of goodwill was as follows:
 
   
Carrying Amount
  
       
Balance at June 1, 2011
   $ -  
Acquisition of FGE (Note J)
     3,175,152  
Balance at November 30, 2011
   $ 3,175,152  
 
The Company’s other intangible assets consist of capitalized patent costs, as set forth in the following:
   
November 30, 2011
    
May 31, 2011
  
Patent Costs
            
Costs
   $ 469,043     $ 469,043  
Accumulated amortization
     (410,833 )     (350,553 )
    $ 58,210     $ 118,490  
 
Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.  Amortization expense amounted to $17,512 and $23,160 for the six month periods ended November 30, 2011 and 2010, respectively, and $8,465 and $11,434 for the three month periods ended November 30, 2011 and 2010, respectively.
 
Page 14
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
NOTE M - DEFERRED REVENUE
 
The changes in the Company’s deferred revenues are as follows:
 
    Six months ended November 30,      Three months ended November 30,  
   
2011
    
2010
    
2011
    
2010
  
Deferred revenue at the beginning of the period
   $ 11,922,215     $ 1,027,348     $ 12,128,362     $ 1,733,683  
Additions:
                                
Deferred extended service contracts
     595,082       561,816       311,755       208,203  
Deferred in-service and training
     17,500       15,000       12,500       7,500  
Deferred service arrangements
     28,500       50,000       18,500       35,000  
Deferred commission revenues
     14,033,375       7,175,651       10,737,292       6,497,138  
Recognized as revenue:
                                
Deferred extended service contracts
     (548,772 )     (631,270 )     (271,285 )     (307,807 )
Deferred in-service and training
     (22,500 )     (10,000 )     (12,500 )     (7,500 )
Deferred service arrangements
     (40,740 )     (27,316 )     (20,830 )     (12,424 )
Deferred commission revenues
     (11,282,094 )     (1,563,836 )     (8,201,228 )     (1,556,400 )
Deferred revenue at end of period
     14,702,566       6,597,393       14,702,566       6,597,393  
Less: current portion
     12,610,574       5,898,714       12,610,574       5,898,714  
Long-term deferred revenue at end of period
   $ 2,091,992     $ 698,679     $ 2,091,992     $ 698,679  
                                 
 
NOTE N – RELATED-PARTY TRANSACTIONS
 
On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”).  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note J), the manufacturer of the AngioNew EECP® system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs, totaling $93,077, in the quarter ended August 31, 2011.
 
Pursuant to the Supplier Agreement, Living Data became our exclusive supplier of the external counterpulsation therapy systems that we market under the registered trademark EECP®.  On February 28, 2010, the Supplier Agreement was terminated and, in connection with the termination, the Company purchased Living Data’s remaining inventory at cost ($469,450), which was paid in 7,824,167 shares of common stock valued at the closing price on the termination date.  Prior to termination, the Company purchased in fiscal 2010 additional EECP® therapy systems for $40,000 from Living Data.  Payment terms on certain purchases prior to 2010, plus $3,359 in commissions for sales of certain BIOX products, leave a balance of $3,359 and $265,863 in Trade Payable due to Related Party on the accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011, respectively.  The payable balance due Living Data included interest charges of $23,603 at May 31, 2011 and was satisfied through a cash payment in August 2011.
 
On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $45,000 and $154,000 were billed by the firm through the three and six months ending November 30, 2011, respectively, at which date no amounts were outstanding.
 
Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company’s consulting agreement with Edgary Consultants, LLC.  The consulting agreement (the “Agreement”) between the Company and Edgary Consultants, LLC (“Consultant”) commenced on March 1, 2011and runs for a two year term..  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  More specifically, Consultant will be assisting the Company in the following areas:
 
 
 
Page 15
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
1.  
Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
2.  
Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
3.  
Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.
4.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
5.  
Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.
 
In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011.
 
During the three and six months ending November 30, 2011, a director performed consulting services for the Company aggregating approximately $30,000 and $60,000 respectively, and the Company accrued dividends of $14,734 on Series E Preferred Stock (see Note O) to directors, management, and other related parties of the Company.
 
Through the Company’s acquisition of FGE in September 2011, it assumed the liability for unsecured notes payable to a family member of the management of LET.  The notes have no stated maturity date, aggregated approximately $285,000 at November 30, 2011, and bear interest at 5.31% per annum.  Approximately $95,000 of such notes were subsequently repaid.  In addition, $10,049 in pre-acquisition earnings were distributed to current BIOX management during the three months ended November 30, 2011.
 
NOTE O – STOCKHOLDERS’ EQUITY
 
Common Stock
 
On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.
The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.
 
Page 16
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.
 
As of November 30, 2011, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of November 30, 2011, 465,000 shares have been forfeited.  In September 2010, 650,000 restricted shares of common stock were granted under the 2010 Plan to officers of the Company.  In September 2011, 475,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 100,000 vested immediately with the remainder vesting over a three year period.
 
No options were issued under the 2010 Plan during the six months ended November 30, 2011 and 2010.
 
In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE (see Note J).  In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.
 
Preferred Stock
 
On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder’s option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company’s common stock for the 30 consecutive trading days exceeds 250,000 shares.  Notwithstanding the foregoing, the Series E Preferred shall be automatically converted into common stock on June 1, 2015.
 
For the three months ended November 30, 2011 and 2010, the Company recorded dividends totaling $1,135,869 and $124,403, respectively, and for the six months ended November 30, 2011 and 2010 the Company recorded dividends totaling $1,221,362 and $152,111, respectively.  Included in these amounts is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,135,869 and $70,709 for the three months ended November 30, 2011 and 2010, respectively, and $1,201,428 and $70,709 for the six months ended November 30, 2011 and 2010, respectively. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.
 
Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of November 30, 2011, 29,956,100 shares of common stock had been issued for 299,561 shares of Series E Preferred, with 712,350 shares of common stock yet to be issued.
 
Page 17
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
NOTE P – COMMITMENTS AND CONTINGENCIES
 
Sales representation agreement
 
The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.
 
Facility Leases
 
On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expires August 31, 2012.  VasoHealthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013.
 
Vehicle Lease Agreement
 
In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment.  Vehicles obtained under the terms of the agreement are leased generally for a 36 month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.
 
 Future rental payments under these operating leases aggregate approximately as follows:
 
For the years ended May 31:
 
  
Vehicles
    
Facilities
    
Total
  
2012
   $ 131,000     $ 106,000     $ 237,000  
2013
     262,000       89,000       351,000  
2014
     242,000       -       242,000  
2015
     28,000       -       28,000  
Total
   $ 663,000     $ 195,000     $ 858,000  
                         
 
NOTE Q - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 
Adoption of New Standards
 
Other Comprehensive Income: Presentation of Comprehensive Income
 
In June 2011, new guidance was issued that amends the current comprehensive income guidance. The amendment allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements.  The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The Company has elected to adopt this guidance in its current quarterly filing.
 
 
Page 18
 
Vasomedical, Inc. and Subsidiaries
 
Notes to Consolidated Condensed Financial Statements (unaudited)
 
Standards issued but not yet effective
 
Intangibles—Goodwill and Other: Testing Goodwill for Impairment
 
In September 2011, an accounting standard update regarding testing of goodwill for impairment was issued. This standard update gives companies the option to perform a qualitative assessment to first assess whether the fair value of a reporting unit is less than its carrying amount. If an entity determines it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The new guidance is to be applied prospectively effective for annual and interim goodwill impairment tests beginning after December 15, 2011, with early adoption permitted.  The adoption of this standard is not expected to have a material impact on the Company’s results of operations or financial condition.


 

 
Page 19
 

Vasomedical, Inc. and Subsidiaries


ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987.  Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries (See Note P).  Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® Enhanced External Counterpulsation systems based on our unique proprietary technology currently indicated by the United States Food & Drug Administration (FDA) for use in cases of stable or unstable angina, congestive heart failure (CHF), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In April 2010, the Company, through its wholly-owned subsidiary Vaso Diagnostics d/b/a VasoHealthcare, organized a group of medical device sales professionals in anticipation of entering into the sales representation business for other equipment manufacturers.  On May 19, 2010, VasoHealthcare signed a sales representative agreement with GE Healthcare (the “GEHC Agreement”), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products.  Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.

In September 2011, the Company acquired two Chinese operating companies, Life Enhancement Technologies Limited and Biox Instruments Co. Ltd (see Note J).  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and will operate through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare will continue as an operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. will operate the Company’s newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (see Note D).

While the Company has achieved substantial profitability for the six months ended November 30, 2011, it has historically incurred operating losses. We have achieved profitability by launching the VasoHealthcare business. The Company will seek to achieve greater profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio to include ambulatory monitoring devices (the BIOX series ECG Holter recorders, ambulatory blood pressure monitors and analysis software) and patient management devices (the EZ ECG and EZ O2 products).

 
Page 20
 
Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended May 31, 2011.

New Accounting Pronouncements - Adoption of New Standards
 
Other Comprehensive Income: Presentation of Comprehensive Income

In June 2011, new guidance was issued that amends the current comprehensive income guidance. The amendment allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements.  The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The Company has elected to adopt this guidance in its current quarterly filing.

New Accounting Pronouncements - Standards issued but not yet effective

Intangibles—Goodwill and Other:  Testing Goodwill for Impairment

In September 2011, an accounting standard update regarding testing of goodwill for impairment was issued. This standard update gives companies the option to perform a qualitative assessment to first assess whether the fair value of a reporting unit is less than its carrying amount. If an entity determines it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The new guidance is to be applied prospectively effective for annual and interim goodwill impairment tests beginning after December 15, 2011, with early adoption permitted.  The adoption of this standard is not expected to have a material impact on the Company’s results of operations or financial condition.

Consolidated Results of Operations

Three Months Ended November 30, 2011 and November 30, 2010

Total revenue for the three months ended November 30, 2011 and November 30, 2010, was $9,953,328 and $3,800,742, respectively, an increase of $6,152,586, or 162%. Net income for the three months ended November 30, 2011 was $2,468,650 compared to a net loss of $1,131,468 for the three months ended November 30, 2010.  We reported net income applicable to common stockholders of $1,332,781 for the second quarter of fiscal year 2012 compared to a net loss applicable to common stockholders of $1,255,871 for the second quarter of fiscal 2011. The change from a net loss to net income was primarily attributable to an increase in operating profit of $4,733,859 in our Sales Representation segment offset by an increase in operating loss of $911,119 in our Equipment segment and an increase of $1,011,466 in noncash preferred stock dividends, due primarily to the recognition of the beneficial automatic conversion feature of the Company’s Series E Preferred that converted during the current quarter.  Our total net income was $0.01 per basic and diluted common share for the three months ended November 30, 2011 and our total net loss was $0.01 per basic and diluted common share for the three months ended November 30, 2010.

 
Page 21
 
Revenues

Revenue in our Equipment segment decreased 26% to $1,332,961 for the three-month period ended November 30, 2011 from $1,789,554 for the same period of the prior year.  Equipment segment revenue from equipment sales decreased approximately 26% to $876,591 for the three-month period ended November 30, 2011 as compared to $1,188,756 for the same period in the prior year. The decrease in equipment sales is due primarily to a decrease in the number of EECP® units shipped internationally.  A decrease in the sales price per EECP® unit, reflecting a shift in the product mix to more refurbished equipment sold, also contributed to the decreased equipment sales, partially offset by an increase in sales of other medical equipment.

Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note N, we are pursuing initiatives to expand reimbursement that we expect should ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 24% to $456,210 in the second quarter of fiscal 2012 from $600,798 in the second quarter of fiscal year 2011. Revenue from equipment rental and services represented 34% of total Equipment segment revenue in the second quarters of fiscal 2012 and fiscal 2011.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased service amd accessory part revenue, partially offset by higher rental revenue.

Commission revenues in the Sales Representation segment were $8,620,367 in the second quarter of fiscal 2012, as compared to $2,011,188 in the second quarter of fiscal 2011, an increase of 329%.  The increase in commission revenue in the second quarter of fiscal 2012 is due both to the Company having just begun operating under the GEHC agreement in July 2010, and the recognition of deferred commission revenue after underlying equipment acceptance is complete.  Due to the nature of our commission structure under the GEHC Agreement, wherein the Company earns progressively higher commission rates retroactively as calendar year targets are met, revenues were recognized in the current fiscal quarter at a higher commission rate than in the prior fiscal quarter. As of November 30, 2011, $13,557,048 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $1,724,578 is long-term.  At November 30, 2010, $5,611,815 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $511,501 was long-term.

Gross Profit

The Company had a gross profit of $7,392,067 in the second quarter of fiscal 2012 compared to $2,361,908 in the second quarter of the prior fiscal year, an increase of 213%.  Equipment segment gross profit decreased to $571,633, or 43% of Equipment segment revenues, for the second quarter of fiscal 2012 compared to $772,683, or 43% of Equipment segment revenues, for the same quarter of fiscal 2011. Gross profit in the equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

 
Page 22
 
Sales Representation segment gross profit was $6,820,434 for the three months ended November 30, 2011 as compared to $1,589,225 for the three months ended November 30, 2010.  Cost of commissions of $1,799,933 and $421,963, for the three months ended November 30, 2011 and 2010, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

Operating Income (Loss)

Operating income was $2,462,613 for the three months ended November 30, 2011 as compared to an operating loss of $1,153,039 for the three months ended November 30, 2010.  The increase in operating income was primarily attributable to an increase in operating income of $4,733,859 in our Sales Representation segment partially offset by an increase in operating loss of $911,119 in our Equipment segment.

Selling, general and administrative (“SG&A”) expenses for the second quarter of fiscal 2012 and 2011 were $4,791,028, or 48% of revenues, and $3,408,868, or 90% of revenues, respectively, reflecting an increase of $1,382,160 or approximately 41%. The increase in SG&A expenditures in the second quarter of fiscal 2012 resulted primarily from increased sales and marketing costs in both segments, costs associated with the FGE acquisition, and higher corporate segment costs.

During the second quarter of fiscal 2012, the Company recorded a provision for doubtful accounts and commission adjustments of $300,068 as compared to the second quarter of fiscal year 2011 when the Company recorded a provision for doubtful accounts and commission adjustments of $548,971.  The fiscal 2011 provision was primarily to reduce gross deferred revenues for estimated adjustments.

Research and development (“R&D”) expenses of $138,426, or 1% of revenues, for the second quarter of fiscal 2012 increased by $32,347, or 30%, from $106,079, or 3% of revenues, for the second quarter of fiscal 2011. The increase is primarily attributable to an increase in clinical research expenses.

Interest and Financing Costs

Interest and financing costs for the second quarters of fiscal 2012 and 2011 were $4,612 and $2,853, respectively.  Interest and financing costs for the second quarter of fiscal 2012 consisted primarily of interest on the notes payable to a related party in one of the China subsidiaries.  Interest and financing costs for the second quarter of fiscal 2011 consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the second quarters of fiscal 2012 and 2011, was $21,666 and $12,612, respectively. The increase of $9,054 in the second quarter of fiscal 2012 is due primarily to interest earned on the Company’s higher cash balances.

 
Page 23
 
Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the second quarter of fiscal years 2012 and 2011 was $13,312.   The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Expense, Net

During the second quarters of fiscal year 2012 and 2011, we recorded a provision for income taxes of $24,329 and $1,500, respectively.  The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.

Six Months Ended November 30, 2011 and November 30, 2010

Total revenue for the six months ended November 30, 2011 and November 30, 2010, was $14,281,764 and $5,076,589, respectively, an increase of $9,205,175, or 181%. Net income for the six months ended November 30, 2011 was $815,599 compared to a net loss of $3,701,291 for the six months ended November 30, 2010.  We reported a net loss applicable to common stockholders of $405,763 for the first two quarters of fiscal year 2012 compared to a net loss applicable to common stockholders of $3,853,402 for the first two quarters of fiscal 2011. The decrease in the net loss was primarily attributable to an increase in operating profit of $6,372,330 in our Sales Representation segment offset by an increase in operating loss of $1,421,166 in our Equipment segment and an increase of $1,069,251 in noncash preferred stock dividends, due primarily to the recognition of the beneficial automatic conversion feature of the Company’s Series E Preferred that converted during the second quarter of fiscal 2012.  Our total net loss was $0.00 and $0.03 per basic and diluted common share for the six months ended November 30, 2011 and 2010, respectively.

Revenues

Revenue in our Equipment segment decreased 31% to $2,094,909 for the six-month period ended November 30, 2011 from $3,057,695 for the same period of the prior year.  Equipment segment revenue from equipment sales decreased approximately 40% to $1,151,711 for the six-month period ended November 30, 2011 as compared to $1,913,275 for the same period in the prior year. The decrease in equipment sales is due primarily to a decrease in the number of EECP® units shipped internationally.  A decrease in the sales price per EECP® unit, reflecting a shift in the product mix to more refurbished equipment sold, also contributed to the decreased equipment sales, partially offset by an increase in sales of other medical equipment.

Current demand for EECP® systems will likely remain soft until there is greater clinical acceptance for the use of EECP® therapy in treating patients with angina or angina equivalent symptoms who meet the current reimbursement guidelines, or a favorable change in current reimbursement policies by CMS or third party payers to consider EECP therapy as a first-line treatment option for angina or cover some or all Class II & III heart failure patients. Patients with angina or angina equivalent symptoms eligible for reimbursement under current policies include many with serious comorbidities, such as heart failure, diabetes, peripheral vascular disease and/or others.  As described in Note N, we are pursuing initiatives to expand reimbursement that we expect will ultimately increase overall market demand for our EECP® systems.

Equipment segment revenue from equipment rental and services decreased 18% to $943,198 in the first two quarters of fiscal 2012 from $1,144,690 in the first two quarters of fiscal year 2011. Revenue from equipment rental and services represented 45% of total Equipment segment revenue in the first and second quarters of fiscal 2012 and 37% in the same quarter of fiscal 2011.  The decrease in revenue generated from equipment rentals and services is due primarily to decreased service and accessory part revenue, partially offset by higher rental revenue.

Commission revenues in the Sales Representation segment were $12,186,855 in the first two quarters of fiscal 2012, as compared to $2,018,624 in the first and second quarters of fiscal 2011, an increase of 504%.  The increase in commission revenue in the first two quarters of fiscal 2012 is due both to the Company having just begun operating under the GEHC agreement in July 2010, and the recognition of deferred commission revenue after underlying equipment acceptance is complete.  As of November 30, 2011, $13,557,048 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $1,724,578 is long-term.  At November 30, 2010, $5,611,815 in deferred commission revenue was recorded in the Company’s consolidated condensed balance sheet, of which $511,501 was long-term.

 
Page 24
 
Gross Profit

The Company had a gross profit of $10,218,594 in the first two quarters of fiscal 2012 compared to $2,999,783 in the first two quarters of the prior fiscal year, an increase of 241%.  Equipment segment gross profit decreased to $933,780, or 45% of Equipment segment revenues, for the first two quarters of fiscal 2012 compared to $1,405,072, or 46% of Equipment segment revenues, for the same period of fiscal 2011. Gross profit in the equipment segment is dependent on a number of factors, particularly the mix of new and refurbished EECP® systems and the mix of models sold, their respective average selling prices, the mix of EECP® units sold, rented or placed during the period, the ongoing costs of servicing EECP® systems, and certain fixed period costs, including facilities, payroll and insurance.

Sales Representation segment gross profit was $9,284,814 for the six months ended November 30, 2011 as compared to $1,594,711 for the six months ended November 30, 2010.  Cost of commissions of $2,902,041 and $423,913, for the six months ended November 30, 2011 and 2010, respectively, reflects commission expense associated with recognized commission revenues.  Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.

Operating Income (Loss)

Operating income was $779,126 for the six months ended November 30, 2011 as compared to an operating loss of $3,730,232 for the six months ended November 30, 2010, an increase of 121%.  The change from an operating loss to operating income was primarily attributable to an increase in operating income of $6,372,330 in our Sales Representation segment partially offset by an increase in operating loss of $1,421,166 in our Equipment segment.

Selling, general and administrative (“SG&A”) expenses for the first two quarters of fiscal 2012 and 2011 were $9,165,913, or 64% of revenues, and $6,513,547, or 128% of revenues, respectively, reflecting an increase of $2,652,366 or approximately 41%. The increase in SG&A expenditures in the first two quarters of fiscal 2012 resulted primarily from increased sales and marketing costs in both segments, costs associated with the FGE acquisition, and higher corporate segment costs.

During the first and second quarters of fiscal 2012, the Company recorded a provision for doubtful accounts and commission adjustments of $320,246 as compared to the first and second quarters of fiscal year 2011 when the Company recorded a provision for doubtful accounts and commission adjustments of $623,535.  The fiscal 2011 provision was primarily to reduce gross deferred revenues for estimated adjustments.

Research and development (“R&D”) expenses of $273,555, or 2% of revenues, for the first and second quarters of fiscal 2012 increased by $57,087, or 26%, from $216,468, or 4% of revenues, for the first and second quarters of fiscal 2011. The increase is primarily attributable to an increase in clinical research expenses.

Interest and Financing Costs

Interest and financing costs for the first two quarters of fiscal 2012 and 2011 were $6,872 and $6,496, respectively.  Interest and financing costs for the first two quarters of fiscal 2012 consisted of interest on related party obligations.  Interest and financing costs for the first two quarters of fiscal 2011 consisted of interest on a short-term note to finance the Company’s insurance premiums.

Interest and Other Income, Net

Interest and other income for the first two quarters of fiscal 2012 and 2011, was $42,851 and $16,144, respectively. The increase of $26,707 in the first two quarters of fiscal 2012 is due primarily to interest earned on the Company’s higher cash balances.

 
Page 25
 
Amortization of Deferred Gain on Sale-leaseback of Building

The amortization of deferred gain on sale-leaseback of building for the first and second quarters of fiscal years 2012 and 2011 was $26,623.   The gain resulted from the Company’s sale-leaseback of its facility.

Income Tax Expense, Net

During the first two quarters of fiscal year 2012 and 2011, we recorded a provision for income taxes of $26,129 and $7,330, respectively.  The increase arose primarily from foreign tax liabilities associated with the acquisition of FGE.

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations primarily from working capital, and, in fiscal 2011, from the issuance of the Company’s Series E Preferred Stock. At November 30, 2011, we had cash and cash equivalents of $3,684,854, short-term investments of $110,148 and working capital of $5,308,864 compared to cash and cash equivalents of $8,130,031, short-term investments of $109,709 and working capital of $2,836,505 at May 31, 2011.

Cash used in operating activities was $3,833,210 during the first six months of fiscal year 2012, which consisted of a net loss after adjustments to reconcile net income to net cash of $1,816,345, and cash used by operating assets and liabilities of $5,649,555. The changes in the account balances primarily reflect increases in accounts and other receivables of $9,204,258 and deferred commission expense of $291,408.  This change was offset by increases in deferred revenue of $2,780,351, accrued commissions of $681,255, and accrued expenses of $785,865.  As noted above, under the GEHC Agreement the Company earns progressively higher commission rates as calendar year targets are met, which also has a significant impact on our cash flows. As we achieve these targets the higher commission rates are retroactive to the beginning of the calendar year, and therefore, we anticipate significantly higher commission billings and recognized revenue in the fourth quarter of calendar year 2011, and receiving payment for such billings in the first quarter of calendar year 2012.  This should result in a significant improvement in that quarter, with cash flows in excess of $5 million.

Investing activities during the three-month period ended November 30, 2011 used cash of $615,966, primarily related to the acquisition of FGE.

There were no financing activities during the three-month period ended November 30, 2011.

Liquidity

While the Company has achieved substantial profitability for the six months ended November 30, 2011, it has historically incurred operating losses. We have  achieved profitability by launching the VasoHealthcare business. The Company will seek to achieve greater profitability through our recent accretive acquisition of the two Chinese medical device companies and by expanding our U.S. market product portfolio to include ambulatory monitoring devices (the BIOX series ECG Holter recorders, ambulatory blood pressure monitors and analysis software) and patient management devices (the EZ ECG and EZ O2 products).

In fiscal 2011, the Company issued Series E convertible preferred stock (see Note O) to finance the initial operation of its Sales Representation segment and ultimately generated in excess of $4.1 million in operating cash flow by fiscal year end.  While we expect to continue to generate significant operating cash flows in fiscal 2012, the progressive nature of the GEHC Agreement can cause related cash inflows to vary widely during the fiscal year.

 
Page 26
 

Based on our current operations through November 30, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will continue to be sufficient for the Company to fund its current operations through at least November 30, 2012.




 
 
Page 27
 
Vasomedical, Inc. and Subsidiaries



ITEM 4 - CONTROLS AND PROCEDURES
 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of November 30, 2011, our disclosure controls and procedures are effective to provide reasonable assurances that such disclosure controls and procedures satisfy their objectives and that the information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized and reported within the required time periods.





 

 
Page 28
 
Vasomedical, Inc. and Subsidiaries




PART II - OTHER INFORMATION

ITEM 6 – EXHIBITS:
 

 
Exhibits

31
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32
Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.








 

 
Page 29
 
Vasomedical, Inc. and Subsidiaries



In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


VASOMEDICAL, INC.

By:           /s/ Jun Ma                                           
Jun Ma
 
President & Chief Executive Officer
 
(Principal Executive Officer)

/s/ Michael J. Beecher .
Michael J. Beecher
 
Chief Financial Officer and Principal Accounting Officer

Date:  January 17, 2012



 
 
Page 30
 



EX-31 2 vaso10q-nov2011ex31.htm CERTIFICATION vaso10q-nov2011ex31.htm
 
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Jun Ma                         .
Jun Ma
President and Chief Executive Officer

Date: January 17, 2012

 
 
 


EXHIBIT 31.2
 
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael J. Beecher           .
Michael J. Beecher
Chief Financial Officer

Date: January 17, 2012




 EX-32 3 vaso10q-nov2011ex32.htm CERTIFICATION vaso10q-nov2011ex32.htm
 


EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending November 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Jun Ma                          .
Jun Ma
President & Chief Executive Officer

Dated: January 17, 2012

 
 
 
EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending November 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Michael J. Beecher             .
                Michael J. Beecher
Dated: January 17, 2012                                                                                      Chief Financial Officer
 EX-101.INS 4 vaso-20111130.xml INSTANCE DOCUMENT 0000839087 2011-11-30 0000839087 2011-05-31 0000839087 2011-06-01 2011-11-30 0000839087 2010-06-01 2010-11-30 0000839087 2011-09-01 2011-11-30 0000839087 2010-09-01 2010-11-30 0000839087 2010-05-31 0000839087 2010-11-30 0000839087 2011-08-22 0000839087 2011-01-09 iso4217:USD iso4217:USD xbrli:shares xbrli:shares 0 3001 588876 464402 3999 0 1789204 1633290 1000000 0 60152117 55743295 1617193 1296947 124474 62792 0.00 -0.03 0.01 -0.01 441886 0 3684854 8130031 481679 1052634 -6026 -722 291408 894833 254716 -490885 -31550 -57822 3001 1327 70522 4924 -94174 203947 785865 612702 -62356 1590 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE P &#8211; COMMITMENTS AND CONTINGENCIES</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Sales representation agreement</font><br /></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.&#160;&#160;These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.&#160;&#160;Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Facility Leases</font><br />&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expires August 31, 2012.&#160;&#160;VasoHealthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Vehicle Lease Agreement</font><br /></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment.&#160;&#160;Vehicles obtained under the terms of the agreement are leased generally for a 36 month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;Future rental payments under these operating leases aggregate approximately as follows:</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">For the years ended May 31:</font></div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td align="left" valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Vehicles</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Facilities</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Total</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="64%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">131,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">106,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">237,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="64%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">262,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">89,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">351,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="64%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2014</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">242,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">242,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="64%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2015</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">28,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">28,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="64%" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">663,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">195,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">858,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="64%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div></div> 250000000 250000000 153103796 117078704 153103796 117078704 153103 117079 -401764 -3853402 1336780 -1255871 4063170 2076806 2561261 1438834 700251 1191184 539297 791855 460878 461709 222031 225016 17680212 14535572 0 124474 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE M - DEFERRED REVENUE</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The changes in the Company's deferred revenues are as follows:</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="48%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" width="24%" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Six months <font style="display: inline; font-family: times new roman; font-size: 10pt;">ended </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30,</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" width="24%" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months <font style="display: inline; font-family: times new roman; font-size: 10pt;">ended </font><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30,</font></font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" width="48%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred revenue at the beginning of the period</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11,922,215</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,027,348</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,128,362</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,733,683</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Additions:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred extended service contracts</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">595,082</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">561,816</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">311,755</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">208,203</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred in-service and training</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">17,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">15,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred service arrangements</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">28,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">50,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">18,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">35,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission revenues</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,033,375</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,175,651</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">10,737,292</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,497,138</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Recognized as revenue:</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred extended service contracts</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(548,772</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(631,270</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(271,285</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(307,807</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred in-service and training</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(22,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(10,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(12,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(7,500</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred service arrangements</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(40,740</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(27,316</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(20,830</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(12,424</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission revenues</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(11,282,094</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,563,836</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(8,201,228</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,556,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred revenue at end of period</font></div></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,702,566</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,597,393</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,702,566</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,597,393</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="48%" style="padding-bottom: 2px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 18pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: current portion</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,610,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,898,714</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,610,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,898,714</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="48%" style="padding-bottom: 4px;"><div align="left" style="text-indent: -9pt; display: block; margin-left: 9pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Long-term deferred revenue at end of period</font></div></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,091,992</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">698,679</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,091,992</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="10%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">698,679</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div> 12610574 10917732 2091992 1004483 0.00 -0.03 0.01 -0.01 -1221362 -152111 3999 0 185114 208615 4469125 0 3673 0 10218594 2999783 7392067 2361908 681255 1078125 -9017 54200 3175152 0 2683265 1786057 27078269 18554545 0 3583608 -615966 -132270 -3833210 -2880383 0 250000 815599 -3701291 2468650 -1131468 -405763 -3853402 1332781 -1255871 -4445177 570955 62602 36271 30366 23071 6872 6496 4612 2853 2452809 1111193 284550 0 17316 27133 779126 -3730232 2462613 -1153039 3999 0 3999 0 176009 267235 2823456 2532048 1000000 1000000 0 299024 0 299024 0.01 0.01 0 3333608 418683 366199 320426 623535 57852 132270 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE H &#8211; ACCOUNTS AND OTHER RECEIVABLES, NET</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following table presents information regarding the Company's accounts and other receivables as of November 30, 2011 and May 31, 2011:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">May 31, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Trade receivables</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,461,811</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,194,953</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Due from employees</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">137,501</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">120,566</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Allowance for doubtful accounts and</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%" style="padding-bottom: 2px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">commission adjustments</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,617,193</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,296,947</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="76%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,982,119</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,018,572</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Trade receivables include amounts due for shipped products and services rendered.&#160;&#160;Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.&#160;&#160;Due from employees primarily reflects commission advances made to sales personnel.</font></div><div style="text-indent: 0pt; display: block;"><br /></div></div> <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 41.4pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE N &#8211; RELATED-PARTY TRANSACTIONS</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (&#8220;Kerns&#8221;).&#160;&#160;Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (&#8220;Living Data&#8221;), an affiliate of Kerns.&#160;&#160;Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.&#160;&#160;Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note J), the manufacturer of the AngioNew EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> system.&#160;&#160;Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs, totaling $93,077, in the quarter ended August 31, 2011.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Pursuant to the Supplier Agreement, Living Data became our exclusive supplier of the external counterpulsation therapy systems that we market under the registered trademark EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>.&#160;&#160;On February 28, 2010, the Supplier Agreement was terminated and, in connection with the termination, the Company purchased Living Data's remaining inventory at cost ($469,450), which was paid in 7,824,167 shares of common stock valued at the closing price on the termination date.&#160;&#160;Prior to termination, the Company purchased in fiscal 2010 additional EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> therapy systems for $40,000 from Living Data.&#160;&#160;Payment terms on certain purchases prior to 2010, plus $3,359 in commissions for sales of certain BIOX products, leave a balance of $3,359 and $265,863 in Trade Payable due to Related Party on the accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011, respectively.&#160;&#160;The payable balance due Living Data included interest charges of $23,603 at May 31, 2011 and was satisfied through a cash payment in August 2011.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On February 28, 2011, David&#160;Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.&#160;&#160;Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.&#160;&#160;He is currently a senior partner at the law firm of Beckman, Lieberman &amp; Barandes, LLP, which firm performs certain legal services for the Company.&#160;&#160;Fees of approximately $45,000 and $154,000 were billed by the firm through the three and six months ending November 30, 2011, respectively, at which date no amounts were outstanding.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Mr. Rios currently is President of Edgary Consultants, LLC,&#160;and was appointed a director in conjunction with the Company's consulting agreement with Edgary Consultants, LLC.&#160;&#160;The consulting agreement (the &#8220;Agreement&#8221;) between the Company and Edgary Consultants, LLC (&#8220;Consultant&#8221;) commenced on March 1, 2011and runs for a two year term..&#160;&#160;The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>therapy.&#160;&#160;More specifically, Consultant will be assisting the Company in the following areas:</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">1.</font>&#160;&#160;</font></div></td><td><div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Engaging the adoption of EECP&#174; therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.</font></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">2.</font>&#160;&#160;</font></div></td><td><div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP&#174; therapy for NYHA Class II/III heart failure.</font></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">3.</font>&#160;&#160;</font></div></td><td><div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Engaging final approval from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) of EECP&#174; therapy as a first line treatment for CCS Class III/IV angina.</font></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">4.</font>&#160;&#160;</font></div></td><td><div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for CCS Class II angina; and</font></div></td></tr></table></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr valign="top"><td align="right" style="width: 36pt;"><div><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">5.</font>&#160;&#160;</font></div></td><td><div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP&#174; therapy for NYHA Class II/III heart failure.</font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees,&#160;approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.&#160;&#160;In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.&#160;&#160;The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.&#160;&#160;The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During the three and six months ending November 30, 2011, a director performed consulting services for the Company aggregating approximately $30,000 and $60,000 respectively, and the Company accrued dividends of $14,734 on Series E Preferred Stock (see Note O) to directors, management, and other related parties of the Company.</font><br />&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Through the Company's acquisition of FGE in September 2011, it assumed the liability for unsecured notes payable to a family member of the management of LET.&#160;&#160;The notes have no stated maturity date, aggregated approximately $285,000 at November 30, 2011, and bear interest at 5.31% per annum.&#160;&#160;Approximately $95,000 of such notes were subsequently repaid.&#160;&#160;In addition, $10,049 in pre-acquisition earnings were distributed to current BIOX management during the three months ended November 30, 2011.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> -53363971 -52955584 26623 26623 13312 13312 14281764 5076589 9953328 3800742 1151711 1913275 876751 1188756 943198 1144690 456210 600798 <div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE I &#8211; INVENTORIES, NET</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Inventories, net of reserves, consist of the following:</font></div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">May 31, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Raw materials</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">875,786</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">514,387</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Work in process</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">814,138</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">484,798</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Finished goods</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">993,341</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">786,872</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="76%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,683,265</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,786,057</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">At November 30, 2011 and May 31, 2011, the Company had reserves for excess and obsolete inventory of $407,154 and $409,490, respectively.</font></div><div style="text-indent: 0pt; display: block;"><br /></div></div> <div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE D &#8211; SEGMENT REPORTING AND CONCENTRATIONS</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company views its business in two segments &#8211; the Equipment segment and the Sales Representation segment.&#160;&#160;The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.&#160;&#160;The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.&#160;&#160;The Company evaluates segment performance based on operating income.&#160;&#160;Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.&#160;&#160;There are no intersegment revenues.&#160;&#160;Summary financial information for the segments is set forth below:</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-indent: 0pt; display: block;"><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="text-align: center; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="14" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended November 30, 2011</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sales Representation Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Corporate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Consolidated</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenues from external customers</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,332,961</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8,620,367</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9,953,328</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Operating income/(loss)</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(733,789</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,463,347</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(266,945</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,462,613</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8,179,790</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">15,175,375</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,723,104</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">27,078,269</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts and other receivables, net</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,099,955</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11,882,164</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,982,119</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission expense</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,097,173</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,097,173</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the three months ended November 30, 2010</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sales Representation Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Corporate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Consolidated</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenues from external customers</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,789,554</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,011,188</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,800,742</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Operating income/(loss)</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">177,330</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,270,512</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(59,857</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,153,039</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,374,898</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,055,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,075,134</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11,505,432</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts and other receivables, net</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">867,837</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,993,415</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,861,252</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission expense</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">984,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">984,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the six months ended November 30, 2011</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sales Representation Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Corporate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Consolidated</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenues from external customers</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,094,909</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,186,855</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,281,764</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Operating income/(loss)</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,402,345</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,739,578</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(558,107</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">779,126</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8,179,790</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">15,175,375</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,723,104</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">27,078,269</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts and other receivables, net</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,099,955</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11,882,164</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,982,119</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission expense</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,097,173</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,097,173</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="13" valign="bottom" style="border-bottom: black 2px solid; text-align: center;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of or for the six months ended November 30, 2010</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="3" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sales Representation Segment</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Corporate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Consolidated</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenues from external customers</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,057,965</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,018,624</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,076,589</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Operating income/(loss)</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">18,821</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,632,752</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(116,301</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,730,232</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,374,898</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,055,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,075,134</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">11,505,432</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts and other receivables, net</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">867,837</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,993,415</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,861,252</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred commission expense</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">984,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">984,574</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%" style="border-bottom: black 2px solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left">&#160;</div></div></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">For the six months ended November 30, 2011 and 2010, GE Healthcare accounted for 85% and 40% of revenue, respectively.&#160;&#160;For the three months ended November 30, 2011 and 2010, GE Healthcare accounted for 87% and 53% of revenue, respectively.&#160;&#160;Also, GE Healthcare accounted for $11,760,974, or 91%, and $2,990,978, or 74%, of accounts and other receivables at November 30, 2011 and May 31, 2011, respectively.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> 9165913 6513547 4791028 3408868 110148 109709 <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE O &#8211; STOCKHOLDERS' EQUITY</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Common Stock</font><br />&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the &#8220;2010 Plan&#8221;) for officers, directors, employees and consultants of the Company.&#160;&#160;The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock.&#160;&#160;The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.&#160;&#160;Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.&#160;&#160;The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).&#160;&#160;The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.&#160;&#160;Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of November 30, 2011, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of November 30, 2011, 465,000 shares have been forfeited.&#160;&#160;In September 2010, 650,000 restricted shares of common stock were granted under the 2010 Plan to officers of the Company.&#160;&#160;In September 2011, 475,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 100,000 vested immediately with the remainder vesting over a three year period.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">No options were issued under the 2010 Plan during the six months ended November 30, 2011 and 2010.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE (see Note J).&#160;&#160;In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Preferred Stock</font><br /></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (&#8220;Certificate of Designations&#8221;), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (&#8220;Series E Preferred&#8221;). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the &#8220;Conversion Price&#8221;), subject to anti-dilution adjustment as set forth below.&#160;&#160;Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.&#160;&#160;Notwithstanding the foregoing, the Series E Preferred shall be automatically converted into common stock on June 1, 2015.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">For the three months ended November 30, 2011 and 2010, the Company recorded dividends totaling $1,135,869 and $124,403, respectively, and for the six months ended November 30, 2011 and 2010 the Company recorded dividends totaling $1,221,362 and $152,111, respectively.&#160;&#160;Included in these amounts is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,135,869 and $70,709 for the three months ended November 30, 2011 and 2010, respectively, and $1,201,428 and $70,709 for the six months ended November 30, 2011 and 2010, respectively. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.</font><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.&#160;&#160;As of November 30, 2011, 29,956,100 shares of common stock had been issued for 299,561 shares of Series E Preferred, with 712,350 shares of common stock yet to be issued.</font></div><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div>&#160;</div></div></div> <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE L &#8211; GOODWILL AND OTHER INTANGIBLES</font></div><div style="text-indent: 0pt; display: block;"><br /><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The change in the carrying amount of goodwill was as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Carrying Amount</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance at June 1, 2011</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%" style="padding-bottom: 2px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Acquisition of FGE (Note J)</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,175,152</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance at November 30, 2011</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,175,152</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left">&#160;</div></div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's other intangible assets consist of capitalized patent costs, as set forth in the following:</font><br /></div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid; border-top: medium none;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">May 31, 2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Patent Costs</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="76%" style="text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Costs</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">469,043</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">469,043</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="76%" style="padding-bottom: 2px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accumulated amortization</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(410,833</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(350,553</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="76%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">58,210</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">118,490</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left">&#160;</div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.&#160;&#160;Amortization expense amounted to $17,512 and $23,160 for the six month periods ended November 30, 2011 and 2010, respectively, and $8,465 and $11,434 for the three month periods ended November 30, 2011 and 2010, respectively.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><br />&#160;</div></div> -16287 -2200 22989076 17372077 145387954 110775966 160078677 111123353 145387954 110775966 153310322 111123353 273555 216468 138426 106079 27078269 18554545 19225 18425 76267 94835 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE E &#8211; SHARE-BASED COMPENSATION</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company complies with ASC Topic 718 &#8220;Compensation &#8211; Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During the six-month period ended November 30, 2011, the Company's Board of Directors granted 525,000 restricted shares of common stock, valued at $189,750 to an officer and an outside director. During the six-month period ended November 30, 2010, the Company's Board of Directors granted, under the 2010 Stock Plan (see Note O), 3,750,000 restricted shares of common stock valued at $712,500 to non-officer employees and consultants.&#160;&#160;Shares valued at $65,550 vested immediately with the remainder vesting over three years.&#160;&#160;During the six-month period ended November 30, 2010, 1,200,000 shares of common stock valued at $252,000 were issued to officers and outside directors, of which 650,000 shares valued at $136,500 will vest over three years.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During the six-month period ended November 30, 2011 and 2010, the Company's Board of Directors did not grant any stock options.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Share-based compensation expense recognized for the six months ended November 30, 2011 and 2010 was $185,114 and $208,615, respectively, and was $103,776 and $116,109 for the three months ended November 30, 2011 and 2010, respectively.&#160;&#160;These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.&#160;&#160;Expense for share-based arrangements was $317,079 and $5,225 for the six months ended November 30, 2011 and 2010, respectively, and was $158,539 and $950 for the three months ended November 31, 2011 and 2010, respectively.&#160;&#160;Unrecognized expense related to existing share-based arrangements is approximately $1.2 million at November 30, 2011 and will be recognized ratably through July 2013.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> 27433 30477 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE G &#8211; FAIR VALUE MEASUREMENTS</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company complies with the provisions of ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;).&#160;&#160;Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following tables present information about the Company's assets and liabilities measured at fair value as of <font style="display: inline; font-family: Times New Roman;">November 30, 2011 and May 31, 2011</font>:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><br /></font><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Quoted Prices</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">in Active</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Markets for</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Identical Assets</div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 1)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Other </font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Observable</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 2)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Unobservable</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 3)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">as of</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">November 30,</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Assets</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%" style="text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash equivalents invested in money market funds </font></div><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160; (included in cash and cash equivalents)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,811,214</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,811,214</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%" style="padding-bottom: 2px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Investment in certificates of deposit </font></div><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160; (included in short-term investments)</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">110,148</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">110,148</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,921,362</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,921,362</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Quoted Prices</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">in Active</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Markets for</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Identical Assets</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 1)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Other</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Observable</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;(Level 2)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Significant</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Unobservable</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inputs</font></div><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(Level 3)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: center;"><div><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance</font></div><div><font style="display: inline; font-family: times new roman; font-size: 10pt;">as of</font></div><div><font style="display: inline; font-family: times new roman; font-size: 10pt;">May 31,</font></div><div><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Assets</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%" style="text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash equivalents invested in money market funds </font></div><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160; (included in cash and cash equivalents)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,029,886</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,029,886</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%" style="padding-bottom: 2px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Investment in certificates of deposit</font></div><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160; &#160;(included in short-term investments)</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">109,709</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">109,709</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,139,595</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">7,139,595</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> 2780351 5570045 350542 282162 9439468 6730015 4929454 3514947 0.001 0.001 6945248 2907780 26129 7330 24329 1500 0 2990 9204258 7010909 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE F &#8211; EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.&#160;&#160;Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Basic and diluted loss per common share was $0.00 and $0.03 for the six months ended November 30, 2011 and 2010, respectively, and earnings of $0.01 and a loss of $0.01 for the three months ended November 30, 2011 and 2010, respectively.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares.&#160;&#160;A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Six months ended November 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months ended November 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic weighted average shares outstanding</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">145,387,954</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">110,775,966</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">153,310,322</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">111,123,353</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dilutive effect of share-based compensation and warrants</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,790,333</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dilutive effect of contingently issuable shares</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,978,022</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dilutive weighted average shares outstanding</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">145,387,954</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">110,775,966</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">160,078,677</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">111,123,353</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended November 30, 2011 and 2010, because the effect of their inclusion would be anti-dilutive.</font><br />&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Six months ended November 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months ended November 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Stock options</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,809,776</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,888,776</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">259,776</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,888,776</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,785,714</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,285,714</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,285,714</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Convertible preferred stock</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">29,156,312</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">29,156,312</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Common stock grants</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,903,333</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,340,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">375,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,340,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">10,498,823</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">39,670,802</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,134,776</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">39,670,802</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table><br /></div></div></div> 83949 72707 <div><div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE J&#8211; BUSINESS COMBINATION</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On August 19, 2011, the Company, through its newly formed subsidiary, Vasomedical Global, signed an agreement to purchase&#160;Life Enhancement Technology Limited and&#160;Biox Instruments Co., Ltd., both of which are based in&#160;the People's Republic of China.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (&#8220;FGE&#8221;), a British Virgin Islands company that owns Life Enhancement Technology Limited (&#8220;LET&#8221;) and Biox Instruments Co. Ltd. (&#8220;Biox&#8221;), as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">LET, based in Foshan, Guangdong, China, has been Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>) systems, including certain Lumenair systems and all AngioNew<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font><font style="display: inline; font-size: 10pt;">&#160;</font>systems. Biox, a leading developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical's partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.&#160;&#160;The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems.&#160;&#160;The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The operating results of FGE from September 2, 2011 to November 30, 2011 are included in the accompanying Consolidated Condensed Statement of Operations.&#160;&#160;The Consolidated Condensed Balance Sheet as of November 30, 2011 reflects the acquisition of FGE, effective September 2, 2011.&#160;&#160;The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:</font></div><div style="text-indent: 0pt; display: block;"><br /><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%" style="border-top: black 0.75pt solid;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Vasomedical, Inc. common stock</font></div></td><td align="right" valign="bottom" width="1%" style="border-top: black 0.75pt solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; border-top: black 0.75pt solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right; border-top: black 0.75pt solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,100,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; border-top: black 0.75pt solid;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Vasomedical, Inc. warrants to purchase common stock</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">304,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Contingent issuance of Vasomedical, Inc. common stock</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">575,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,000,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%" style="padding-bottom: 4px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total purchase price</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,979,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table><br /></div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).&#160;&#160;The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.&#160;&#160;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><br /><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%" style="border-top: medium none;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash and cash equivalents</font></div></td><td align="right" valign="bottom" width="1%" style="border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">441,886</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts receivable and other current assets</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">591,460</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inventories</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">669,926</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">32,587</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Goodwill</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,175,152</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom" width="88%" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounts payable and other current liabilites</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(931,611</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="88%" style="padding-bottom: 4px; text-indent: 9pt;"><div align="left" style="text-indent: 9pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net assets acquired</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,979,400</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table><br /></div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During the three month period ending November 30, 2011, the Company expensed $122,224 of acquisition-related costs.&#160;&#160;These costs are included in the line item Selling, General &amp; Administrative costs in the accompanying Consolidated Condensed Statement of Operations and are comprised of accounting and legal fees.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">After elimination of intercompany transactions, the amounts of revenue and&#160;&#160;net loss&#160;&#160;of FGE included in the Company's Consolidated Condensed Statement of Operations for the three months ended November 30, 2011 was $227,200 and $61,290, respectively.&#160;&#160;Loss per share was $0.00.&#160;&#160;Prior to elimination of the intercompany transactions, the amounts of revenue and net income recognized by FGE from the acquisition date to November 30, 2011 was $453,011 and $114,494, respectively.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2010 (amounts in thousands, except per share amounts):</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table cellpadding="0" cellspacing="0" width="100%" style="font-family: times new roman; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="text-align: center; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Six Months Ended November 30,</font></font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="text-align: center; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="6" valign="bottom" style="border-bottom: black 2px solid; text-align: center; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three Months Ended November 30,</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; border-top: medium none;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2011</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td colspan="2" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2010</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenue</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">14,655</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,527</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9,953</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,918</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net income (loss)</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">977</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,589</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,591</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1,047</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" valign="bottom" width="52%"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic and diluted earnings (loss) per share</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.03</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.01</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(0.01</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr></table></div><div align="left">&#160;</div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">An adjustment was made to the pro forma financial information to reflect the acquisition-related costs in the six month period ending November 30, 2010.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div> <div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><a name="notes">NOTE A </a>- ORGANIZATION AND PLAN OF OPERATIONS</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;Company&#8221;, &#8220;registrant&#8221;, &#8220;Vasomedical&#8221; or &#8220;management&#8221; refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (&#8220;CHF&#8221;), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.&#160;&#160;In April 2010, the Company, through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, organized a group of medical device sales professionals in anticipation of entering into the sales and representation business for other equipment manufacturers.&#160;&#160;On May 19, 2010, VasoHealthcare signed a sales representative agreement with GE Healthcare (the &#8220;GEHC Agreement&#8221;), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products.&#160;&#160;Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.&#160;&#160;The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In September 2011, the Company acquired two Chinese operating companies, Life Enhancement Technologies Limited and Biox Instruments Co. Ltd (see Note J).&#160;&#160;Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and will operate through three wholly-owned subsidiaries.&#160;&#160;Vaso Diagnostics d/b/a VasoHealthcare will continue as an operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. will operate the Company's newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174; </font>therapy business as well as other medical equipment operations.</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.&#160;&#160;VasoHealthcare activities are included under our Sales Representation reportable segment (See Note D).</font></div><div style="text-indent: 0pt; display: block;"><br /></div></div> 541238 480661 1440094 632374 30000 61550 2645081 1963826 3359 265863 374369 160321 841728 -3693961 2492979 -1129968 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE Q - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Adoption of New Standards</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;"><a name="Xbrl_Tag34"><!--EFPlaceholder--></a>Other Comprehensive Income: Presentation of Comprehensive Income</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In June 2011, new guidance was issued that amends the current comprehensive income guidance. The amendment allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements.&#160;&#160;The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.&#160;&#160;The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.&#160;&#160;The Company has elected to adopt this guidance in its current quarterly filing.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Standards issued but not yet effective</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Intangibles-Goodwill and Other:&#160;Testing Goodwill for Impairment</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In September 2011, an accounting standard update regarding testing of goodwill for impairment was issued. This standard update gives companies the option to perform a qualitative assessment to first assess whether the fair value of a reporting unit is less than its carrying amount. If an entity determines it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The new guidance is to be applied prospectively effective for annual and interim goodwill impairment tests beginning after December 15, 2011, with early adoption permitted.&#160; The adoption of this standard is not expected to have a material impact on the Company's results of operations or financial condition.</font></div></div> <div><div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE K &#8211; FINANCING RECEIVABLES, NET</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">At November 30, 2011, the Company had financing receivables of $36,541, net of unearned interest of $3,059.&#160;&#160;These financing receivables were generated by a sales-type lease of our EECP<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174; </font>equipment in our<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#160;</font>Equipment Segment for a term of three years ending September 1, 2013.&#160;&#160;At November 30, 2011, there were no past due amounts on these financing receivables and the Company has consequently made no provision for credit loss.&#160;&#160;At May 31, 2011, the Company had financing receivables of $45,558, net of unearned interest of $4,842.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div></div></div> 12982119 4018572 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Basis of Presentation and Use of Estimates</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended May 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</font></div><div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><div>&#160;</div></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">Significant Accounting Policies</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended May 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.&#160;&#160;Policies newly adopted for the quarter ended November 30, 2011 are set forth below:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Goodwill</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350 &#8211; &#8220;Intangibles: Goodwill and Other&#8221;. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment, at least annually, in accordance with this guidance.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Comprehensive Income (Loss)</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In countries in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date.&#160;&#160;Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the year.&#160;&#160;Resulting translation adjustments are recorded as a component of accumulated other comprehensive income.&#160;&#160;As of November 30, 2011, accumulated other comprehensive income includes income of $3,999, which is entirely from foreign currency translation.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt;">Reclassifications</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Certain reclassifications have been made to prior period amounts to conform with the current period presentation.</font></div><div style="text-indent: 0pt; display: block;"><br /></div></div> 42851 16144 21666 12612 -69358 18869 85892 93696 -18568 49320 -931611 0 0 58360 1221362 152111 1135869 124403 false --05-31 2011-11-30 No No Yes Smaller Reporting Company 22065523 VASOMEDICAL INC 0000839087 153186296 2011 Q2 10-Q 510000 510000 127500 382500 35497 53245 0 8874 12186855 2018624 8620367 2011188 2902041 423913 1799933 421963 0 1250000 <div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">NOTE C -&#160; LIQUIDITY</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During the last several years, the Company has incurred operating losses. We have sought to achieve profitability by launching the VasoHealthcare business, and by expanding our U.S. market product portfolio to include ambulatory monitoring devices (the BIOX series ECG Holter recorders, ambulatory blood pressure monitors and analysis software) and patient management devices (the EZ ECG and EZ O2 products).</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In fiscal 2011, the Company issued Series E convertible preferred stock (see Note N) to finance the initial operation of its Sales Representation segment and ultimately generated in excess of $4.1 million in operating cash flow by fiscal year end.&#160;&#160;While we expect to continue to generate significant operating cash flows in fiscal 2012, the progressive nature of the GEHC Agreement can cause related cash inflows to vary widely during the fiscal year.</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In addition, under the terms of our agreement with GEHC, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of $3.3 million from October 2010 to November 2011, and $1.0 million for the six months ended November 30, 2011, and are expected to generate additional commission revenues estimated to range from $1.3 million to $1.5 million over approximately one or more years.</font></div><div style="text-indent: 0pt; display: block;"><br /></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Based on our current operations through November 30, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will be sufficient for the Company to continue operations through at least December 1, 2012.</font></div></div> -317079 0 EX-101.SCH 5 vaso-20111130.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) link:presentationLink link:calculationLink link:definitionLink 001010 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 006100 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 006110 - Disclosure - FINANCING RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 006120 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 006130 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 006140 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 006150 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 006160 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 006170 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 000990 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vaso-20111130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 7 vaso-20111130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accrued rent expense Accrued Rent, Noncurrent DEFERRED DISTRIBUTOR COSTS, accumulated amortization Accumulated other comprehensive income PROPERTY AND EQUIPMENT, accumulated depreciation Acquisition of Fast Growth Enterprises Payments to Acquire Businesses, Net of Cash Acquired Additional paid-in capital Accounts and other receivables, net of an allowance for doubtful accounts Amortization of deferred distributor costs CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) [Abstract] - basic (in dollars per share) Earnings Per Share, Basic Cash acquired through purchase of Fast Growth Enterprises Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Interest paid Interest Paid Deferred commission expense Increase (Decrease) in Deferred Charges Inventories, net Increase (Decrease) in Inventories Accrued professional fees Accrued rent expense Increase (Decrease) in Prepaid Rent Sales tax payable Accounts payable Changes in operating assets and liabilities: Accrued expenses and other liabilities Trade payable due to related party COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Common stock, $.001 par value; 250,000,000 shares authorized; 153,103,796 shares at November 30, 2011 and 117,078,704 at May 31, 2011 issued and outstanding Comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total cost of revenues Cost of Goods and Services Sold Cost of revenues Cost of sales, equipment Cost of equipment rentals and services Total current liabilities Liabilities, Current CURRENT LIABILITIES DEFERRED DISTRIBUTOR COSTS, net of accumulated amortization of $588,876 at November 30, 2011, and $464,402 at May 31, 2011 DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred revenue - current portion Deferred revenue Deferred Revenue, Noncurrent - diluted (in dollars per share) Accrued preferred stock dividends Effect of exchange rate differences on cash Share-based compensation Fair value of assets acquired Losses (gains) on disposal of fixed assets Gain (Loss) on Disposition of Assets Gross profit Gross Profit CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) [Abstract] Accrued commissions Finance receivables Increase (Decrease) in Finance Receivables GOODWILL Inventories, net Inventory, Net Total Liabilities and Stockholders Equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Issuance of note payable Net income/(loss) Net loss Net loss applicable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract] Total other income, net Nonoperating Income (Expense) Other income (expenses) Interest and financing costs Interest and Debt Expense Total long-term liabilities Liabilities, Noncurrent LONG-TERM LIABILITIES Notes payable due to related party FINANCING RECEIVABLES, net Operating income/(loss) Operating Income (Loss) Foreign currency adjustments Other comprehensive income/(loss) Other current assets Other Assets, Current Deferred commission expense Other Deferred Costs, Net Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Proceeds from preferred stock PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,789,204 at November 30, 2011, and $1,633,290 at May 31, 2011 Provision for doubtful accounts Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment ACCOUNTS AND OTHER RECEIVABLES, NET Loans, Notes, Trade and Other Receivables Disclosure [Text Block] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Accumulated deficit Amortization of deferred gain on sale-leaseback of building Amortization of deferred gain on sale-leaseback of building Total revenues Revenue, Net Revenues Revenue, Net [Abstract] Equipment sales Equipment rentals and services INVENTORIES, NET Inventory Disclosure [Text Block] SEGMENT REPORTING AND CONCENTRATIONS Segment Reporting Disclosure [Text Block] Selling, general and administrative Short-term investments CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) [Abstract] STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY Stockholders' Equity Note Disclosure [Text Block] GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION Income taxes paid Income Taxes Paid Total current assets Assets, Current CURRENT ASSETS - diluted (in shares) - basic (in shares) Research and development Total Assets Assets Financing receivables, net Other long-term liabilities Other Liabilities, Noncurrent SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] ASSETS ASSETS Inventories transferred to property and equipment, attributable to operating leases, net STOCKHOLDERS EQUITY [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Deferred revenue OTHER ASSETS Operating expenses Total operating expenses Operating Expenses Net income/(loss) per common share EARNINGS (LOSS) PER COMMON SHARE [Abstract] Common stock, par value (in dollars per share) Total stockholders' equity Stockholders' Equity Attributable to Parent Income tax benefit/(expense), net Income Tax Expense (Benefit) Preferred stock, $.01 par value; 1,000,000 shares authorized; 0 shares at November 30, 2011 and 299,024 shares at May 31, 2011 issued and outstanding Accounts and other receivables Increase (Decrease) in Accounts and Other Receivables EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Depreciation and amortization of property and equipment BUSINESS COMBINATION Business Combination Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES (NOTE P) Adjustments to reconcile net loss to net cash used in operating activities ORGANIZATION AND PLAN OF OPERATIONS Nature of Operations [Text Block] Accounts payable Accounts Payable, Current Accrued expenses and other liabilities Accrued Liabilities, Current Accrued professional fees Accrued Professional Fees, Current Accrued commissions Accrued Sales Commission, Current Trade payable due to related party Due to Related Parties, Current Sales tax payable Sales and Excise Tax Payable, Current Income/(loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] FINANCING RECEIVABLES, NET Financing Receivables [Text Block] Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $1,617,193 at November 30, 2011, and $1,296,947 at May 31, 2011 BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Interest and other income, net ORGANIZATION AND PLAN OF OPERATIONS [Abstract] FINANCING RECEIVABLES, NET [Abstract] BUSINESS COMBINATION [Abstract] COMMITMENTS AND CONTINGENCIES [Abstract] GOODWILL AND OTHER INTANGIBLES [Abstract] FAIR VALUE MEASUREMENTS [Abstract] INVENTORIES, NET [Abstract] SHARE-BASED COMPENSATION [Abstract] BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] DEFERRED REVENUE [Abstract] SEGMENT REPORTING AND CONCENTRATIONS [Abstract] RELATED-PARTY TRANSACTIONS [Abstract] Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Other long-term liabilities Liabilities assumed through acquisition Issuance of note payable for purchase of insurance policy SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Preferred stock dividends Preferred Stock Dividends, Income Statement Impact Weighted average common shares outstanding Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Text Block] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Deferred Charges Related Party Current The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which will be charged against earnings within one year or the normal operating cycle, if longer. Deferred related party consulting expense - current portion Deferred Charges Related Party Noncurrent The amount of deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date, which are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. DEFERRED RELATED PARTY CONSULTING EXPENSE Sale Leaseback Transaction Deferred Gain Gross Current The amount of the gain recorded in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller to be recognized within one year or the normal operating cycle, if longer. Deferred gain on sale-leaseback of building - current portion Sale Leaseback Transaction Deferred Gain Gross Noncurrent The amount of the gain recorded in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller to be recognized in periods after one year or beyond the operating cycle, if longer. Deferred gain on sale-leaseback of building Commissions Revenue Net Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare. Commissions Cost Of Commissions Revenue Total costs related to commissions earned under the sales representative agreement with GE Healthcare. Cost of commissions Conversion of notes payable to preferred stock The value of notes payable converted to preferred stock in noncash investing and financing transactions. LIQUIDITY [Text Block] The entire disclosure for when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). LIQUIDITY LIQUIDITY [Abstract] ACCOUNTS AND OTHER RECEIVABLES [Abstract] ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract] Increase Decrease Deferred Charges Related Party The increase (decrease) during the reporting period in deferred costs capitalized as a result of related party transactions where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Amortization of deferred consulting expense EX-101.PRE 8 vaso-20111130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
SEGMENT REPORTING AND CONCENTRATIONS
 6 Months Ended
Nov. 30, 2011
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]  
SEGMENT REPORTING AND CONCENTRATIONS
NOTE D – SEGMENT REPORTING AND CONCENTRATIONS
 
The Company views its business in two segments – the Equipment segment and the Sales Representation segment.  The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the marketing of other medical devices.  The Sales Representation segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the execution of the Company's responsibilities under our agreement with GEHC.  The Company evaluates segment performance based on operating income.  Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment.  There are no intersegment revenues.  Summary financial information for the segments is set forth below:
 
   As of or for the three months ended November 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
              
Revenues from external customers
 $1,332,961  $8,620,367  $-  $9,953,328 
Operating income/(loss)
 $(733,789) $3,463,347  $(266,945) $2,462,613 
Total assets
 $8,179,790  $15,175,375  $3,723,104  $27,078,269 
Accounts and other receivables, net
 $1,099,955  $11,882,164  $-  $12,982,119 
Deferred commission expense
 $-  $3,097,173  $-  $3,097,173 
                  
     As of or for the three months ended November 30, 2010 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $1,789,554  $2,011,188  $-  $3,800,742 
Operating income/(loss)
 $177,330  $(1,270,512) $(59,857) $(1,153,039)
Total assets
 $3,374,898  $7,055,400  $1,075,134  $11,505,432 
Accounts and other receivables, net
 $867,837  $5,993,415  $-  $6,861,252 
Deferred commission expense
 $-  $984,574  $-  $984,574 
                  
     As of or for the six months ended November 30, 2011 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $2,094,909  $12,186,855  $-  $14,281,764 
Operating income/(loss)
 $(1,402,345) $2,739,578  $(558,107) $779,126 
Total assets
 $8,179,790  $15,175,375  $3,723,104  $27,078,269 
Accounts and other receivables, net
 $1,099,955  $11,882,164  $-  $12,982,119 
Deferred commission expense
 $-  $3,097,173  $-  $3,097,173 
                  
     As of or for the six months ended November 30, 2010 
   
Equipment Segment
 
Sales Representation Segment
 
Corporate
  
Consolidated
 
                  
Revenues from external customers
 $3,057,965  $2,018,624  $-  $5,076,589 
Operating income/(loss)
 $18,821  $(3,632,752) $(116,301) $(3,730,232)
Total assets
 $3,374,898  $7,055,400  $1,075,134  $11,505,432 
Accounts and other receivables, net
 $867,837  $5,993,415  $-  $6,861,252 
Deferred commission expense
 $-  $984,574  $-  $984,574 
                  
 
For the six months ended November 30, 2011 and 2010, GE Healthcare accounted for 85% and 40% of revenue, respectively.  For the three months ended November 30, 2011 and 2010, GE Healthcare accounted for 87% and 53% of revenue, respectively.  Also, GE Healthcare accounted for $11,760,974, or 91%, and $2,990,978, or 74%, of accounts and other receivables at November 30, 2011 and May 31, 2011, respectively.
 
EXCEL 11 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R M9#!C.#%B,#4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]#3TY$14Y3141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5! M4DY)3D=37TQ/4U-?4$527T-/34U/3E]32$%213PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13 M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E)%3$%4141005)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A M-30R9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W M9C)B8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA2!#96YT3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#@S.3`X-SQS<&%N M/CPO'0^+2TP-2TS,3QS<&%N/CPO2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!& M:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M4VUA;&QE3QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,C`Q,3QS<&%N/CPO'0^43(\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'!E;G-E"!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS-S0L,S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4@9'5E('1O(')E;&%T M960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)FYB'0^)FYB2`S,2P@,C`Q M,2!I3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R9#!C.#%B,#4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B8F)?8S(S-U\T-S,R7V%E-#=? M834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA2`S,2P@,C`Q,3QB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D("AI;B!S:&%R97,I M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P,#QS M<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A M-30R9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W M9C)B8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0Y M,BPY-SD\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&]F('!R;W!EF%T:6]N(&]F(&1E9F5R'!E;G-E M6%B;&4@9'5E('1O M(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M/B@U-RPX-3(I/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&-H86YG92!R871E(&1I9F9E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5S('!A:60\+W1D/@T*("`@("`@("`\=&0@ M8VQA6%B;&4@ M=&\@<')E9F5R7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`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`Q+"`R,#$P+"!S=6)J96-T('1O(&5X=&5N6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1I2!F;W(@=&AE('-A M;&5S(')E<')E6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.3U1%($(@+2!"05-)4R!/1B!04D53 M14Y4051)3TX@04Y$($-2251)0T%,($%#0T]53E1)3D<@4$],24-)15,\+V9O M;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SLG/CQB6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&UA3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$ M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.;W1E($(@;V8@ M=&AE($YO=&5S('1O($-O;G-O;&ED871E9"!&:6YA;F-I86P@4W1A=&5M96YT M65A2!O9B!T:&4@2!A9&]P=&5D(&9O6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA M>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY';V]D=VEL M;"!R97!R97-E;G1S('1H92!E>&-E6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1I2!F M3H@8FQO M8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F M;VYT+7-T>6QE.B!I=&%L:6,[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SX\8G(@+SX\ M+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1I3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM M97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY$=7)I;F<@=&AE(&QA M2!B>2!L875N8VAI;F<@=&AE(%9A6QE M/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE2!I2!G96YE'!E8W0@=&\@8V]N=&EN=64@=&\@9V5N M97)A=&4@2!D=7)I;F<@=&AE(&9I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V1I2!O;F4@;W(@;6]R92!Y96%R6QE/3-$)W1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V1I3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES M<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@ M0V]M<&%N>2!V:65W3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P.R<^)B,Q-S0[/"]F;VYT/B!E;FAA;F-E9"!E>'1E M2P@87,@=V5L;"!A2=S(')E2!F:6YA;F-I86P@:6YF;W)M871I;VX@9F]R('1H92!S96=M96YT6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V M,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`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`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`P<'0[(&1I6QE/3-$)V1I#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`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`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`U-2PT,#`\ M+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F#LG/CQF;VYT('-T M>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`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`P<'0[ M(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#`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`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`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`L(#(P,3`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`P<'0[(&1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I'1E3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#`U-RPY-C4\+V9O;G0^ M/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT3H@8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SY/<&5R871I;F<@:6YC;VUE+RAL;W-S*3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXI/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I M6QE/3-$)W1E>'0M M:6YD96YT.B`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`U-2PT,#`\+V9O;G0^/"]T M9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE M/3-$)V1I6QE/3-$ M)V1I6QE/3-$ M)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I2`S,2P@,C`Q,2P@6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A M-30R9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W M9C)B8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4 M:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I65EF5D(&EN('1H92!C;VYS;VQI9&%T960@8V]N M9&5N6QE/3-$)W1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE65E2!W:71H('1H92!R96UA:6YD97(@=F5S=&EN9R!O=F5R('1H M6QE/3-$)V1I2=S($)O87)D(&]F M($1I2!S=&]C:R!O<'1I;VYS+CPO M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I"!M;VYT M:',@96YD960@3F]V96UB97(@,S`L(#(P,3$@86YD(#(P,3`@=V%S("0Q.#4L M,3$T(&%N9"`D,C`X+#8Q-2P@"!M;VYT:',@96YD960@3F]V96UB97(@,S`L(#(P,3$@86YD M(#(P,3`L(')E2P@86YD('=A'!E;G-E(')E;&%T960@=&\@97AI&EM871E;'D@)#$N,B!M:6QL:6]N(&%T M($YO=F5M8F5R(#,P+"`R,#$Q(&%N9"!W:6QL(&)E(')E8V]G;FEZ960@2!T:')O=6=H($IU;'D@,C`Q,RX\+V9O;G0^/"]D:78^/&1I=B!S='EL M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P M.SPO9&EV/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SY.3U1%($8@)B,X,C$Q.R!%05).24Y'4R`H3$]34RD@4$52($-/34U/3B!3 M2$%213PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I2!T:&4@=V5I9VAT960M879E&5R8VES960@;W(@8V]N=F5R=&5D('1O(&-O;6UO;B!S M=&]C:RX\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI9VX] M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I3H@8FQO8VL[)SX\9&EV(&%L:6=N/3-$;&5F=#X\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@8V]L6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E"!M;VYT:',@96YD M960@3F]V96UB97(@,S`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3`L-S6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-3,L,S$P+#,R,CPO9F]N=#X\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,3$L,3(S+#,U,SPO M9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@6QE/3-$)V1I6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-#4L,S@W+#DU-#PO9F]N=#X\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`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`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V)O3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF M(S$V,#L@/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=T97AT+6%L:6=N.B!C96YT97([(&)O3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@8V]L6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E"!M;VYT:',@96YD960@3F]V96UB97(@,S`L/"]F;VYT/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:')E92!M;VYT:',@96YD960@ M3F]V96UB97(@,S`L/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#LG M/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F#LG/CQF;VYT M('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$ M)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M6QE/3-$)V1I M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#(X M-2PW,30\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY# M;VYV97)T:6)L92!P3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]F;VYT/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$.24@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SY#;VUM;VX@#LG/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$ M)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@ M#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXT+#,T M,"PP,#`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.3U1%($<@)B,X M,C$Q.R!&04E2(%9!3%5%($U%05-54D5-14Y44SPO9F]N=#X\+V1I=CX\9&EV M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I2!S='EL93TS1"=T97AT+6EN9&5N=#H@ M,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA6QE/3-$)V1I2=S(&%S M6QE/3-$)W1E>'0M:6YD96YT.B`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`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`P<'0[(&1I6QE/3-$ M)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/8G-E M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SY);G!U=',\+V9O;G0^/"]D:78^/&1I=B!A M;&EG;CTS1&-E;G1E#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)W!A9&1I;F3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY5;F]B6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I3H@8FQO M8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^07-S971S/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$ M)V1I6QE/3-$)W1E>'0M:6YD96YT.B`Y M<'0[(&1I6QE/3-$)V1I2!M87)K970@ M9G5N9',@/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`Y<'0[(&1I6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXR+#@Q,2PR,30\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXM M/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$ M)W!A9&1I;F'0M:6YD96YT.B`Y<'0[)SX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY-87)K971S(&9O6QE/3-$)W1E>'0M:6YD96YT.B`P M<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1IF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@#LG M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V1I3H@8FQO8VL[(&UA3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SY/8G-E3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY);G!U=',\+V9O;G0^/"]D M:78^/&1I=B!A;&EG;CTS1&-E;G1E#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$ M)W!A9&1I;F3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY5;F]B6QE/3-$)W1E>'0M:6YD M96YT.B`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`P<'0[(&1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@ M6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[(&1I6QE/3-$)V1I2!M87)K970@9G5N9',@/"]F M;VYT/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD M96YT.B`Y<'0[(&1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXW+#`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`Y<'0[)SX\9&EV(&%L:6=N/3-$ M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE M3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V M,#L@)B,Q-C`[*&EN8VQU9&5D(&EN('-H;W)T+71E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T M:6UE'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ M,#DL-S`Y/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;FF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24@6QE/3-$ M)V1I#LG/CQF;VYT M('-T>6QE/3-$)V1I6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,#DL-S`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`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4 M:&4@9F%I3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!4:6UE3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@9F]L;&]W:6YG('1A M8FQE('!R97-E;G1S(&EN9F]R;6%T:6]N(')E9V%R9&EN9R!T:&4@0V]M<&%N M>2=S(&%C8V]U;G1S(&%N9"!O=&AE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1IF4Z(#$P<'0[)SX\='(@8F=C;VQO#L@8F]R9&5R+71O M<#H@;65D:75M(&YO;F4[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI M9#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9&EV(&%L:6=N/3-$8V5N M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I2`S,2P@,C`Q,3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`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`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`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY42!D=64@=6YD97(@=&AE($=%2$,@06=R965M96YT(&%R92!S=6)J96-T M('1O(&%D:G5S=&UE;G0@:6X@6EN9R!S86QE6QE/3-$ M)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6UE;G1S+"!A;F0@ M861J=7-T;65N=',@87)I2!R96-E:79E('5N9&5R M('1H92!'14A#($%G3H@8FQO8VL[)SX\8G(@ M+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO M8VL[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)W1E>'0M M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE M/3-$)W1E>'0M:6YD96YT.B`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`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`P<'0[(&1I3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R M9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B M8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SY.3U1%($HF(S@R,3$[($)54TE.15-3($-/34))3D%4 M24]./"]F;VYT/CPO9&EV/CQD:78@3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$ M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!!=6=U2!F;W)M M960@2P@5F%S;VUE9&EC86P@1VQO8F%L+"!S:6=N960@86X@ M86=R965M96YT('1O('!U"!);G-T6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I2!T:&%T(&]W;G,@3&EF92!%;FAA;F-E;65N="!496-H;F]L;V=Y M($QI;6ET960@*"8C.#(R,#M,150F(S@R,C$[*2!A;F0@0FEO>"!);G-T2=S(&-O;6UO;B!S=&]C:RP@=7`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`S M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`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`\+V9O;G0^/"]T9#X\=&0@ M;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY) M;B!A8V-O2!A=F%I;&%B M;&4L(&%N9"!M87D@8F4@861J=7-T960@869T97(@;V)T86EN:6YG(&UO3H@ M8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`P<'0[(&1I6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)V)O3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXT-#$L.#@V/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93LG/CQF;VYT M('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M:6YD96YT.B`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`P<'0[(&1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXI/"]F;VYT M/CPO=&0^/"]T#L@=&5X="UI;F1E;G0Z(#EP=#LG/CQD:78@86QI M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`Y<'0[(&1I6QE/3-$)V1I6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SXS+#DW.2PT,#`\+V9O;G0^/"]T9#X\=&0@ M;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY$ M=7)I;F<@=&AE('1H6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE2!TF5D(&)Y($9'12!F2X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO M9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R M9VEN+7)I9VAT.B`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`L/"]F M;VYT/CPO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M#L@8F]R9&5R+71O<#H@;65D:75M(&YO M;F4[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:')E92!-;VYT:',@ M16YD960@3F]V96UB97(@,S`L/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@#L@8F]R9&5R+71O<#H@;65D:75M(&YO M;F4[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE#LG/CQF;VYT('-T>6QE/3-$)V1I M#LG/CQF M;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F#LG M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M:6YD96YT.B`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`],T1N;W=R87`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`],T1N;W=R87`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`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`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA M>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY!;B!A9&IU M"!M;VYT:"!P97)I;V0@96YD:6YG($YO=F5M8F5R M(#,P+"`R,#$P+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T,C=F M,F)B8E]C,C,W7S0W,S)?864T-U]A-30R9#!C.#%B,#4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B8F)?8S(S-U\T-S,R7V%E-#=?834T M,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/&1I=CX\9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!4:6UE2!H860@ M9FEN86YC:6YG(')E8V5I=F%B;&5S(&]F("0S-BPU-#$L(&YE="!O9B!U;F5A M6QE/3-$)V1I6QE/3-$)V1I2!M861E(&YO('!R;W9I2!H860@9FEN M86YC:6YG(')E8V5I=F%B;&5S(&]F("0T-2PU-3@L(&YE="!O9B!U;F5A3H@8FQO8VL[)SXF(S$V,#L\ M+V1I=CX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1I3H@8FQO8VL[)SX\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6EN9R!A;6]U;G0@;V8@9V]O9'=I M;&P@=V%S(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/CQD:78@3H@8FQO8VL[)SXF(S$V,#L\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`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`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`R,#$Q/"]F;VYT/CPO M9&EV/CPO=&0^/'1D(&%L:6=N/3-$#LG/CQF;VYT M('-T>6QE/3-$)V1I6QE/3-$)V)O M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B!4:6UE6QE M/3-$)W1E>'0M:6YD96YT.B`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`Y<'0[)SX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@.7!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`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`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`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`[/"]D:78^/"]D:78^/&1I=B!A;&EG;CTS1&IU6QE/3-$ M)V1I2P@86YD("0X+#0V-2!A;F0@ M)#$Q+#0S-"!F;W(@=&AE('1H2X\+V9O;G0^ M/"]D:78^/&1I=B!A;&EG;CTS1&IU7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3H@8FQO8VL[ M(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.3U1%($T@+2!$149%4E)% M1"!2159%3E5%/"]F;VYT/CPO9&EV/CQD:78@3H@8FQO8VL[)SX\8G(@+SX\+V1I=CX\9&EV(&%L M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA M>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL M>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY4:&4@8VAA M;F=E2=S(&1E9F5R6QE/3-$)W1E>'0M:6YD M96YT.B`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`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`E('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O M;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M:6YD96YT.B`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`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`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`E('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,BPU,#`\+V9O;G0^/"]T9#X\=&0@ M;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M:6YD96YT.B`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`E('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXQ."PU,#`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`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`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`E('-T>6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`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`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`M.7!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#$X<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SY,97-S.B!C=7)R96YT('!O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#LG/CQF;VYT('-T>6QE/3-$)V1IF4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3`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`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`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$ M)V1I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.3U1% M($X@)B,X,C$Q.R!214Q!5$5$+5!!4E19(%1204Y304-424].4SPO9F]N=#X\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I2`H3$54*2`H2!W3H@8FQO8VL[)SXF(S$V,#L\ M+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SY0=7)S=6%N="!T;R!T:&4@4W5P<&QI97(@06=R965M96YT+"!, M:79I;F<@1&%T82!B96-A;64@;W5R(&5X8VQU2!A="!C;W-T M("@D-#8Y+#0U,"DL('=H:6-H('=A6QE/3-$)V1I2!S>7-T96US(&9O6%B;&4@ M8F%L86YC92!D=64@3&EV:6YG($1A=&$@:6YC;'5D960@:6YT97)E2`S,2P@,C`Q,2!A;F0@=V%S('-A=&ES M9FEE9"!T:')O=6=H(&$@8V%S:"!P87EM96YT(&EN($%U9W5S="`R,#$Q+CPO M9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I M6QE/3-$)V1I2!A('-E;FEO2XF(S$V,#LF(S$V,#M&965S(&]F(&%P<')O>&EM871E;'D@)#0U+#`P,"!A M;F0@)#$U-"PP,#`@=V5R92!B:6QL960@8GD@=&AE(&9I"!M;VYT:',@96YD:6YG($YO=F5M8F5R(#,P+"`R M,#$Q+"!R97-P96-T:79E;'DL(&%T('=H:6-H(&1A=&4@;F\@86UO=6YT6QE/3-$)W1E M>'0M:6YD96YT.B`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`S-G!T.R<^/&1I=CX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I M6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z(#$P<'0[)SY%;F=A9VEN9R!F:6YA;"!A<'!R;W9A;"!F'1E;F0@8V]V97)A9V4@86YD('!R;W9I9&4@9F]R('1H92!R M96EM8G5R2!F;W(@0T-3($-L M87-S($E)(&%N9VEN83L@86YD/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXU+CPO9F]N=#XF(S$V,#LF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0^ M/&1I=B!A;&EG;CTS1&IU6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I2`Q,"4@;V8@ M=&AE(&]U='-T86YD:6YG(&-A<&ET86P@&-E'!E;G-E(&%N9"!I6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!4:6UE"!M;VYT:',@96YD:6YG($YO=F5M8F5R M(#,P+"`R,#$Q+"!A(&1I2!A9V=R96=A=&EN9R!A<'!R;WAI;6%T M96QY("0S,"PP,#`@86YD("0V,"PP,#`@2X\+V9O;G0^/&)R("\^)B,Q-C`[/"]D:78^/&1I=B!A;&EG M;CTS1&IU6QE/3-$)V1I2=S(&%C<75I2!M96UB97(@;V8@=&AE(&UA M;F%G96UE;G0@;V8@3$54+B8C,38P.R8C,38P.U1H92!N;W1E2!D871E+"!A9V=R96=A=&5D(&%P<')O>&EM871E M;'D@)#(X-2PP,#`@870@3F]V96UB97(@,S`L(#(P,3$L(&%N9"!B96%R(&EN M=&5R97-T(&%T(#4N,S$E('!E2!R97!A:60N)B,Q-C`[)B,Q-C`[26X@861D:71I;VXL("0Q,"PP-#D@:6X@ M<')E+6%C<75I3H@8FQO8VL[)SXF M(S$V,#L\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SY#;VUM;VX@4W1O8VL\+V9O;G0^/&)R("\^)B,Q-C`[/"]D M:78^/&1I=B!A;&EG;CTS1&IU6QE/3-$)V1I65E&EM=6T@;G5M8F5R(&]F('-H87)E6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!4:6UE2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA M>3H@8FQO8VL[(&UA6QE/3-$)V1I M2!B92!E:71H M97(@:6YC96YT:79E('-T;V-K(&]P=&EO;G,@;W(@;F]N+7%U86QI9FEE9"!S M=&]C:R!O<'1I;VYS+B8C,38P.R8C,38P.U1H92!O<'1I;VX@<')I8V4@2!I;F1I=FED=6%L('-T;V-K:&]L9&5R('!O65A6QE/3-$)V1I2X@07,@;V8@3F]V96UB97(@,S`L(#(P,3$L(#0V-2PP,#`@ M2!W:71H('1H92!R96UA:6YD97(@=F5S=&EN9R!O=F5R(&$@=&AR964@>65A M3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES M<&QA>3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY.;R!O M<'1I;VYS('=E2!S M='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA M6QE/3-$)V1I6QE M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$ M)V9O;G0M3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY03H@8FQO M8VL[(&UA6QE/3-$)V1I2!T:&4@0F]A2!T7,@97AC965D6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S M='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY&;W(@=&AE('1H"!M;VYT M:',@96YD960@3F]V96UB97(@,S`L(#(P,3$@86YD(#(P,3`@=&AE($-O;7!A M;GD@"!M;VYT:',@96YD960@3F]V96UB97(@,S`L(#(P,3$@86YD(#(P M,3`L(')E2X@5&AE6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M9F%M:6QY.B!4:6UE2!C;VYV97)T M960@=&\@8V]M;6]N('-T;V-K(&5F9F5C=&EV92!*=6QY(#$L(#(P,3$N)B,Q M-C`[)B,Q-C`[07,@;V8@3F]V96UB97(@,S`L(#(P,3$L(#(Y+#DU-BPQ,#`@ M65T('1O(&)E(&ES3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R M9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B M8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I M=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@ M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$ M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!4:6UE2`Q+"`R,#$P+"!S=6)J96-T('1O(&5X M=&5N2!A8VAI M979I;F<@8V5R=&%I;B!S86QE2!I6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT M+7-T>6QE.B!I=&%L:6,[(&1I6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4 M:6UE'!I2`R,#$S+CPO9F]N=#X\8G(@+SX\+V1I=CX\9&EV M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@ M9&ES<&QA>3H@8FQO8VL[(&UA3H@8FQO8VL[(&UA6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6UE;G1S(&%R92!F M:7AE9"!F;W(@96%C:"!Y96%R(&]F('1H92!A9W)E96UE;G0L('-U8FIE8W0@ M=&\@65A6QE/3-$ M)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[(&UA3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N M.R!F;VYT+7-I>F4Z(#$P<'0[)SY&;W(@=&AE('EE87)S(&5N9&5D($UA>2`S M,3H\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T M.R!D:7-P;&%Y.B!B;&]C:SLG/CQD:78@86QI9VX],T1L969T/CQT86)L92!C M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@#L@8F]R9&5R+71O<#H@ M;65D:75M(&YO;F4[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@ M8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V)O"!S;VQI9#L@8F]R9&5R+71O M<#H@;65D:75M(&YO;F4[)SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$ M)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V1I M#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X] M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R<'@@#L@8F]R9&5R M+71O<#H@;65D:75M(&YO;F4[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R<^)B,Q-C`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`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`P<'0[(&1I6QE/3-$)V1I3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$)V1I6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0[)SXR-C(L,#`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`\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#LG/CQF;VYT('-T M>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG M/CQF;VYT('-T>6QE/3-$)V1I6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@#LG/CQF;VYT('-T>6QE/3-$)V1I#LG M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[ M(&1I6QE/3-$)V1I6QE/3-$)W!A9&1I;F3H@:6YL M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z M(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#DE('-T>6QE/3-$)V)O"!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXV-C,L,#`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`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`P/"]F;VYT/CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!X.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^ M/"]T9#X\+W1R/CQT3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE M/3-$)V1I6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[ M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$.24@6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^ M/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R9#!C M.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B8F)? M8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/&1I=CX\9&EV(&%L:6=N M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4 M:6UE3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)W1E>'0M:6YD M96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SX\82!N86UE/3-$6&)R;%]4 M863H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$ M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@ M8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY);B!*=6YE(#(P M,3$L(&YE=R!G=6ED86YC92!W87,@:7-S=65D('1H870@86UE;F1S('1H92!C M=7)R96YT(&-O;7!R96AE;G-I=F4@:6YC;VUE(&=U:61A;F-E+B!4:&4@86UE M;F1M96YT(&%L;&]W2!A9&]P M=&EO;B!P97)M:71T960N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@:&%S(&5L M96-T960@=&\@861O<'0@=&AI6QE/3-$)W1E M>'0M:6YD96YT.B`P<'0[(&1I3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M=V5I9VAT.B!B;VQD.R<^4W1A;F1A6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0[)SY);G1A;F=I8FQE6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I6QE M/3-$)V1I2!T:&%N(&YO M="!T:&%T('1H92!F86ER('9A;'5E(&]F('1H92!R97!O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W7S0W,S)?864T-U]A-30R M9#!C.#%B,#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-#(W9C)B M8F)?8S(S-U\T-S,R7V%E-#=?834T,F0P8S@Q8C`U+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5].97AT4&%R=%\T,C=F,F)B8E]C,C,W ;7S0W,S)?864T-U]A-30R9#!C.#%B,#4M+0T* ` end XML 12 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
LIQUIDITY
 6 Months Ended
Nov. 30, 2011
LIQUIDITY [Abstract]  
LIQUIDITY
NOTE C -  LIQUIDITY

During the last several years, the Company has incurred operating losses. We have sought to achieve profitability by launching the VasoHealthcare business, and by expanding our U.S. market product portfolio to include ambulatory monitoring devices (the BIOX series ECG Holter recorders, ambulatory blood pressure monitors and analysis software) and patient management devices (the EZ ECG and EZ O2 products).

In fiscal 2011, the Company issued Series E convertible preferred stock (see Note N) to finance the initial operation of its Sales Representation segment and ultimately generated in excess of $4.1 million in operating cash flow by fiscal year end.  While we expect to continue to generate significant operating cash flows in fiscal 2012, the progressive nature of the GEHC Agreement can cause related cash inflows to vary widely during the fiscal year.

In addition, under the terms of our agreement with GEHC, we are entitled to commissions on certain undelivered sales orders received by GEHC prior to our agreement and transferred to us from GEHC as of September 30, 2010. These transferred orders, though subject to various risks including potential cancellation and changes in credit worthiness and availability, as well as the Company's continued compliance under the GEHC Agreement, generated commission revenue of $3.3 million from October 2010 to November 2011, and $1.0 million for the six months ended November 30, 2011, and are expected to generate additional commission revenues estimated to range from $1.3 million to $1.5 million over approximately one or more years.

Based on our current operations through November 30, 2011, we believe internally generated funds from our Equipment and Sales Representation segments will be sufficient for the Company to continue operations through at least December 1, 2012.
XML 13 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (USD $)
Nov. 30, 2011
May 31, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 3,684,854 $ 8,130,031
Short-term investments 110,148 109,709
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $1,617,193 at November 30, 2011, and $1,296,947 at May 31, 2011 12,982,119 4,018,572
Inventories, net 2,683,265 1,786,057
Financing receivables, net 19,225 18,425
Deferred commission expense 2,823,456 2,532,048
Deferred related party consulting expense - current portion 510,000 510,000
Other current assets 176,009 267,235
Total current assets 22,989,076 17,372,077
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $1,789,204 at November 30, 2011, and $1,633,290 at May 31, 2011 418,683 366,199
GOODWILL 3,175,152 0
DEFERRED DISTRIBUTOR COSTS, net of accumulated amortization of $588,876 at November 30, 2011, and $464,402 at May 31, 2011 0 124,474
FINANCING RECEIVABLES, net 17,316 27,133
DEFERRED RELATED PARTY CONSULTING EXPENSE 127,500 382,500
OTHER ASSETS 350,542 282,162
Total Assets 27,078,269 18,554,545
CURRENT LIABILITIES    
Accounts payable 541,238 480,661
Accrued commissions 2,645,081 1,963,826
Accrued expenses and other liabilities 1,440,094 632,374
Sales tax payable 374,369 160,321
Deferred revenue - current portion 12,610,574 10,917,732
Deferred gain on sale-leaseback of building - current portion 35,497 53,245
Accrued professional fees 30,000 61,550
Trade payable due to related party 3,359 265,863
Total current liabilities 17,680,212 14,535,572
LONG-TERM LIABILITIES    
Deferred revenue 2,091,992 1,004,483
Accrued rent expense 0 3,001
Deferred gain on sale-leaseback of building 0 8,874
Notes payable due to related party 284,550 0
Other long-term liabilities 76,267 94,835
Total long-term liabilities 2,452,809 1,111,193
COMMITMENTS AND CONTINGENCIES (NOTE P)      
STOCKHOLDERS' EQUITY    
Preferred stock, $.01 par value; 1,000,000 shares authorized; 0 shares at November 30, 2011 and 299,024 shares at May 31, 2011 issued and outstanding 0 2,990
Common stock, $.001 par value; 250,000,000 shares authorized; 153,103,796 shares at November 30, 2011 and 117,078,704 at May 31, 2011 issued and outstanding 153,103 117,079
Additional paid-in capital 60,152,117 55,743,295
Accumulated deficit (53,363,971) (52,955,584)
Accumulated other comprehensive income 3,999 0
Total stockholders' equity 6,945,248 2,907,780
Total Liabilities and Stockholders Equity $ 27,078,269 $ 18,554,545
XML 14 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND PLAN OF OPERATIONS
 6 Months Ended
Nov. 30, 2011
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]  
ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Since 1995, we have been primarily engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems based on our unique proprietary technology currently indicated for use in cases of stable or unstable angina (i.e., chest pain), congestive heart failure (“CHF”), acute myocardial infarction (i.e., heart attack, (MI)) and cardiogenic shock.  In April 2010, the Company, through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, organized a group of medical device sales professionals in anticipation of entering into the sales and representation business for other equipment manufacturers.  On May 19, 2010, VasoHealthcare signed a sales representative agreement with GE Healthcare (the “GEHC Agreement”), the healthcare business unit of General Electric Company (NYSE: GE), for the sale of select GE Healthcare Diagnostic Imaging products.  Under the GEHC Agreement, VasoHealthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.  The GEHC Agreement has an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.

In September 2011, the Company acquired two Chinese operating companies, Life Enhancement Technologies Limited and Biox Instruments Co. Ltd (see Note J).  Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy and will operate through three wholly-owned subsidiaries.  Vaso Diagnostics d/b/a VasoHealthcare will continue as an operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products; Vasomedical Global Corp. will operate the Company's newly-acquired Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

We now report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment reportable segment.  VasoHealthcare activities are included under our Sales Representation reportable segment (See Note D).
XML 15 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 6 Months Ended
Nov. 30, 2011
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]  
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE Q - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
 
Adoption of New Standards
 
Other Comprehensive Income: Presentation of Comprehensive Income
 
In June 2011, new guidance was issued that amends the current comprehensive income guidance. The amendment allows the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single or continuous statement of comprehensive income or in two separate but consecutive statements.  The amendments in this update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  The new guidance is to be applied retrospectively and is effective for fiscal years, and interim periods, beginning after December 15, 2011, with early adoption permitted.  The Company has elected to adopt this guidance in its current quarterly filing.
 
Standards issued but not yet effective
 
Intangibles-Goodwill and Other: Testing Goodwill for Impairment
 
In September 2011, an accounting standard update regarding testing of goodwill for impairment was issued. This standard update gives companies the option to perform a qualitative assessment to first assess whether the fair value of a reporting unit is less than its carrying amount. If an entity determines it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The new guidance is to be applied prospectively effective for annual and interim goodwill impairment tests beginning after December 15, 2011, with early adoption permitted.  The adoption of this standard is not expected to have a material impact on the Company's results of operations or financial condition.
XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 17 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
 6 Months Ended
Nov. 30, 2011
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the consolidated condensed financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these consolidated condensed financial statements should be read in connection with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended May 31, 2011, as filed with the SEC. These consolidated condensed financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying consolidated condensed financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the consolidated condensed financial statements, the disclosure of contingent assets and liabilities in the consolidated condensed financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.
 
Significant Accounting Policies
 
Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended May 31, 2011, includes a summary of the significant accounting policies used in the preparation of the consolidated condensed financial statements.  Policies newly adopted for the quarter ended November 30, 2011 are set forth below:
 
Goodwill
 
Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350 – “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment, at least annually, in accordance with this guidance.
 
Comprehensive Income (Loss)
 
In countries in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date.  Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the year.  Resulting translation adjustments are recorded as a component of accumulated other comprehensive income.  As of November 30, 2011, accumulated other comprehensive income includes income of $3,999, which is entirely from foreign currency translation.
 
Reclassifications
 
Certain reclassifications have been made to prior period amounts to conform with the current period presentation.
XML 18 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) (USD $)
Nov. 30, 2011
May 31, 2011
CURRENT ASSETS    
Accounts and other receivables, net of an allowance for doubtful accounts $ 1,617,193 $ 1,296,947
PROPERTY AND EQUIPMENT, accumulated depreciation 1,789,204 1,633,290
DEFERRED DISTRIBUTOR COSTS, accumulated amortization $ 588,876 $ 464,402
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 299,024
Preferred stock, shares outstanding (in shares) 0 299,024
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares issued (in shares) 153,103,796 117,078,704
Common stock, shares outstanding (in shares) 153,103,796 117,078,704
XML 19 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
GOODWILL AND OTHER INTANGIBLES
 6 Months Ended
Nov. 30, 2011
GOODWILL AND OTHER INTANGIBLES [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE L – GOODWILL AND OTHER INTANGIBLES

              The change in the carrying amount of goodwill was as follows:
 
   
Carrying Amount
 
     
Balance at June 1, 2011
 $- 
Acquisition of FGE (Note J)
  3,175,152 
Balance at November 30, 2011
 $3,175,152 
 
The Company's other intangible assets consist of capitalized patent costs, as set forth in the following:
   
November 30, 2011
  
May 31, 2011
 
Patent Costs
      
Costs
 $469,043  $469,043 
Accumulated amortization
  (410,833)  (350,553)
   $58,210  $118,490 
 
Patents are included in other assets in the accompanying Consolidated Condensed Balance Sheets.  Amortization expense amounted to $17,512 and $23,160 for the six month periods ended November 30, 2011 and 2010, respectively, and $8,465 and $11,434 for the three month periods ended November 30, 2011 and 2010, respectively.

 
XML 20 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information (USD $)
 6 Months Ended
Nov. 30, 2011
Aug. 22, 2011
Jan. 09, 2011
Entity Registrant Name VASOMEDICAL INC    
Entity Central Index Key 0000839087    
Current Fiscal Year End Date --05-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float   $ 22,065,523  
Entity Common Stock, Shares Outstanding     153,186,296
Document Fiscal Year Focus 2011    
Document Fiscal Period Focus Q2    
Document Type 10-Q    
Amendment Flag false    
Document Period End Date Nov. 30, 2011    
XML 21 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
DEFERRED REVENUE
 6 Months Ended
Nov. 30, 2011
DEFERRED REVENUE [Abstract]  
DEFERRED REVENUE
NOTE M - DEFERRED REVENUE

The changes in the Company's deferred revenues are as follows:

  Six months ended November 30,  Three months ended November 30, 
   
2011
  
2010
  
2011
  
2010
 
Deferred revenue at the beginning of the period
 $11,922,215  $1,027,348  $12,128,362  $1,733,683 
Additions:
                
Deferred extended service contracts
  595,082   561,816   311,755   208,203 
Deferred in-service and training
  17,500   15,000   12,500   7,500 
Deferred service arrangements
  28,500   50,000   18,500   35,000 
Deferred commission revenues
  14,033,375   7,175,651   10,737,292   6,497,138 
Recognized as revenue:
                
Deferred extended service contracts
  (548,772)  (631,270)  (271,285)  (307,807)
Deferred in-service and training
  (22,500)  (10,000)  (12,500)  (7,500)
Deferred service arrangements
  (40,740)  (27,316)  (20,830)  (12,424)
Deferred commission revenues
  (11,282,094)  (1,563,836)  (8,201,228)  (1,556,400)
Deferred revenue at end of period
  14,702,566   6,597,393   14,702,566   6,597,393 
Less: current portion
  12,610,574   5,898,714   12,610,574   5,898,714 
Long-term deferred revenue at end of period
 $2,091,992  $698,679  $2,091,992  $698,679 
ZIP 22 0001140361-12-002690-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-12-002690-xbrl.zip M4$L#!!0````(`/E^,4#=C&H?=GL``*(Y!P`1`!P`=F%S;RTR,#$Q,3$S,"YX M;6Q55`D``U;@%4]6X!5/=7@+``$$)0X```0Y`0``[%WK<^.XD?^>JOP/6&5W M;[>*&O/]\.Q,RF-K)L[-V#[9LW>IJ_L`D9#%+$4J!.E'_OIK\"%3$B61>E(2 MMI(:F<2CN_'K1C<`HG_[Z\O00T\DI&[@?VA)[\06(KX=.*[_^*$5TS:FMNNV M_OKQSW_Z[8=V^POQ28@CXJ#>*WH8!$,:^*A+X@@:0!>V33RHTF:%7WJAAZ!M MGYZSG^Z'UB"*1N=G9\_/S^_8DW=!^'@FBZ)RYOHTPKY-6EEYS_7_6%"YA M.B[^,E/^64E*2Y9EG25OQT6I6U80FI7._N?;UWM[0(:X/4T/Z]YYJUBD1C]+ M7^9%71JHLF0L8C8M,:[@/Q$:3;9-B?WN,7@Z2]]!-4EJBU);D?)*(.-'C$?C M6GU,>TD/V8N2*@YQRSN!%R7%_7A8SH,3A6?1ZXB<00D2NO:X0N!7J!/X[:EZ M=A#[4?A:3EOVLH0^.P[#.77@#0"XK)*/79N6UTI>E52AKEU>`5Z4%8]&<\AB M;THJD!=[4%Z!O2FI\(1I,*[`_A@2Q[6Q]\X.ADEQ25+$K'`5E0-51>@WIB/G M-$%_E_11HC/G;,@^M*@[''E,%9)G@Y#T/[18O^V\LW)';O2:/1L_=1WVO.^2$"7DD`D>>O9ELN=!*_BAC?J$\ M1`U&].#D(6H`Q.W(0Q>E*#@HI`#W870%4V$F&QWT-&_E[=U4)>([;U4FX)6_ MV80XQ;$XQ<,4IUA?G.+VQ"F)UL&CTVH2.JV#1V==<6X1G>(ASB7B]N:2PP'5 MA#RVZ&N8LGQH\@"+9;9E>3OR`'M^@/)@1GP3\HA]-Q7&=PAZI^0P))C&(?F8 MQ:CGW^^O\I;R5\7665/SFIZ&G.,^@4BF660U;EA`B*,@'+^L2T]1".4M%KJ[ M(GXP=/W%'6:6?8!#0JOT.-MH_K;`=Q6Q*7-&9!E!LVW_T&Y?V'88$P=U`7," MN@G\-#:.D@4:*)*M%IQGY5BQMT(HPTZ7!7QO01QB/23/$OP@A]CN$'L0:X+1 M!0.VL,UM499,@0LI4T0V85'VRZZO+U_N!<0 MMNUX&'O)"A@>!F'D_AM';N"7$)Z7NR@4N^W?1@,27I$^@3Z=RX!&=!5!:Z9I M&OH$0U6[:PZ;RT=-U555E-=CLU`'!:P8$#(3Z\#=9P%C2]F6Q MSG52Y6M`Z0V);OL/^&65,50LRRIEK4J'^V9O^=B)Z_-VU[V]ZW0?_H$N;JY0 MY[^^7]]]Z]P\3*+3(="4[2Y#YU6A&/SV"/MQX4_`Z"X,8`J-7N\\F%OA7>=? ML3L:KF@*)<.T9%$M%<):Q!R`=):#0](51;;*(;(AZ>!7]C=%48`N;'@=$O0I MIJY/*"44YAP2H:"/+C$=Y.^=:0GE;3P$68FW!A*LLLIYW1(I3*YI+9:'F/SW M)H\Z73>'Y^F%IZH&8B5N+QS'95C`'AIAUVF[/K+QR(VP-X/T<\\6V2N5R_-,U00<&T&F3:R68+1=C/)Q+00N(^X9['L..G MV,$^PIX7/+.]`]0/0N0$<2_JQQXS.TD#,USEQ3\'X556..^L.^[AFR\`"H84]G2+=586P`%^\HX=3)W"CDNC4*W%T-P`^3160Z327W2 M(1O[8A"Q/)(RYZ^.=915U2A,I!LZ]A&@0!O'C`(WBT!Y@2I@>?L8T0E_"X#D:H`Z0 M%8Y"%V;[:4:*$__G,!@FOVDRD:UG4E15,LU"`+V@H_URM:I+59TAF.YL]H-` M@2?LD9(I+&G,=]@_G;=2%]$E#L-7@,'OV(O)2C&P;JJFIDZ1O:RGG3&P?.XU M@451D1K*@%AAB<64=,-J*OU5(B=-UI65$73-M)2`UC*O>)KH_"5[MYZY:>NB M7+`VQ88W0$HM&]$V9'DI)79(F$G[Y8JDOWY%$+;D_@C*'))9&M/">:5K?Z-> MH&Q)JF@625_2W>[YJ340IJ6:BK)!?J[])X!Z$+I56"D47G-8--60]$5L%+K: M&0OU5$*U1-/4ZO*0;V*,PJ!/*$UC_#ZI0GKJ[:?UO[JXYWHP,Z\[$FU%TC1Q M$1=SNMTE1_4&1C/,26M5EZ,Y.+L+"5N,2?:?EO.6E>Z6Q^0NRL.39M2Y6,A:R4];EM%FJ-A2PJ M$TMQ]5E(##!Y&1$?(L?"8J3W9MTJ,;;1J<4P-5-?.$%6F%5VP%2]%3A)-L2% MMF`!4RE6,J0A!X*7*$`A2;?=1AC4K8([&9.'H)O6N8,JT/[\9>!:T8:L:`M= MLOD][XO!>K.09BWTT%['0-^M\' M=GKLDQ?8?_S?3%3[U@@+.8M-O+7`ZB?5EP[JQY^]Z+WC/OW\&+W/?B+LN8_^ MA]8_8QJY_=<6HM&K1SZT6#MMUV>'S,Z1.(K>LP7MD8=?SU&/]?4>#2%FQ)Z#X.LD>MO*<^4)8W/6[(]3W7)^\1>]GNXZ'KP<,'=PCRN2'/J!L, ML9^]I>Z_R3F2QFW>W#YTT!WZ&0]'[_]BRI+T'EW>?OMV_<"VJ.^3'>O+VYN' MZYLOG9O+Z\X]H^&,M903=#8EAJILIQPEW4JZ6-K4[B6:BHC]!J%&T+]=:'P- M*:=>2,CVRRF0G6YRX,>0$`;)&9GV0G0V3[X[$,K:@Z+HC]%U!_N-?0#X$%A/EV($A+P;+[P<12!):!Q:`0&P/7/+$Z,V;IPGZ M'@,@3,A*NSY[PPIA!$2YPWB(_'C8`Z*`?SH#UR>VL\*A&\04>>01!,:> M)%(=!:`KKU`E6<=.[&PI']\3OL&C2*1!4V&3-U40DC_9L2/LO[(1REITF""] M)+IRDL_HHN10PW#$OF=-EC/3$R[],!BF%/63[4+?AT%PG]SHE34`;;LAVQ]^ M#L(_WFU<[=:%_8D8P\_89C[:*_K*QI/.'X9CM$.W/KJ('X%H)&G,DHB&@)X) MHH$'GG8]'`QN!+)38L:9KF)+F)R4%?H!.?]H(P M8,>!PVB`+G$(VN]CML%&8^PG1@]GVCI)"=3_AE\9%:SJ+ M38C3)C#3#C%ELUVJ6&-M3V8ZUN(H#)Y4H'FF;37C:E1P0G#HX+L53J MDW8G?5)*'EF;Y28B;S+H,>F/H<1RQ>9U%^`=!?7.;Q,F^7.?'L%!T]/\A1W-6$LA''+3,T:6`$%@D4E$WG MBC0K^_66!4IDE#^/TF5XXGDC[*1WWXBMY&\ZPG;^][/K1(,/+4D4?VI-S*DY MQU'"L0\G,>A8Y!28WRE=U$"X=DO3!,TG9ZH'+7,K7!`PG&+,# M!A*?'9.;QV3&3\YCSV.>-7#*/'37J3>.-F%G-O:OW2L+-I_Q%VKWI(C]X#ED M]QVE_\X5/+JXV7&V*"QPN5QRN.%QQ:@CV(8"`@.O,4FB= M%7S2$/4>`6=!^*'U%]LFI-]O%22TT%_-G&1=_6FG7NAF)9FTR98U:^"FBE2D MG[9&[&M$_KD:K54YK`HKM$2LIDB"*XA*2EYF/?8J[,D8XEH\= MRZ+.L@XU6@4YZ&-K^T.4_;U"-PD^L>15W30*G[Q\?J!@J(3R[7 M]\@N+=3Z!U]J,;-ERZ3KRIY,4S.@Q_6'Z\]:IR0MC>L/UQ^N/ZL>6M'VY1HW M`'I5UX\K;/-OCP&TLO(<@%X?9&"[0_6L3/7A;^9P*',H31?!00&EB=83C:!"$P(F#?F$WG"9/?RV[ M]3GP[UG-)/<9O7BK5B$'EC*30$6=,S";0FJ;#+B4QC6)OTZKK"!Y M"5@3%MKXSHI=+6Y(,T3"-8FKIE8@.XHA=^@>0$$)T`LAN_CM!-\$22 M"Y85,;F'54IN(00*!2!1`!I9H?0ZM>Q]AM8D"<,;D0MDMG)VOW2L2X4TE4;N MJ`13(6,O`Y!533"CD`S8->!/!%W[=C`DZ)>O`:6_CM-Y/^`7`5U$:3;;Y!J[ M*$!W."Q)##317-I:DE\;FE@SXX0J2H8^J0_S>FH"<_6R4"FFIJC%3"$-YVYA M`MK9C$Z*;ICBP3"W,&OMS-!)LJ:9AE27.YIP\"4(G#0[R#T)GUQV._Y]X,WD M9F3%;_M)8?!`\Z*LY)HY:D5=`4-1I'U>1SL@O68:)$,W1;TAI-?2!UG3)5F7 M&D)Z+;1+JF*:$[E0JY.>W.0LO.4\6$#S^L@V1%'6RD6\%>+J)1>2+$DRRZ6X M)='5@*>F6+)E[%)T-0!H6)*I:=6)>\NPD=[:G.H.S7!:3NI8L]:SK;IH&N8T MI7G;VR6T7G(_':8`:S^$UK.;LCR9"'NG$JT!4AG""6EF:IHAM)#T34!9]K!I ML@IEYB9NJV!PV%PI2P7_)]FKYD%YFP)J>;A M?]703+K'ES/K<_?C9'6UKQC2BYBWQ^.]^Y(FSZ%H&\VGF3UFQ+?I;HI3ZNQ8 M[?806C,@R55IYZKTD*3ZY,IT9,HT<:+S(&;9U8]W'HAM*,F!D/-0_0O(LL_* M#B;M07[_@K30UST)_>2`/B9`EWPVP`'-`7VX@.86F@/ZJ`#-+?2&[S]@$4.M M!=NVM107UHYQ<36U)CLW:_*(A&[@U(`0OV*P/M$K?D\JB7OY]$&2!$N6!;GL M,KDC^_2!X_D4\"R(LB$HJLGAS.%\!'"6!4DV!44O28O(\2$"/_J>A]$[\<8G-!GUQS+',L*?D,(L1V1&M$(WQYXF3,AL:NH37Y MHAM']5&A6I<$4](YJCFJCPC5BB0)AL;WKSFJCPG5LF@*LLCW24XW9H'^\FB% M?:(.X8K+#G/Q@*4!J&V7F/)`I0&(;9RED%1!5!1! M,?C9`@[L8P*V(4B&)NA:R?5('-=-@TBCA=LL7$NB8"B&(%O\X"X']C$!6Q=4 M"XRVT*PKDB`; MAWQN@*.Y@43O"&XA`, MA7SHWU[R6:^!1.\)S-*A?W+"P=Q`HO<%9FZ9.9B/!^+Y*0O3'M_^('*3KZ`KR3+QBGJ&]V]('1(.":[YV'[#T8\HH'G.N_1 M85J?.EQMW3JQ,PBR(%H[L%!HIS##=*@IF^#[?J:@G%PF464"$>( M^`X*^FA$0C=P-A]A-E91^1)59;(E53!$&;S80]X_J"Q[#NR3`;8N:)8A*-;Q M9W#CN#XE7'.#S8%]E,`^'8/-]\WJ2?4KH?0E MO:O2B4]*F]Y1FZ=OZC:"TEUOMWT-@*.(A$/D['[CK9)D&Z?T2W0>B$=.$/<\ MLDM3]N.6+-@\;K:=VU40+4FP=I&`8\:$-0-]7(6X"JVW#@T^@&Y87(&X`G$% MXG,05R&N0GP.VE,<>A9A$'UIW)3]_NTLINU'C$?G^0'(;AJ&7;G4]@(:A^0! MF/[$0L:/?_X30K_]T&[/G)5L3^\NMMMIX3F-7V:EV17LT'J7]#^T;%F4X#]% M;*'8=]-GWT51:D&$:+M#[-$/+;'U49)U2=0,=2[A6=L[(%;4%&D)L6#)#4.1 MZQ.;O1?03>!GY"XA\ZW@*F*5@5*8'`&Q MO[@^6"3/PR%EZPN(#G!(?IVFMX-#=@TGO2/A/2MPE=6>I587I2@HE[%(;T7.ZV#K)XIAD<3G);:!9V3_-H$>UQ"SMGV1Q3')%,=>@^<*VPQCZ M'(7CJYLBL,_`R9/K$-^A,^J7O[C#KVQ&N!@&\6IVHBW)LJ3H14-1VO;6:2V1 MZBRMF@PL52:UT^\3.V(+C^3%'K`KL%"((P*DP@LP)S9,T8&/;$P',ZA(JM[V M.UG%+M2[]2^AY(7OL'\Z_XI=\"_8E5KUC,@T4XIE606DU.AW[WPNM#S3?(IK M,IDH3KN':7I?P(CX%)=-]DFY3ZS89:'4>F,DF9HD%3R4\CZV16HM,YI>5OAW5O:V?Y&4O,@*KB==5=4M22[0 M/+>?_V?O67L;1W+\*X5##[8;4/?H+7D;.,"=N+N]ETYRB6?V%H?[H-B56#.* MY)'LI+V__DB6'B5;?LCO))K!8&);JB*K2!;)XF/?8&]*T*L!_N;!8?3^(DJ2 M#\B*H(R/HL2G[08$Q$NS<.,[^,95*#V>S;"ET+$=20M8.M$!4=AT^=>$/X9' MV'4)("#Q9&UZEU"LE2!FX7$,5JZ M:CO[6I,E>MG=QY'`71 ME/,;'L"1-KCPO3L_`&KD6[*K[8)\E`1D[>D/BULM,M54QRU)_\V1R]YD[[-W M/S"065_]T`,=",S:/@>U`O3$-7!.7Y+>V6X+/P*5.LN0G)_P6'C5VC[+U&4C MN!9>WZZNSO_9O;B88_3GL5U#MTOL4PRX$QC6\-\XKJU:S@H89(F!K5%0R1]/ M9V&1G@)CX!9-RV$4#'BUKQ_!"&W9]DIT*R8^ M$71K[>Y'S=!!RNP3W:L1C[W-T,U?W=GN&JYAZ-IJ?"MF/A%\ZVVO[KJJ(=M2 M&^#;39()Z6M@+8?1F+.1<%K.(@5C]CD?)%_CZ/&&PT-4M__J_A+>R1R=.Q.Z MZTQV&`SJV;:6JJJ;HH&$%X#95T%-H+Y&CQQ]"=NML*M9ENS6+0V])2#U*-=P M5$UO:?L!I9870#=MU[;4?2U*#2_`1WA$`VC6`45\G?F]VD^>'Q#YCB-V!C9T M%#)9$5/8%R_Q^TMAS\?H16($>0!Z?4OA;((N;AL+D%L]^^FA7Y/B7_6E MEGA_UE>R+=N;IJ4YDA5>9^X3PKJ>^\E16[)G=".<+Z,PRK7-C.0[/_&V;!XW M^6'Q;/KDEBY>W2[)K$6S[!OH>D:MK9*&#+Z.YUW5LD6<7J5=PW/;KZMK6B7C;HUY#HY&K8N<6AA\ M[5ZV+\^ZE]_83>>LT_V]_>6B"LJYK2+S(=P./I/7`R8CG&6#M&+@1F\/@8W`6O0IX"B^=KYT,`@5_<][^<^ M#,QRH.JA8'Y9"[II!%NSFM7D6<>L:\AS#?*L(>^.29XT81I3JK"S:J6;'A+/ M;)-_YMBJ.DLYI5%W#]4:^I#MZ(95`ZH\>>LL2A"ZBC`?>C![CA[;-.;(U0W3 MLF>@FQUY;P"NL7J6H:NFNRZ`UW$IE441F4()\R;C813[_TYSB<2W/FD7;ZZQOL9\/MSL]>:R*8Z$Q_PV[!L//TDF]7'HBKC09)V,OQ(3HNO!?2:_N?NFET8^&Q&YV8BU,1EZ6[;)>3F-Y MHFLOOHIOQ^C`H"25+`MQG7TI)39V+[_.9F.N-]/Q,9O?K)UC)B)0V'T!:[V4KIE@Z`V0 M)<<_WKB-\>*M%WL#3K@)6U+.7BKJVK#_Q+0GYJ][WSDWY;NBRTUM:QQ578EWDJVHAU5U4PSZY5>T-.?P0 M!-$SV@]4N0FUI828V`]!WCZ*@S'F#UY,1@:0)`;6C;QP^K)XM);:D=#I+"Z>-H]'?V2,?^)-'%D9`0P5"CW/:J`GJUJK>?,`$U;/#J MV4`^`!L.6*NQP8;]]AR[9K/PTR,685](NE7]%@4$9M.2<[_E:5O'ZC!KVIKB M5@F25]:)LZ'G-T#/EJ*U3*5EO=G&LAMU\'D%Q]SYA(L[&Y[64FK.N9,@TU,3 M$)KA*);:G'8-5;\JJM95Q;+M5T_5C74WLVQM=,%3W9+**T[TE]8MO0\H'78M^=Q:ZWAL[,$R M7+:LQV>#M]1ONK494GN66.\UQ=8<16L=P#%UV'[3'W9DA38<="I(G2P'Z2U; M:9G.F^*@]2W>#0[]`S4`7!6YLZV(.($^AF^DA^8JT7"D%IJ:KK1<7=&T-]I% ML^&AAH>VQ<945,U5+.>-=G*NU8AVQB)&P]*_G^XG>'N=T/&]`E!K2]:,'I^- M28+!^L$$\R`>A=\:ZV2A1SL9^J,1=62,!I-^&BZ>\/C)Q\9_,0<<8S[X)*U2 M_E<['2HMJ11,:=`)OD&QZ-\ZW\]8^R'FG+)",+4RF=S]@=T&QY'D+L!V-/!# MPO^:4!]>JNZ0`&31)!C02#1F,,4@]\1#;(BM4UP4-AE%(7L>^OTA/5V@S?R$ M42<]A8EF@9^6>B;VDW;PTFAGC1L/5NWVR8D,VQ0\4@X?%N,F.DHF`95=HA`" MW"4_%+7IIIB'$$UB(*,$9!6/*4?IT?L3-S)MM9?59!F966PF-8"V_*I)(O:Z=B2<7TY)(QNT[`6LJT&]U2FMHG<^]I6)>E-*R; MSD6[USG_>-W&A-O>3?ORMGW6ZUY=WC9B<.5Z7H7L'Y.0,YWBP%5'8<\@V*@> M*?88P1.,W7(X^T2+D.M)##(GX=*!]^R/A^R_>`S$_<,+)_=`J?`T"*NS*!Y] M8N^SK=+5S_14_EG[_*%2DISEY0N#J1@=Y29\C*<"(I1(2V$B)+P@B68Q`?89 MQ_[=A%+*I#,;Q2V[G8Q&@8_5B\JX7?A/B,ZY-_98C_>'811$#U-"+XI%=IJ, MI/2XC"H*=>;=W\-A@'V'X32@U:A<`<`($_!)@4!DJ\%6,+O->T3=94`8W_$^ M?*0W^$\XHK`(%7N.XF``RC2V.DY'@?,.IL?'VN&#'R&)=#IGU^N1ER`@1_WE M,WOB\=CO>T&FE!.MCZ-1B5T2BM]2?66X@Z M&WH#7$\_!!+P`I@YAH/GYYB':8J@&$U*<-`K%_JV.$HQ8WCR`-R;IT24SLBL M<2Y`>,]9)QSBV46@2"3Q_J+3^\#>)YQ35B[[!^PZ#B*A>@)+OXCITI4(ILH2 MHD-=,XQ`X0&]`YB2NE0#F0F5I:14Q+`"'Z/[^U19??1\[.\.2@5H(``\UDNZ M\X*L5TY>^NIX2C:G*@E5C MSR":42B!^H^*(#`'$6T?-5O2Y,31@F]GC\&72HF#1NFY-I"WX&^)Q$M^UD,2 MBX#T@5G8^W>FW5),2P7)(TQ%A&3D^7@$,D=Q=5/1;">O^W1/&CF`0X5I1)FA M`8Z&@*"FB=.`'H],&LZ"RP:`7/4!!K9M3$2U&CF`ZQZT6J`77%&&+AU\'#X? M4#+.4B;:A.],55%555@U\L%4B;&PW0CA!->J#W!@-_`,43*'Q*((RAD!^[!W MAF)8+4$:>;=AX;$0]MQ]/M"7[M7_Y/X+A07<`][S9!F:#D;U873;4ES;P)&% ME^2Z7#F\;**D>XO&+VU/6LR+;N?H,?@PP)KTA^%SH(U'U'^Q],K@P8O9 MC1\E(/K!#/9&HPAWDWH;(A5^B;QX0#H!*%Q]$&]$98/\0WK,I)*DDI1^Q)]8 M/BOH)L`W:$!3GU-O#*.$?)HI$52QC(@8'/$8*V8DN4=M*%A(*KHS`#H40JIV98XMFEHH6-JRZFE61)XCK"E($NKR&%?<19MQS M8DVT;$/T8WKDBKRX.%.*]`_B-]BQ`AZZ M;`#](2G[=M$SS/F?N$YW<>0-J#Z._W@'BC]/JUB!Q@0CTOX?3.&J,\O**[A4 M>:L^"2*\CP&9XM\CD"A5I#4CS_<=3Q=NIKI0=D`4]8D\K,"]NE30L:_S\EO6 M(Y0'RJYQ@0`JPHK3L()T%IHY78K_J(!_UQ)P,Z*;U0,KB&PI192NO3?RP1_U MV.B@O,DXPQM$HZQ.)0F+G+MS"PH/!U0#0`[AG"Q]`<77U_,VV)0@_4A_'P`_ MBCL1>,4?I[V,Z%KL[.R6G07`E*S;[?[:_1W$,X#@B9/"`^S_@-%(YL9]=/\- MN1>,AWV\>AT/_7CPD?HAH5K/X^6J0=V;^X:[=LQ=>L-=Q%W+J9HH&3F#"N+! M*8:%C0+O#N\?>'I5_3$9H<6.6D8RG@S2JY/?O23"LCKH7\E5B'L\"_MP%-)? MONC%$0Y^I?F!<7.W;LB3W-Y:P.\XZ.6_OK=SAOT5>!9AC\?LWO.#2;PB'*%A MP2.SH-&P(+'@O8].1[)[GY!;LA".,[I$%!KX#V*E6/"<^.`/V&UF8)=,A1^W M)1MA_2-S#&JF"!G"*1<\+5?_F`WN?TPH*N^BB"&76AO,,(?+H#FO_$N@L-K,'$6*C]%D M%)J3N7O(&`2"!=Z>,I0^XDHG\V%[2P.">Q317@3["`!]A!V)0NQU'O93OH\^ M*[S[6;MUV!,,.]GC%75SB;1:CIV+T,X-;O:D>Z*4Z\6>9?N\Z)(2J.P!B_^+ MJY[RI:2A%I>2MOA[Y@)Q)B@-J"=&CH`=P$NO@0@;T$S%,4R\N@%##B-*.ZQH MPB5Z+14Q?5=WD+9)48<8I1-&,%JT'8"Y6'8\91NI)6<-E&8 ME4E3=],+\X4MG.Y0A.9A+/"<](``60\[2T?-08G&Z9$WM*41) M6N'!K+0HI`2\.+-?(M\BR/=JF)%SI2Y[H)W7`,P^"#3KIZTBOG MXHU-.I)]M`S#-EJ.)L._:J)]@[VZ<]A'2V]9EN6:FX$M%(F\3=H@$]`/&.@2 MB00HD&^@1=YY0D.]F_@!Y8?.H'<+3UYD#TJ[G78-%GV7O\&P-Z!E/80+6KO6 M:&REV[8N=9#;8/Y3789:/:]>[S+4ZL*N&8:FO\IEJ-4[?8?+<,.?>#CAE0VS M<=PD?:"ZY6$-1M9,W=4@-$MS-*T:LFR*G8)7KTMA2S-T MQSH@>+4HS75LQSKLXM41<)KK.I9=&SP4=S!&J43!,FBSV\>MB;%E&EIK`=]* MD^P9Y'H$JIFFW5*/#7,MJC4M6]>.#G(M4K9!?M:AC&Z>F+1FOGO^PJX2W&O7 M!MA+HGJWE*C>O?R]<]F[NND>KSGH[A/^]WQM(LC"QVR'M'-G_`+NE%) MQIEK)X_3W74SS_(2'KL#IW3M^T)Z]#4=-];CIL-&S0=-Y?0 M3JE"[6*V.+GCZI0Y[NBP;4JYQX?\U%:RV>6F"]2^CZ<;[QEON'GL@^%?XWQ: MMVCPT0GUE/JVO*A^J*YC*8[[^AO#-<3\!HC9TDS%<`_0_^$TS[>WVMKWGU'\ MIPAMBC`.N3G?3H%&3TTVN"`;-,-]];*AH>JW1-6F:RI.Z_53]>XMNF5>V)=^ M('[U0S\98K08!B/LX3Q<:_%.C4.;7FP'$TNMEJ$89H4G_&4W8MOY"=SPT:D@ M=9I\Y+BVXAZEX]()4."Z5F[3U_`D.:KIR;9_^:`KMFLHNFT=04*@ M6_(QEQH_8/ZZJ3J*9IDB#]Y46XK94F?K[2\S[O?<2VU9;'<>,7[+'RC$_8:* M0U"]__4BQ],7\_=>5P#Y>2F`_+;S[4?GLL=N.M=7-[WNY3?6OCQG9U>79_#M M3;OI>;9N.8*"W9Y\_IQ099R[2>)3O4LL^_R,-?\?1/-%>0>H$&:12)02;59F M@M(BD(21@<.Q2,M,'UI89V!^.#])JWQ3)1I1L0XY-/G-VGA982454"-@*+ MD\&P"AM.1#6C!,#N\[13J1_2O*+%4]$-#5<0PW-C(*A_BR9(>5F4M.X0'&L! M"`0OK2/!/9AN!;]@[/C[B)`@TL2R6#7)3B2AG> MQS6EXINP&7<\B)Y/O^;[9BDM31[,"\B#D0T$$>[^L@*[Y>!5S=PX*Z!J&0Z. M<9LJ.8'`R(3&.G5MMC09WU)T_Y%O.G:8J79"3&=LRG,O/^&F4*Y3.W'I0=YL M]HO>[$I]_ZWL^\;I=B]_W[-.W+S&)N_TT#T^&30T^^)HMBA=^T;)MDGX;%(! M3S?BY^CP-+O<['*SR\TN-[M\@%!_2W_QZ6UI.;9$M(XIKN,F"2#*XR;?[>3C MG0X:SF08NM*R#Q![?WPJ:MVVE91X@3;21R0T1[PE8'62RKMB:\8*I MN+D"V6C9>A%V*/>2A(^;ZXY&)LC^8&WK.S6A'-Q1--1MR;LCYY9.S[BBJXRKZ_[/WMC50E# MVI>0IBB%86D.GI*2'4=P;@*<==[I&%QODR%'>&X`GBD.BV#<`!CK!G=0+>M[ MNQ_9WR.14]$3<2SP"M)@X"<)ID3(DV_13H1T!"UU!.,FP=B$#;7-=;OYA_\$ MYSV`,VEE@G$#8+P_6OF%Q6C*&X[7&\"Z60Y)!%^%Z-W(XLI4UU\8"S19%.QA?V<=RJV0)BM'V:IV`(=3)'? MB/Q&56<]09F@W!#6$Y0)R@UA/4&9H%PKUM,UF!FV47$4"E==F5@=\Q)SRZ); MS`3G!L#9X)JN<[W3_#3\!.<]@#/=B2$8-P#&)N]H&K=;1N/A3#G"IIA&Q5%( M.3RY`[%M;IJ4K9C`W``P'^CZJBNQ-[#V')XQZISI1_"\-YC6.>Z M97+-K',FL$=A3"%]T,F6SGO%,A%,)L_3!+A5#H6(J\1N0UJCKK"*1"+8-P`&.L&=U`MZWN[']G?(Q$JC$(Z@I8Z@O&> MP-B$#;7-==LD.!.'^T,F6AVA\1?"G1E"2"\ITTA)\$98)R M0_A)4"8H-X2?!.6*6OLYH526X-5255-QE/TNCO+2BQ[+%$Z3,E^3%MJ\[.YQ MO0PJCK)'DTW%4?9SWJDX"F&V?IBEXBAT+$5>(_(:59WU!&6"$ M]01E@G*M6$^78&;81L51*%AUG6!5R^9.F^[D$YP;`&>#:WJ'MPVZDD]P;@"< MZ48,P;@!,+:X9K>YU=G;&_G[FB&,2J.0'=PR]\9J!L+P'6#XP>=LT MN&T9-<8SE938>QCK>IN;6IV5,H%X[T%L>XK96FZ+1MWC'K7'Z8ECT"\_B0WW%,WM(IDI#@W``X4^@5 MP;@!,&[S3EOG1JT/I.D>R+/81L502$702D%]T\@8R3A5$KYJ@[/4&^OS,5`4]%$AX2'A(>$AX2GJK,%PE/A09%PE-%X2GM[GY),91K_%?IU&3VD&A!\^4S MEB6?2ZW\.TM2OS?:_6G3C63E!;#RZA%6?EJU6(DNH^.P:@EGG\_8[\(-TK[G MQH*Y*GP.WL'*)QWK)_ED2_L)ZZ'$*JL9AP_)4'BI?R^"T5&)P^-/!25I/Q9B M0[38BA;+7).6XR")'F_ZK:YSNZUQQVYQ+/KBZ#]QV==;@SL.?M^1W]LM^![Z M=A^-,61NNF207]T1,W7UQ2SA<]B?0>2J"%P1]+_]DB6'=ZX[_#6OH7`EAE&, M:2)._<0+HB2+Q0WT]1$;_?#7OS#VV]\.#Z]%`."\X^Q.A"+&>UXP*K<[\$,_ M23'+Q+TX/%1/3YJ7KWQ6+QR'W>.IQ\_482CS8.C0W97H_?V-A_S1VIJ>1OA) MUTWM#!> M)"E*93(W$GSJ!AXZGSPS/QU/4PM3IK?*Q"YH]U5(TRQ3?X(TS;$U9U724M!/ M_2@`.RWYF6%%H'0$VC<5;*+'V#]1DS&IROXU1W6I`?4ZOKU`"3ZIHC[DJKK^ M=L3%YD8NOZ>7=]KX'4LV!"WG3G(G!,(A&0BC;#40ZR8+414T%),#U#-UQL2=Z@ M;2U)\9,D0V,/%!DHC@FADL2D[P8!NQ7X`8R\F99_AJZS%'0:<*?+;K,4E2$T M!W]$:$>Z'FBA(F0,@"([7$K.P/WA#[(!"S-I;D)7DT[+#;"'ON_UX?$1$I;W MMXAX/V$6US0-_^5MS1NG8Y@V!YPWLUP`[@UC/Q$2G.E#Q!(Q=+$0%1-JE0&0 MWL7N`$"%'+P<8D6RA'V.`4WLF_J-YRQ6S!?`&1]!,P14XK/Y;-SA*]A/WD0: ML6$6>WTW$4MF4^U.L%LE&><(Q]`3Z_6;HV`)8)30!".0&5]N<6`O%V5W?=FM M/QB(KH_,&%.*T,N@MZ*YF+F`='8;A5DBY3$1\3T(9`(81^)0OJ-ID7MJ/=D& MM)JH>*>QCZX?(RC^(U)TVF5CGD]))7S`[["T6/&['!,[0,I\]:N7R^.R M,11<@"D!N8/'`-M^%T:DGE/6,!M&22*2!#-'#J(8YPR8I$\(3F6F%Z#N%F:T MR^XCF61R&#VHB<$AYM_EO4\M@YSI>5M2:\R-_MU25LI]"'8`I.=LS:>NY__` M)77T&*C]=&K]'2.9N2L/;+5Z&8Q#&KLSM%=3`SEN8I&99>6KF1DA(U]=MX$_'@QM*:P?T"IO"8:AQ6-S><61RQ MQ[?:D:6AB*H'<=\!.[74E]9)F("=&:MRT;W\5$INL1-??@?O?_I\Q@X2$'7I M-_QCL>4!#,%347P'=E=#U#@&IG^:&?WTD&/E4P:4PSP'HXG;(.E'6="5/;MI MZN)R+F+YWVB M$XZYW7"AB2JF<`<:+9Y;)V4-T_,#-&C9"<@%;+2\W'H]%0D,ULWW8CVFYDV$ M7FY?72'A\I=K6++ARS-H,;S'1E#N9J:9'90\B8_T5/8MB+U"@PS&-N19)UA_+^(7Q0^4A'+$;N:_$MN25U'C,->E3FGM9 M:C+I+A!NX>)1^_[;HAU%DU31(QGY@?L.="+TT"?PAQMF;CQBX\/OW/.@MIH_ M)\5&S@]!K^K+->K!X@7@2&^7]/^P&(UB6K3 M"?`"P4D!BT$P*O$835CDT!+N3'$\"^;9#?^`?[V>"CM`1SLH4+D@E<&`F.?, M[_&IZ>Q%`8RS,-C&'L=3$!?%X?%TS#DM<`7#=DQ-+LC"RV3W:>Q*9G3=48). M53>0[A6UW4YR\UL%$2G-,#UM8V<0;(=B]PYWN*!]QJW>1T$FR8YGO.]SI.'/ MCY*6$V18TU[Q!3,.%@3N*\;S+!T[42SN(GEBO42ZQOZ@Z7F?F?39J59G*7*& M+3**MQE?M6944WE9@[4!@PJ[3+K+YMA_^#H!2U6G7[^4F M`C0+1K3(G:23=H=3ZB1WGN5?IOEBUBN%/JCU4.D;$ZX\;@O+_%AND\RH1%*!VU"!W[(8%WYI'ODJ MOJ>8*?3+)TO7N`>PF;I"#%`:EJQRLVO*PO4_%8GR\O3_]Q_N4+.[XX99>3V$\MO MX:31\%>&QS<8[10!U"IX#;^BPWAB%%Z$%'CB6>N!165_O)M9:UZ^J"I^IK!O+):-RHEIEH=LY;<]%;I6P^.+L MDYU.[;-/?G0#Z:-UT[*S<$%)0JOE9SC99(`.5PJ-6WI1&<&9V MY$_K$*=R.N1X0:Q$'B?Q"GJ$TB!495#53(-@8:WJ+M:N\?-\W47$,^Z478;B&TJKY=;4&L-IL%*JP+@>^74+2LI MIPJ>I-U,!:5$^0V/\;F)JJ"L`E@3Z7[VW*&,>,2@LZ&;XJFI%R5IPJ?#D7+_ M]3A<9]X]_=BY*/F7R;],_N4M&BDOL4SVPL-,8K`/8E!.C442\!J[OIIOYKXI MB^<$+9XU`%*UHQ4Z]MG"`K%S>FB6*^W%M]L_+7>_U]UAOZZ&I".^IA_QM=H. MUUKFZWN?=H\1`C.!N1E@WNQ13WG%VY=S:R\;9($KK]\,,+7Q_\J[O*^P,M*A M=54&5-!I=[_"6LZ<"M+VHI-I=\9YI><)20R3PTML+DU%GJ7SF;DP0!;:5IX60^K%)?8CX7P'IW\L<)`>7E8`ZU-M&IU0J::;QS5&U5@6G0\/0M*>)4LSD["2+8YCI69+4S_F/SRGV M8QA.Q]'L]H22J28W1,<*E7ULTS8TVWZ*CD,FDZZ!@!WX89Y9X]TL-?\0B&_1 M/5;9ORYD1OC+WJEZ\UJ^=%E*N;86O,Q9REN6V;$=JS4A?>,;2Y M-C_*AK8D;XM[W]ZP7DG2=CVL]63,,DU=,PVC\L-Z)>EZ8EA7(A%N[/6E==@5 M8!%&P\&"!;9X#BRMT\E3&RF1:=BF95F3@3S:U2L3OI8)9>CM5KFJXBX)7ZO, MI6YV6D:[&H2O5<@2<64[ZQ*N++G%)N.S;%8;EFVC[7R`V3J_'#%R)]@1&O.X91(N[)/K9# M]RI\;3V/[DOI;_CBN[=^X*<^TGP1A=[BO8E\N/3LY,GG\-IN&^V2P;B\\=3>`W M:?JR5VXX;UYG1K^SZ0JKOQ]?G1U^/+X^.V4GEU^_G5U<']^< M7UX\Z3I:[\I>$Y.2EJY2RK*-`:;JE-DYCZ]/V$TT!$O0UCO3.>!+H)^:!IFV ML_SS^"WXM9QC']N&5DL_OYOD'Y8U/!-9!"TIR9#[X,8RU_*D+!3/G:RHH&6) M(YE$M/B9355NXWDNT3R/\O].D@Y[9=^K-_:]]I3NEY7=X"RC!5K M:O%2S;BW>L?AMJ5-E]%2%7M"6;?`[XIQ%=TCMOX0M-6'P&=K196+_XZK]%R^ MDU7;5BYG5AHL9NRU-&WE.FT+3RS4CJ_<;-OBEO6L2F.3.F.+^WH6NS&U]Z/% MB4JD&Y8AGRP7["J7=T.&S*(@*559:T_7-BD#RVQ+7LNTJ3CH!2.F]>T55,;B M\@.+!:_KXREOFA<2Q45TIJ8IS=!3,U2VD[VR:5$<9I96[.?4;L",PZ"E+:[K MK?P05.OPMFXM.LI4#VN@'NUV<:")*=`W4CE@65G61!1CG3\YQC05JC3;J[O!G)9U.WN6;G!1HL#GOTYTSP\FFT.MPR\^8=2UMM M"O7UI_![6(+H!+5J-XCVZ@]?+5E+V>$G6%`HCGY(:Q+6O;?ZD<%`B@)9/6E! M$B8US+R,5*E[F!GW%DOYY!7'9?I_>,',BD1&&#%C,6^G!.5+>8+/G%Y"UI5H?U<.0-> M>-INV"VSY!5_HJ_*CWTMA[2IM6 MCMB!?R2.YNH%PM*7EX,JDX[F!NZ.,9Y3E9V#%<&31E]19JJH)(7%:#U_*'T[ M>26^P81_LC)[??PMM4NR5BI<*(\^L,!F@GSW0S"F!LI.=V]A@SNS57W\N1<]<_!]=]9A)L]65SU\0PBM1TBK-G'8R-8Y"^O`=<8+A]\0>\3T]=)@%^[RZD;O,!53;H?T_CC=7WE^]#UU_[7 M0+/?`WE]HLA5;0>H0G0:.K;;1,0RD*J9XSL/A]D36QB1TJWMV'*E:Y+2):7;'*6;7[5OILA*!WLSAU9V^3=SA!O.ZU]35;NL M6O(J*3S1^;_644RE0*"^>!"JE]LHR-5MR36X&C(JG-.WSEG?JY\0M[9S7[9$ M=DXGX8!P0#@@'#0'!YM-E%X.L6A<3O03-^G+X%H8O`K9#HOK2B&&DHM1$;+6 MR\)NLO)929UXL"C@$/.-E&XK()?D';`9=JWC*ZJP:JJ2B->J](3!.[K.#;W5 M>)U*`&XD@`\)N!4EC8!+P"7@-@^X^V,R;+(^XU-Q[LVK5G4N-V(#=2N%>2). M9>Q$JO(V=,4P2OQT3_=C23^*T\-4Q(-\OSK8W&:LVL?;5'IHUZ6'=%WC>JOS M^MJ[BJ>5)#DD.54VV4EF2&9(9DAF*DTWR0Q9:-O>="\X^WS&3IO*1.Y>45"9 MNTWXX!Q#YV;;V(&.J`;X2(1(A&IGF%8#="0Z)#HD.B0Z)#IDN%5C19D3E`G*!&6",D&Y'JPG*!.4:\7Z#5C[.SXJI=3` MS4TL0ZF!ZSZ\2J4&?HT!+DPWW+A14N[AIB\I^YBWK/')(F7NX88.C;)@UG9L M$X5%28AI7:%UI78#I"3$=1X;)2%N@M)M_`P\,_!?R>+4*O):(UPQ[_%K=;]2 M9N+7<^S(PH"[ZIX2^Z[CO5\U^\&"I8T2_=+!'AWL-8GU!&6"$ M]01E@G*M6$\)L%=F*"7`G@(5)<#>N8C7*INES37#X9U.N_$ZE0#<2`!3'N&J MDD;`)>`2<)L'W/TQ&2@!]JLGP-Z;[5@I+H\R85.>Q4KD6=0<;FO.ZZOQ*A[O MD^20Y%39=B>9(9DAF2&9J33=)#-DH6U[]TV9L*N5TXX2*NXRH:+-==/AEF/M M0$=4`WPD0B1"M3-,JP$Z$AT2'1(=$AT2'3+H$Q0 M;@CK"^UF3< MR,FX@,FX>F0R;OJ"]5P_1H1D*LPRA:].HL'0#4<_)W.WOYZZ+.?&@G4%1B<" M25UH+(ZRNW[^#&>31&7J;ED4QQ'LL5UL,(FRV!/)T3PL9AB]B+>+TI\\,6?% MY]]^R9+#.]<=_OH)./$G,N+43[P@2K)8)#?0RT=L[L-?_\+8;W\[/#P5/1'' M0'`L[D68B<-#]5/1RGGHQ<)-Q*E0_ST/BS>NU`LP[!")OQ*]O[_Q,'>.UM;T M-,)/NFYJ;U@6^NK7[YJFOP&&>O[`#9*_O]'>?##LCF9:^H3J)_M[17: MTY1;EJUI+>LYE%_>_'YVQ8ZOK\]NKF>IEFE556:9BRCT,G@?A&2.QT_39UJ: MU3(FY"UL>),D:9:I/S'9'4-OKT[24(`H^>$=._LQ%&$BDCG"BB>*!UZ&1:=E M.JUVIT3?;/L;I6TMM+5M$[ZTMD6;KCFK\ZWE&$[+:FV/;\[J?`/=TG):]BJT MP3(!2P#H8U"/G`W=?!G!B\2L&P6!&R<,7F9)'Y:%=[-TJ[>O\>5O;GP97Z>X M#$C]^TW$U_C.*E)LE.D_O_CTYH-V!*.:T+]"/[LG<\A0S\*C^9/Y%5ZU]+(MFEJNR5W+25MM,S=LW<-Q:U;VAKL_187QF"N[-X>:?I$X[UG.MF?9;VHQ@V$-WW;/)ERBZB>S&X!:5H:IPA:Z5I;S@.UXQ6Z;D\1Z5Z MQ$^2#/K&)Z,L35+X@.=-,WP:$RG%4"JXYZB@$EL6M-A`EJRBZ)P5N5(8Z>R@ M,-/?,5DFQXLRW!`BO=(L95?"$[[?J%-:F@MP^H\ MMLMXI.\J#7L]Y:JA.NPS-PX!=0D#0X(IB^6?N`5F<@_\K]D!%H\79L=X MM_SD''[(=_-K>5"VF>1T-0?*Q>7-&?N4W]6$S9K^GIT=7UV<7WR^9@=?+J^O MW[%OL$T\N?SZ]?*"7?]^?'6V+?]&B:/_SI+4[XUJXY::#.JCF_@>$P4JT?;V MCJ3+2R6K%=U# M]QZV.W>"A9G4X%%OJL.DK)N!^%B^#&3Y4?=HT37>4S^0Q"T?`NC>0'B@4F1+ M48H5K-P`Z(,7?7@J[;MH&60!K`L>;/F9WV.)@`]^ZB,]0*/40RAQL2L;BM1B M,D/Y@X#>Q`\1>WX"%$7R%1@MDC?#I*TYX6H,4@5-7`>Z^1P'4;)@?A\`EV]Q M!R>?Q4_F&#B)_P.]J&D?H!LB&I=8#J#<.0`E&0I9G2X8TJ M0L;?%9VE_5B(YW5'>'@:#PLE/8>`D#O_7$_=NE+\PBF]P^;US@*%,PPRT&U! M,-$3P2C7%/W[@NU*Y0#>W$L>@``H8Y_UFB?+R(Y4+QN2Y M@9<%JA70PBY6%0R"Z"'Y=9M86:^I!7;&^-1,KA6>"((\]@VM*OEW,G2]XN]Q M_9Q2`9WGG(')(+9'CAFGPP_3:/@K&XBNGPU8&`$\*QC)MGN*GR!X7!:IO;2" MZX+"%6SK`[I^;$EXX;GOTGC/ZDX;X>R5!G3SN#6P9TB;BBY^&GXUJ:Y=Z":WW@2MJ5X%HCN.ZK=MU\^8K*GBNM6LP2G7)S MSL%YE^`:@%GU!O+.E4']PM6K=E-`;UG<[-C$[/U!MJYQV[:X MTVY^-G%"]EXAVS*Y">@V#8.03L&H-LR&X]L*@(^'Q2!L0FPC1-> M.@YK.%1!$!@3(<)$11%@Z,F#&\=NN%:-<%(D>Z-(]J("$N&9\$QXK@XTJLW= M2N&YQ6T'-C!F\\T\PO4^X;KY>OKUZH<_>MK4G%T-WKZ`80+!P4C>OI#QQ.J\ MYA4V,]4^S:4Z(+NN`[*_M7-(@DB"2()(@DB"=BU!.G?L#M>V<9Q%DD22U&!) MVM.U:%O5U%M-VI+N)F9P)=963=BK6;7DM578CLJ7;#4DL8H%3$B:2)KJ&09) MTD32U&QI:FM<@[UJV[9)FDB:2)KJ$^Y916G:2!WRUQ\"%:NK!-%42X;*(C6$ MGP1E@G)#^$E0)B@WA)\$Y2H6JUOU6&D1'S"),E&M2K([SFW;79Z3MYR"&6^>K9D=^59X M;I8(E1UW'`4*?_DQ\`3(2I"$!YFV^Q:KW:7^89&H=SZ;\FW,?GEZGM>#3$#) M;E\YKV(E\GBNK&?KDIB4$N`2]B@I;A4FCI+B[DY0]CL/'J5M)+C6"*[[FK:1 MX%I+N))V);C6"*[[JETI*>ZL9T"Z`J,A>O4=SN&U3D0K@G7#<.U89&V)E0W#=7[HZTIW>T4T_Y!Z6LK!,ZJJ06+VQWXIU-- M#L)UDW#=X@;AFG#=.%SKW-(TKFD+'-"$ZZI!I-K MQ*F/\;_#6/1$'(NNBK&F/4L5$%LU7='\U->$YWW"L^%PW6IS4Z+WQ/942X*6J MH@(Y9BG7\6JC>NT0$8VWG`[O&'N:ZIB$B81IIF:SMW4$B62)8:+4O[OC`M37`[SEL:I$N3W1:??_LE2P[O7'?XZUF> MC?6;B*\Q%^L-\.`CGBU^^.M?&/OM;X>'IY@&UO-5'E=,NNH.HCCU_W>-R:QZ,&0BX$KV_O_$P.X[6 MUO0TPD^Z;FIO6!;ZZM?OFJ:_85UH<>`&">9(_=`QG98S&=DJ'59BD-IXD-K3 M@[0-6[.?.(!1S]EMXG=]-X:'_G23"#-O>F[`/@?1K1MPE@`_L(XJ".==+`3*'DLC M-LQBK^\F8L+-+WY/L+.P[X:>>NI&>/TP"J*[$?OB#WQ9C37L3E[XZ$<_V'F8 MI'$VD"FM3Z(CSKZD7?A_4/M]%/Z'ON_U&6:JOH7.NL"BR?LXOF\B`M'[.6%7 M8@@+HN_A2R=]D)/Y]-*$F@6HN1;#5&5V-0KSBH.Y$ M5R*L``(RW@T"^5VIRB[SW*&?8A,J;1'J<__>344P.NR+H,L^N0#:SW'T`!-^ MACFYX/<$:"\@Q*=FR%0IUV6B=%M.^GS#7@_4P\>5W,M]Z%SCG`L^!(T-W)!N&9]_J M#&`1R!4V80\"ILE-)#E^DF3($7S*&C\4"QBB[R%+BKK)O;(Z^7DZ+SUGV1!U M@G'4&C6\J@SVN4H`*H`N`)#O'.QC9$![`]EVO[XM[4=#MP;KOPJRB`>#B M>\A&U%N2Y!0$1:0)EU/SD-\YAQ[N18R/ZD?6$]20BGA:18`8\+'N99\BX&3( MV6<`S5TW"N^X4K:<`9K9K1!A67L`3))L.`Q\P#X6&L"U!ZVYV!#L[.3;:N-2E-O:3^^9O-P#!!1;"LGD-!I.S9/= MFK;VW[%DE(`N!$`I49+:*T?@%Q1XUX^+9Y2E"G)T'-[Y$3!Q.S2NT\N3VYM\ M*$=2K:$N#80K!]T%$0Q0YN0H`1M9S_52L#9CJ>0'MUG@IA%,($B2#Q_R=WQ8 M(A`D.2)`/0%^W50AYQ_9#Y^S/WS`39*-48/M+T'.T(W3$'M4FN'C^>7_80E( M-O1Q=O*9_1X%`!305)[<(:OY``B-$N@WB7KI`QH-)6U7(AOD*NKBQ:]$&M^E M48Q94EX#D<#H%F$`0_ET>LP\8%2L5%"$LO@?D2*-"5XFB[J9ETHV(-7?0[FN M7*?`AN2H-`_C3S=2ZTVT.#`81`X;NO=1F9<)>?!AC<2%`$^#)6-37,/D;],S ME2^\[JT?^+!S`FI0]E"6V&VQ%5&F5=*7Q3EP]?%[T))2S*$7"UR>[N((GE3J M1F$>I``U=FDQD$P0P`*L[N'YPWS&90L*&0-\L5``DHB"SRMR1*Z[L%*Z2)Q0 M6B.9P0N(`JQ9MYE\)Q3I0Q3#PI1.%GDD(I\?-H0]6@^X&.6+AV(L[J]$MYA1 M_"%Q`^A(](#X=+P(0M.Y?0%@Y`4'P9@9,G^`$R>FEJF\WQY80?ET0#O3M(]W MM8#P._POK4RK%;D%B MVR=ED8,_@"5)(=6%J7(YS&VSY:!>TLQ'-Y`XN>Y+(9)#F"&F24S2[>#3(Q!GN$QONT]9F"\DOR2[,/0/!;\\BQ MG<+8XKEFD>\D.-:\J7&5HU\WC.X9%UR%ZOV\^+)UIS/G"Y;U,90C6#NRK6'Z M2);C.MUI**E$#ILL[VC*5G\4,B\[\5B5KU4[)GC4?[ZK0;U]\9''_(G&S@9C M<'U;J4]V-L;M7\Y"G=8X737V/Y1\HZ^MP.JHF"I+]&[N=YI::R]2*VTV!4T# M-,C)V!$ZY8/=NA%457&L,):KID,LV^*M_=4AS[9!&GU!W$WZK[AEJN"-#;HU M5(%;0SH:,W1K:/.^GT7A<&Q*!SEE=;*2UG(JI[5NI+-QO'T:QKXGMJC%*A!C M6+=0UY>[>RH5X\(SHW=+3Y>F];@\*9H,L$P( M#$2>EJH8W2R.57B0>^_Z`0Z4YZ?;(W8+_7<17CC$'@8`J(-YG*=!%$^W%(L[ MF#8?@U1@/S`;-5)==.Y4T&U\:CM4WGN:/S5GMOG>?[ M>P!W'MX#91$&%)-FJ`)"JZ89VFV'.P85K]PSO?!MX75C4A%5@&K55(1I<*MC M[ZN&V%_;X7,4=1_\(""M4`5X5DXK<-VVN&Y1R8;G^DV;&)$S=E4,W=$2/T7A MVW^5'0F%[E1E4-4,W3EP3)VW=7T+OM6M0O#==BV;_0K8N1#I["GE%E57!4(F M*%Z'XG6J8'[M5;S.J4IP("-J^K&0&1S2/EZZ]R/,4""36,Q=H9Y*B,7$CZ&Z M?OU6-PQN&"V9VF(207$8BT#&97A1DBX-[Y!!/`EJOP5WR'%\#*PYO(@>!#(. MY;,(1>P&3#:"_]AQ=^"'F+K`E7>W56LOOX2N\F'$\@J:3*C45>,;1S7)6!)Q M![3T!(:O/*:U*=^`-.!EO%$>^U-BW>]/)I(SN!`V?SP9"SN M19B)Z11HDT\8Z15$2;+HMSRGP2R^)LF8UL0&IN*8$9X$Q09>F4\\("_X&X;- M#4V3J'G;UKGAP,^Q2(8JY4`P6B@@7S!Y"*:1D>F75$O:D:8M?/@;"&^,<6\S M'%;Q8<_@L@R>`YY%`R'3Q-R%,*%==CN:)(A8%#6U.$>$I+UEF5PFC$`NZ'J+ MMYS6+!M(CE;)VS&)BI,)HB1(,3(RCIB,WYN*X\-$/3+;FDPB`=`(/1\>+C)^ MP,SXO25I,5C?!<7GR0UVE_V1@4+6Y8QJ[*!`C92F*$LP;QR'=<$3P[2$VORQ M=]6.IJM0!-TCUN0C+HA=!MP\52AER3#*-J(G4$4MWMI6-98H1>,&<0!#:\\; MQ<]P411K\_??:SE)ZDPF$A,JBXF-]+@6P/4 M^X?C*8_@\Y:RZJY8U?3]CZ7+>*YT+3*#E)#5Y70(-QEK>$XW*HJ[1P#!M7YP M7>!S);A6D%B"*VE7@FO=X+JOVG6S!_)8A'>9AZPF6+A2#NTUX$"1ACLY%]]F MEIT6;UO6"W?KU8\N)"SO`98M;AG-CZ`G*.\!E!WN6%LH@+Y[A!"4FPYEDSMZ MI_%07O7ZP@J[B^JX^DG\7H7HW2OXK(WQXY!0C*!&6",D&9 MH%P/UA.4"/EEE1,:GGP.V*HMKV)/WD),MD.1$E/!:+7B"\N7K+ MT]F"BP2MB?]CI=3$VM;2AA:??_LE2P[O7'?X:U&YO%2X_-1//-B)9;&X@>X^ M8KL?_OH7QG[[V^'AR>77K^'ZH6B$VA\X$N>)\=A]R22*8@%,!BFS(._H)LKT?O[&P\3=>BZJ;UA M6>BK[[YKFOZ&_4C\7T,_``[$F7C#?MDF09IEZJL3=.&FP+F9C+O_1$XRR]1IK MP#_=),)T>YX;<'8>>D=2"V(8:#R,8JG#0'N=@CI[4#G-V1]9,&*ZT[&/V/

_QS_@_8IS&'5,H1['\\^SLY-MJJ%&XL+6? MWK-[`2\#Z87E(B&<1L.IQ<1N3=NB0&@?EDATW_U(11S"4BESRXMXF`6)6B^3 M49**0<)N79E_/F0PPZA'_R>3:RT,6J1N/((.O7X8!='=J"B%!(P`&0*B$(^8 MKCQ+)!8]:$GF^4Y48F/\),OULE2PP2CRW+B;VP)N+!./%[VHUMPT=;W_ M_/_VGOTY<2/I?T65NA]VJ[##V["YNBH6XPU?'-LQWN3V?KD2($`7(1&-9)O_ M_NO'O"2$029^)4Y=?OQ(1T(](N`H_L01"[CUA2G/ MAZ'3@TT(2`;(E"?`O\11.E\XKG.WB()@?13=A=[4X-.:D,XY]=UY"#*'/Q$2 M\Z;?C[]WZ>./GALD"P`%KF04SUW.?^XZMB`&P)X>3=N>QQ]GO[WP0P;X,'*OK!X3; M.OPO@Q_[3D_UR.(!-EV8KGI1*!'@AJBB#@.4#&,X<55CXL/%M]'@$\P,@ZB< M^P@J(;!'GYD1 MTU_@98,KP](QG"37@0!^6G'._9GG#)@1$4[<*$Z"@ORYOR22Y1B&_X.GH+E,Q#;IHY@0L)F23-9$G_T@;,_1M:NB;GZ-O/]A"E/,EB,;P M?WT02H_S:[<+GX3>'2Q=(XQ"%HTB/]#FV2./@,K(TB%:^L47/A\;GJ4F:& M$5VZZ^REVYS,^3!2-.[TXS.BQZ:R:5/5H=4FNCSJ%9='K3A]?@KDU26JH6PG M6^VI1IJ"`+,$'H]53_[5:M;JC8Z!KGCDIX.P4*^4@;#9J;;;M3(0QBE@R+FL M(TL\L!.UIK-:K7;S`!://I3P[I[3]N->N/D4:!>62\CY\S;#;#= M`=L?L,.-*ORS`?26"9X1\CWVN]9J/1YR)G&DKJ76NP"G]J;Y`3M>;S=;U4YM M`_+B&9X-\-T;7NNV&YUZNRS@IRG90:ZE(>/*C1^\D]#\)I*-9=M#T+O1ZAJ` MMX_]'-#NWN%ZN]5I-TK!.](JDL']Q`<1]<:]W\E(J%,OG'(7Z'$XSP/2UVA; M6[UCBF>&?P_D;E<;]5IY^(1A2\3^V^J3X"+%,+V,/7@.>(]O#@(A5 M@WMXB_%S`-X\0U1J5D"@"G$!<42U/:$'/-[@'9C?!!X)YSV#6XG3FT8K%#\>,N];`U_.8%@S:G90&/.;EZ@1#_``>!W! M`/NI83R7 MI\S;VU#^X<[C6<91($NA$$I9:#U*0(QSXZG8N95/O?[7M/F\F_AGV/\$)I]8 M@_])#B[_'L?!?V_<>:.I/P'E&9Q=!>[$6\"!>?'1D3X,6NJX&'(A:'9K(..E_/4GZ))B5UCA$C)7.HF#IQB M.)7^+_H-8V^Z3*>F!CAV;J@\.?0B1:R+5:^%5#6*[!&6P8:S+!JV M(AUOEJLH]&2]:!Y0*L=PNT@8PJ)!QO-N.?R*8V\P5:%\B,S2?KD]O%4KJ2 MPH]C#VY(2$Y`,_CDG'H3MD_66A6)S.3X@"9LF$5Q@15:LA/8K:W@*ZLF&MC) M2X$73B/PX9C%L753788_4A?.`:>;^2AE/9M?ZU^'6VONK`@/7J=0RIL:1_[" M^_I4C!@D?O00&P>>./H215.R*N/%(A;[R;H"Z"D&MTHWPOLXA"OAQ^0;],Y1 M'^'?`337-<\I(9%<4?G8FZ/#''Q)Y.8#;9[;^^_K_;>8,K)77VR,-H<+(HP/ M0)[=>C':^X'E`;4*?.4L)H0G!(V/_AM^#,2??T.>05P"AYD!$!@'DI(/ERLY M#P),SF``C'20=25A=.-X321ZB6L_=H8SW`J8QD_6\.QEMR*`D3OC/5_B,S_P M?T?60./@C\3N-@'`7TJ"0$)$J':!MASECKL([IRWLO<9CP*'2\,0.(L0\)!F M>>9A]K;*,+=F%G\F?V,QS'H')1F\D3OOW:\TLR/77!YH:;UO)':0ZT0N.,`8#M MNX:-\V]1*_YP((+N8770$2"/T4B\_?`$TD_\I!U%:[4?G+/A1>^BCXH)U%D, M?^U]/A^,*L[%X.:=,^R.OTHV@I]RKG0+=ZKN#J!N;*$N7+%_--J55I->:?0D M@6>;&X>>I"9(KZA1I=KJ;I-NA;=E^#L8P)F3*R_2@/%:^14?)>L54&3/%41S MG]D9S+AX^>0__S33YB--C>_22/H0$?DN=+*506V&X[.7;:/8FW(;`J#3(?XG M!`[MPD%.T>]PR0XW3'6WGIQZ]]KO%GJ`_I%R*`'%^.'`<73KDZLOKF82>T"7 M'DTZ\\>^5?,:AXD_9L>4+CC_'2V5JZ7 MB[(>*CI(/L"=GD;I.)FE@1(!A72P5*X(5DPF[U^MTJZ=5&K=AN,6X@MVAT;U M;KO2;9Y@(_NDMOEC]<(IR?K6&B^\Y!"WIWH7>4)WTT'KP:G^IONYA[M;M=9I MG=0?NYV868C6FU&,XMI&&$E_X.J8A&O9S98P(XUHB66";' M.TAH>F-Z#",F?7:.G,^]T7"$49E7UX/1X.+&A&OVKX=W_PA+70$]89K#G*)!1PG:("2YP!OF`G$V\EM=B; M$5-PHKTEO$4GKO/ANZ_'HV/G2Z]W]1V'&Z[26*0NZRX2N1(Y%2=:4P']3IR: M4+UY&AB'=^PV\B9I+#W.V=.+U>[&:9#CYKX;#?K??3QV^C($RLZ1D)T/'];P M):!X3NF_+I=79H,?VE:]%]8QF.$P[I#5`9E-$NED4;P7Q\0@2!D54!@FQY/L M#ZM81&DP9DC$8)3.0-^A*F;8?:4)_ZB%R:C69?"R1KBX?$*7T7DIQI,Y# M'AYKV(JU2JQ!6^UC1OFR$B94^\"UW`Q&'-+#).D_'=$H%*U:08M-^A\-37)VC585(ERO& M#C90D[K5T@MC^.-27SW4:$N2$IAX!XHKXWM)^G-]1_>^2GP1+39#YF*95"79 M-NTC&(%ZZF?N/%%%8_XN6GCLW7IABJT0^T,A]V_BBH4S(YO\E%(KK)T/[-ACO0&XQ-C'W!OTT__2Z5S9\+-LPN`7PZB@\-#` M0+"B`6$[Y,3NX;_S"+=NC!+I`62BU,55@Y9-6/7&I?X=#]EW#?3NIRJ&07Y6 M=^&"!:H(G6X-$3K3I&=DD;B\N'6(D"7'$JAC3I=+E!DD1,(Z8?O%H%05J3`0 MY#A-26):J/34*A&*K&:;F105<'CIX"'7M*%)(LH%M![;`TL;>T!:/[TVI'P; M[@K*^^"U[=XKO-+:44.G'Q`JNPE:PDD609W[;:$1'Y6L4D"!OZF8>[R:,JM` MEC?JEPQ>"6V\3G4B%FT8EQ>R-^H[-_!ZF3B-5C5C2+2RSUB^*9^<3><4*QW- ML?5993T@_SUXW<)K75CI:28FHQ^_RI6W@67@QK?[U)MA#A4/20LJE0-,JJ$> M%2#QQ`GF#:J0(Y(?B@1?M6BAEV3!V.TKJ#A&.UDB#?WX@"YXL6=PO M0!Z*?'UE%,EKV]!72#&&(2K-%Q M))*^0:Y4VN$K;AH%@1M7MCZWX&YA2CK!2AV\K\#@TW'@BP7E4Y-JMYA%\%`Z MT3C2!2C#XL=N0!<+>@(=P]\*V?JU?/\0+-N>0(5PN90S*H[NZ0W@L$B*CRN@ MII@J)0-M1O#9`@B^FNBE)6?*VZL0BMA#BH&SH(2D_9GI"3N!%T_*$&[WWBTV MZ!*%+S)_[36F$=J4/S'Y&G2[W8I$(/3B!7$M1L@EB4!)F`-((8RWZG?`] MZNI>:W?L":O%7MLVOD)RI_3T<7[O+)6YRH.\BGVXPTJU*/4=\+M45QFML-)! MR*:VGO-%<\P<8J^UPC*EHX:QS*LH"Y`7-T,IN;4R4TMV?%!T=K/>:65B@HNF M>%IX2X4QU]JU9O-EX2T7[5MKM]LOO;\EHF)K]7:M7@+>24P.:Q]./?[31Q0D M9#29O+D]$D\*XH*I@^HX#*F7[,1]#D/MHW:WT?LX77F&I`^PVVMWVXU?(2S&9'"VIO_1RK(14 M!UZW6J?5WGW="F=^]I65.JUFMU&O'KBP\XP=3*24"%+E7K8*/.06:77K<:_: M@:?4;0`+M3A^P0S/`72I`ZCN!^Y0H.,%Z\306.>L.$D//1>UXHJ,XR*-J27I MN]<;I1)073^DV)\#M]N"W![TF4$NM=FM3J.]"^PK2DD?D]L0^A^>^K?^%&.6 M*TI'I"T:%-(VV9!=]`@T@.[/O75G[GO8$=3J]5JC;?&3,E._EA67$P]:]9I] MQ=_B@DL)V="BE9&(WN**2XKIS6:U<>"">SIAP%G@SM5BII[_27_!#[N]BV<` MEO?/[S=ZFNHY4N0ZXW#S;VBO',`3YQ0`L^>5[;@9MH)&V&8W"$='U=91H\9` M;!O&9.&))I2?V[EBK4(1+*H--]D;$/)DA_\UJ@Q+X3`:D`%':/[F!<'1[V%T MAQ&MKHC0>$(T-[8AXL;8]B=LJEIRP]V0740,T8/#Y"'[-0K2D*IGG/F!%XM- M>'0+;E`6CESW_/P*!\\X0-3_$P>;`(6*>/B=.C M>+T)#'U7GW?#,$+?51C0K%(:"&S(,F/F`;I"O?X$+G+D)IO@\%?Z6`!,IU[? MH<2H5]NM5KUA0V,-F8?E6A?#<2[7/@U/RZQ]>]&TP MLD-M8`^<));,&(93[][YR2LX*=F$6D"#WI_!CZ*(7!JB2TWV(YA94ID;8BL@DGCO`(5;[0G,+_4B4*PA-H&Y6:\* M^0;^OGO"6O7HE^R4V,]*%R=%DCX_?NNP=)`/2H6\*2USS+,+"^SDMT'TNC4 M'[L2S,;KG*/N9>R"H'Z#UDZ7(Q_T(K^@)>I+'`E1B&0XA![!&D#UQ^[4^Y`D MR*UF]T0NL.Q\KVNM>URO1KW9>N:U;L'8O:<_["96RZ[V<$1^R@7O/N).!^L9 M'+QF$^6%%(C\19P++[LBJXUL`BT.50.!^--I*1PMG.$)8"REN(%6(*(UGQG$ M4JH6@*_::)\\^RZ6T(W00CJ=/4$4B7,YO[WSX MR]?AZ?#F6V$>"!KSW/\C]:?P,/][IG;H.T=6,C6]7^\AH7MLX*D)+`S0-5YX MMU0M5J9VS2SU$S;`KC%U M5>"F(7R3\^8*RZD(`?9MAM;>_4KJKS"Y%;DPRPJOLCJC@]K/613XD6/BSAUW M.4:G652D+B.XGA$ME(L)"\X4\'EX^6]8,?E9#_I?G!^C(.$L-^C?2ZEMS2!P M6M*1D&)(Y9@R[#!T@S5FO!#1+,'*Y#+Q`>R0Q[6$5:1L9O[!?VA:RF;P'^>R MKLM-/F<=O#>,O,-092+>3($E\]..Y.DB0:1<8\@6$ MSK*`KXYT)[-Z(HK+&ZJ:AGBDZ$F.7NG!VDK`&L;,L8VE;H/?[;P@\\SE&PDL6!9:9LXH(*@$P`7\%TY-!O]K1>D9%\ MT1SQ'KW-0RJ2J.*'Z*%=1L+?$= M]?=$?7?*B3LK5GP7>C\)E0=PH\3XC_T*H@A268P$2`(.MII8\BL@HBH=C:,& M<.1T3PC9F2K*+&"=F@02HX]("Z<6"_R^^%VE]>"8U`07B0$Q>)F#P,2:<4P(YSG@ M-'MW&!$JR]DB/;]U_4`RK(I=X#8;H:YN&&4W6P4^$0US&/FJYX8*F!U7L?\< MKG'64U MF5"X10EB\[":H'OJ%%.`#<$+P)@5P"?X>TO_G2(9*!?#J`$V33)G@WI&'TD19;'D-;?KX M*B=,YV'K1N:5E7?@?,#X<*"S9:-V4L527V6G??EUEO7/?,0*__G]_3@.X`__ M#U!+`P04````"`#Y?C%`"9;;A%T1```-YP``%0`<`'9A`L``00E#@``!#D!``#M75MS&[<5?N], M_P.K/,NT[":M/7$SNGHTHY@:2XY!^?RX>`._/C3VSJW\RP5%`YR1:?CE)^"GB`2$G M/_WKKW_Y\6^GIU]QA!F*\7SRO)T\K>B:TVCR@)-8")BHRC`)Q-!_YFG/][1`,6IAA7VMV<6%@(^3G=E:2GDOTX+LE/YT^G9A]./ M9^_>^/PD5U%^MBBD(']KT>9)+YC]$0/^#% M1/[YR\/MCOL%<;K&;O"7$T[6FQ`7OZT87GPYD2*%3\[$?Q_?2X]\9Y8W]57S`0=":+B]Y3S! MT4C\-<"R3.ZCL*UD;]4OZ7I-XE2*<,HE3:6+VD*PE[Y&<=Y* M/L8T^'U%P[FHDM?_343(Q=LGAB*.`@DBSR#K9'FK=X47 MF#$\?\`O.$JP5UUIBO!6YBNE\U<2A@(1LWB%V6TDLL*2/(=^&#.*\U;RAD0B M50FTRBI'7I`4]PW'/@IJ17DK=Y%P$F'.1?5Z%L)]TY]2C+=2MY$`1DP9\794 M4X*W*GEBY`4D]H]AET1_G"'"?D5A@G_&B"?,OVG0"/)6[!JQ2&"6WU'.[S&3 MF9Q&CRO$O+*'29I_.R#Y+T1?1;0LZPT6B=*W)N@D^:N&ES(`#WA#F6SSLM9/ M-MX,>3<,%D*]%;XCH@F<>S:E%6;_G(8XX;/%/<-<&)3:(^UC))9TE:X.#8EO M=\2]#&]S9FR)(O)'4<9]B*+98K;!>X2_4^0>O;Z("Y/GLMLA_CX7%0#/'X6# MLBPR6UPBOKH)Z2O_)4*)"#2>^_4&/8KISZC2=?U:I2SGL&9=H%`.K!Y7&,=E M*:('*318X13=!S/-JJQCF->S174CA))!$J9AO!/_KA6-WV(L1.T4DH8R\Y'3PO4#\.1V!)_QTB=!F*MTQQ6',BU]2!YV^/\NG M";[+?_[MCJ!G$HK4B&6O1S_F"M$S#K^Q+3B8U,R@1//AOYBLER M%>?_&`PGYW.1;X15*+Q'9'X;7:(-BZV@/.`? MX`0\'X1),]*!8R/2NL^Y+]J?H<:VPQ"+H+8EY-'\"">:8E"33=!I`VJ@R%VA MI(`:UFYS+"*K%)(']^]P@EMI0=+I)SE+P?!*=!O)"[Z-1+\2RYF5;SB>+9[0 M6S-G^W$7N=R5&RI@]G.#3>YW+2`'VO<=0#NF"ZV[\=2B'USS69=DZ4&51'@] M)8M%LDH;VK6<5C:G'2MET.%@;ZPS+HRBX?6L*B9]HU&0,#DWHA\OMVG:@^0J MS6!VI5G-QKANPMQ"$R$(U"LTIP[VZ9!>,DAXF\0=,OVUY\/D+[\]HA#?8<3Q M,PI^KZPX%TN^7\5H]BN3+94+6QE40;\$ZZW#T&.L"!M[7.+O@&:?"& ML]]HC/D]VLK]$Y7=3J8>A0M+[C@[%L`(\;#9#BQV@D<^.MVG>Z8=B)@[:8!R M;$71RZ[QQZ72-RJ"X9J,!#_1.E359G43%HV&@1`$P)MJ4P?C=+B^K#08!EGP MIESROLT]HPO,>;J^!DI`4>NN0=`,.B5?9J;M^"PC' M3^@M[_SJ$XD%=25O&*FAPL#-3,NL8!1H.:(X?K^BL[?<25?O373WG>'`P-8T M^SZ$2E0>^A_`A3X%;;J^E/9ZC.$WT]8AH*,%#@,K$^VAH!.7P^$?H."0GO`Q MM@QFHA(`2B+`D>\VRB[D2CEYK/\Y_GDD-]?83"(![C.='OH6VJIKOC5]=8W23`\0`*Y6 MFL%@(0U>[ZBXJV#;KNRJ3[DCZI\`1M:@NSF(=4:0$SV&"QS,HSTKGL;@KX,' M8.A]K#5CPE(BO*FAQQ5E\1-F:XEJ'M?NY"CFB`TDQ<2PD@1@Y"UL,0=:+0#> M'(^\7T#N'Q=_R-'X"PJEIN?Q)6)L2Z*E\AB<"T^QF=^.!R`4?*PU8\-2(L!) MHL96[M.]G4<5 MK'BZ)WVA1MO'S*X:;Q8%;W!8680PGW_4T;27;*"&V\8,37@UK!UCPA^G3:OO MQ+\A7,-EN-_L"#IU724EDT&S*^#'7?0*7+F!7$)S15Z(P.^<9]KO0'R[WJ"@/;AT9U5> M6]/%.ER"]45!Z[(;)^_4$K2C"NTK34QOL`17K1N[>N@VBU`::B`U(KZ6I2-17IX9\M2&AD`<5IJ?B,J6<\79FF8UK&LN`M410UOGSA M0]K9RFDFHETZ4A,!QXR5;?:PT(F#MU11T?0*/\?J+&LF:D>^1C2>R.MM\XI\ M39QJ6435&SJF?X[12:'V;73-R3WJEDV%:W6"EYUG=4T5@RP#13$7JJ(8WJ+< MZUI[FM^;UI3?![S]G6-1VU9IC7_!(4U7IM6)U(IV=^>[D7:XM*$/#G6SL%;A M6U*S>]Z-TN!5U4>-G<# MQE:L94=L$'>IYVJZ4J+:-_6Y&H4,@+,TZ;46\I:4U@R2(#Y(PV;`_=NPMU2C9[P<.OQ62GE(6+>>,6RIK6>K*:SBFRX MRF7A<&IM8*VJZ25GURKK),)KNS)="PN4L6]^K$6\_#B..&N,<8YN*0?>\+ZB MOSD-F7./*N%`#:O.'.>X5@19;FH\IDM4;2%U:%EJ[J@(:]C?$@*PPY!>@5%< MR]K:4ZWY6KU;J/KUD*UJ,^NWE3/25!\N:-,,^`B(QJ/4SI[Z.Q]U6;NG"-HR MX#685=V+2F+&GX)*@<,:%<@PV]G4%6BM%'CM:%75-"^:X]PD402Y)`$?88TU M+N$M18RG*34W'*;VL\4YOND&_5#;9J*AQ@W0^".M?'1/RQ]SS4.I#<#@=&Q7 M.L:F&ILM3SWI`3T@;KLJ3;O_]MTVV9`-T'$V6[*;3G+>N]P8UVI+;+G,IB1X MG6[=NW\WHL*19;[Q)MA6]N*((6SZKSSH\_\DV0'ZPC'9)ATAA:.#!CYPMZ@>#1/[(?L#R\*3\Q8`Y=R$*%+H(&3,NO9UU M(*2ZE`]QF./3+M(]&HUZG\RA]'P,9%TJO$2AT3Z[%LRCA38PFEMH)>-P^3// M]$_T/!`@8%A[95`S9SHS%GG2@1%<;C1%G>[A%)M\J"@[S8<.90)<@VZI?Y%P M$F'.TR6M;`24?VGNPO!AU8'0R#IZ&-H[YI!`-):J:HX'AF)50=F[2/_.B?2% M:D!KIJR.7W648\.5O=E[P,A8",!%T`-WXKK[%7UTXI2EPMM-H-%^MT#GVHDS M,)H[<4K&(8_GUP(M]),3JN7M1I5G71J.\6$M#]`[L(++=:;8T[T<8Y/\%*7G M*Z0.I<(;9;7UMWX>V8=5BT283R@?"HE^CRWOBT2+9YD!-16:FM1^!]`N(>KY MS-E0Q3=^`-JYY/!Y4%4DO'MSV\K?,[Q!9/Y@D_44M%J(U6C'#RN]Z0>%4JT8 MU7V^P]^VU$R]]>>,NUM.-;V^N6S2CQ]+9A<0[..7!:,Y4+[[;BM@4>G3./?MF?LTMVW-Z8H2,&Z%$= M32_R>KT)Z1;C?"SC/!;HYC>/"4S\XP>BFXL./T8P%6WYE,_02;#Z5O430_/N M!MG$9$J$"J;Q(]#"&8=.AHKRRF9;O=WQIF0Q@^WR3XDTDR,.#[-+-<8@[2#1#\CS!URLITL: M])W3)3OZ\4/+[()>IDMV116@@K07I*UVML\15UZ*[<25GD4++17+^-'5Z8B# M`DQ56H&QSGMD!\58\52US5!40:M%58UV_'#2FWY0'-6**0`$>Z'`\*ZU]1C2 MP-LYE%3RCA]P]J[I96"I++8`Y/<'`:3F*J:F3H:G\3KP9<&I09>1<^S8LG?+ M`9%E++3`U0^`$MVC4!1?",WG\I`PCCA2;,HU$Q4W"6F(QH8C*V/W@(Q.?H$. M0+/\V4[40#HV&#D8O@>`S*44T`$TU?[_)ZJ.U0X>^,TJ MMT9RCT>L/D":IK_"&X8#DCI!_#W$^14KU9S=P*<+R^Y5<1N6L2'0PQ%[0,ZN MM`)C@$X&]/+4*7QTN-SCY@`#S15N@/;?R[0GE9M%5X1O:':`;[90+OE9T18/ M5IAIQX8/%]/WP$M',05^0+VR=N"#E=UG_?HX6*DL%=Z1A>O%`@?Q;'']%JQ0 MM,0/*,:S2.V#1N7U8XQ,B MD:?*"V)W6O50M+RZDZ=7"7'AF4*#2R9JK:#+QYNB*M_3D`25I;0^=+DC(D1S M4DYQ]U'((U[*&QL>\$9V'D6.BN0MA('XZ0C>-L_$]E'B-6*1L)++AO`^O6]2 MWMTJU>BSU!M$V*\H3/#/HGHF++O9L<\"#:M&E6OS^RBYLF#:?'_*PG#\B7D6*1R4EU1[:-8S4FP/HJJ+CM5)D_Z33J5FYIE M(]AO?DT?9$FOI>59:I5)%D=]MQT2I%$<;N7M>'A>:;<8C<1?@_Y3T!4-$EF( MO'U*%!UO;Z,%9>M*/`L``00E#@``!#D!``#M?6MSVSB:[O=3=?X#3N]435)E=Z*DMWLRL\,M19;3 MJG$DK22GM\_4J2U:@FSNT(2&I)RX?_T!P(MXP94`!::S5;O3#OE>(.)Y@!>W M%__V[U\>0_`$XR1`T5^_&WW_^CL`HRW:!=']7[\[)I=^L@V"[_[=^]__Z]_^ MS^7E!QC!V$_A#MP]@\T#>DQ0!%;PF&(#8+S=PA"K7!+A,(C^\6?R/W=^`@%V M$B5__I($?_WN(4T/?W[UZO/GS]]_?OL]BN]?O7G]>O3J/S_>K+C[ M+\GNN[R(Y+6"DT+\2TL^_TVC=^_>O:)O2U%L*!"8+G\V_GH`9-\O1B%:'GMCZMJ,ASFU\9,Q*> MX2M7W)@7>@GC`.VFT:[_@C==V2K\.O7C,T"E[72-MK6K(:D%T$Q\^=0@WL_N:-6<2]V[_L';'TT M>@7#-"F>7)(GEZ]'>;?Q+_GC_\)]7WR$NQ6,TCF*MLKI:3:_`U6R]6 MWVX6*S!9K#?K"^"?C`&_8LTY+;71A(RKN<5@52,-7NOY'@+9:=DFZ/$0PP?< M:0=/\CG:;]&K:]HBOXJ\G\FNX5FP`E"UZ%26` MB!;85M5`0/4&0WLM3+&IKUO17/JK&.(T`>IE&$(S<`5Q.;^F_SP&AT?F`,JJV7;#86C67HMB5)">FAH;95)L@\Q= M>\C>[1K/0136O%SU5PV9+ MQYERTR2:FJRW4!W_5<2$!0"M`?7?I*"#S'ZG#Z`:93"^!`'6-EM M^]()2\B\CNOMA(Z5:EN@[_W,D+8V3];%L4TTCW#'F:N0"LA?@9/6!ZG<[F[7:TH?/#I1_L9M'$/P2I'S8#=;%4$7?SI$S#:+9= MJU&QT(4PR!5H>J>7X(#?7@81V&;O'4>GDOI$6A^_$3NR%6JAH,BF.RJ$(?I, M=FQ_2_3'$02LZ8BJOX!8&3_Y=""?LI<`NN@5M]'1-R:3CS2K%.C@6 M$D_;GE>\!GY43'#%I23N":.L)_0CX!?&P1[%8)>;)V--:L`Q>SN!#5G`0(/I M.F9J_-?W[ZQ5H+-S]5GZI:<75ZRG6KG%3UY(R(Z]1/(8FK M%_OK(,*M1X##!Y0-T\=WN*[];;-7UE')OYV:BB$=59S8)*2&/Q$EEXE^'MAX/^Y MI:D69%#W*JU3546[2E9U;\[H.O7C*(CNDR6,U[C]@._])-@V^""4R;\01\:0 M@4RK/6R@$_D148VOYUV"._(/\`(/)G`?P2T+<7@+[_V@'"F:OKCA"7LV_5F8I.I1R4,E.SL9H![;D#WB2'@#;E$'1Y)U.G3$8*%-O M<5'-W[G0J!4:'7C'K#HB4Q8U:1CB8Q/@*!S>!Q$)*4B'D?V(WSMB.;%7?Y!M MQV:]8?:-/F9;YQH[(O:-+<2^$2,6DE6/;P6K;\Z-U3<.HYX9B5%ADI+EU`81 M6*_R3U)_94BTJK$>-H4QS(LHTQ+WBB=T(=XM^)E5@N2?LH[DJE05L&UMRS5K M;>*#95BG4D>56EU^=;7*Z4Q5J]7EM,4LVL80#Y6O8/;?621>$E66+QLFJ;PQ MIB4>>FG"U'R**:!BPRL>DO,[CT%"8DI]S0,]B M&ZOHS1AUM#7.WH,7A>1+$$2@1&,N_7N%(+=%MXW!8;7]L^@)A\0H#A3:?88L MM\VOR5HG7<7Z6=KZMC\]QC7UO#*"$[_QK@C^WA"FW%YWA=BPVNELAU>64N0F\.^",$A5VFR)'K?]YNI9 MYQW'D\V%$5VG>FP4V2JSXAQBM(E-5GKS*Q8/TN4U?:G1\2F_@#3E:E5MY!KG%J1\:NB M)N94RW[?N.HQTF)X,H(4/]+*!6GVL]\;Q)1#K:X8&U:H520O&$=9=I>-_P4F M2_^9'&M1:+WERH+F7*3<`P_Y[OH-OQ0\Z_)48M!;^R&))OPOX)`]'AY+%9`C MH:U:?7%H+2_?)O9W999RW-/6%J:JY1-4^:3)-4D"Q7&#HVP M7:*<""(\,Z!OT)HN/'V<;DE1W37/L3A;SS6S^83J?S*9KQ\<%NH$) MV:CBQOD!+3NU@P0=2G!V7%M;2.GFVBZDR0&NDQ*-1VMJX*0'_DXT`55UG('$ M!=9Y![O."':GQ_!Q:5&T3G%1:&Z`9'Q,'U`<_-9*X:P@6>G"N)(6>,VQ;?4P ML-2-C*\B;2\3``F1N,C2EV"2ED(TP4GVU'%6$Y5*1]JUTZ8:1ZG)*Z'MX7!H MEB1'.7_J4CSN%%*V>9/9[94S-1=:?*EHLKD24($!\Z11N2*.M&M"PH],0_'3NQ_+URF8HR?X>`=C\/;U M!2!U18=7H]%/%Z]_^M/%3Z]_($(?_6?P=I2_SWLKNBIP@M-@:,?/.""H8BZ] MVFD$F%9W! MM4RP;*GY@L;,XIGNH9V6N!)32ZCL;8AWFC>>4"B&3S`ZNMZ]H%"_2+PF55>0 MML+6=H_*7=@=L"IZZT:LQB[1KZ1I%NT`U:L>57ZQ=GRJ>AH"W<21C3BB'(D(^@QNS'%NX!:,8N*V^;(& MV]-+*Z@MS-D';<.R'+,UA1*R)5;ID6H_S&*C))<=`H!;U=7"+^LCL^!;1GPM M]-8M.`-O94,Q>[,N7R#_O2P!0R"W35H?.G)=B%#-42J&BOE6S\'L=1=4'5+] MV'50MV6KP.99Z@4-UD:!?//Z4,"COLJ+"Y"_^GIAP!G:=<&!RZ%K MV?O;S6(%)HOU9GVZ-GB[/3X>LV,R?N-6TC_\ZY_^=/&GGWYD+IU?T!#X#S_\ M^,/%#Z_?-!?.W5*'7?M(H=+J!*F)53G!T'=.@U4VIR0_Y**NT"",2,$2B_@N M>CC`HNQ4A782(R!G;6X7=V= M.>)&E83JN>0PCX[T"47.6*`/++H<*S1*R)X5$0NQFWI;LR-LLWU$2TP/&FRJ M39*4!,K7:\!E.6-R(*$2B@9%'<%065X!0H8P1LPBBT,APAQ_.A4NM.78=*C* MV67$R7+_<4[+EP8]&KHMA@R*#XQJY5."70-"5IQ4!,1HVNT3-WT%*FTOG2'# M"$LNP$GD]X(?M<"C`X!6[79J@A=J%S M]WE5T[L$N^R?](#/#H6A'R?DWL/L`(/C?=:R6A7<@LZH`O$UZ+F"Z"+TFDUW MX4;P%.Q@M"L2"XX?29K!9JPA%"H"#8Z0:6_!-&LU[A9Y$/82?,7*Y0%%5T&/ M`6&"Y#J.NPEQC2*=[]_H'YCRMG[=T9VVD'_-Y/R/+'(TF;2!>,&KP1"^7?C"=D MR%6V69NL%'H0\4^@Z-%WEW?D);D"LWSKEE:2BD0ZG[U.%;9\E10BB\[@?^T' M,3T-N]B/:7[?\193,VZ-@Z1R^=<0R!GR@&O9)A5D3D1L$.MZY'5VWINN5.?) ME',1MZR05R[2K(/?)<8X M<[SV0.9RKO=#C$NVC-$^:,YG,=X4[7/UC2D_3K:L;Z1OVQ;"OR'MT0?T8LO` M\7H%JRJ0]!LVX'H2JH&SJ6NW/NVU;FV[&I4Y*FIS^=75)J_U4:I.QQ?/H4>X M3G%\],C?U2Z1.N769TN9I]%GV;4Y;A*[D"3'YVIZD\5\O;B978TW4YH,^VHZ M7^._UAO\(,N2O;@&B^5T-=[,L"AX<8S\XR[`L>I+\/?"E.,=8;*Z1UH5U-%PJ\=FCADO?P[BTXNA$5@`""%GQ14F MHVE;6\Q,GK4[O>U@T^D4#D*[ST$8-E#? M?%Q,WI2/34?ZN2&;T5C#IG"$7Q7U/BP65[_,;FX(H.,Y M)F:M(/G7;+:6)ZEZJ]C4MERY%GO@MF&=>AV=*O:9YJS]NJJ5VPNJU>M`\F*0 MI'!D7^@#"G35D,,"'9R#6FE<5-L,#4YB38$7LZ`OS[R%`F=F8*OGL.(XN[W M##5YAB,K6!MR*R_/A:2DIMCJ]Y$G2>BHIZQ)*CY-N%A?BJID4J)7LZXWB\G? M?E[<7$U7ZS^"Z7_)9,_Z,D;DM,KN M_?-M`G?%'$D0W8^W:?#$6J725\R_J8ZB(8G575D/YK1=B]BL:SHMA:2*COUAZ$1QF&B098 M5C#\@FB!('H)2D4P_@;1S(DKSP%GE[&F>DDY46=W`]J=E[5(5-^ES9BTLW<[ MC4%CRQ1I#_8A^IP`PKFONDL31:QF5=ZU36!%L5U+,K0F@LR+)FF'>%:@*&X2 MF(K]-`4,5^>*9_FN._"?9^P4SQZS[A__7RXY=.*+X",GO*1BE8C.L*%`<*[G MLR*X[UA6X-8>?.6Q;*DX]%BV%S3KQ;)6X3S`6)914KU85L&`=L?5=RPK<'F& M6%;NW4YC((YEO^8NK4,LJUCE7=L$C5A66I*A-1&+`XS]+K&L0%'<)#`5^VD* M&*[.%30B2^"CYSPDHI5(CK#A@+!N9[/BN"^8UF!6WOP ME<>RI>+08]E>T*P7RUJ%\P!C649)]6)9!0/:'5??L:S`Y1EB6;EW.XV!.);] MFKNT#K&L8I5W;1,T8EEI29PU$;BD6PAWR36NCA4\^,_DP&ZRV,]1"HL,F0VB MZ:CDWU9-Q9#X*DYL4EW#GXC776: MJFA7B:GNS65OG1V<)REMVAUQ^]VICZV^,^\^3];Z&.*UK$MZOH8\#70#^NS5 MBY"D2W+>@S%J!BE\T%:_B)D';G#>?;L#5=+*:CM=3,)N#R7C],SU= M0_\@AVH^C6](GC>W].\$)F1>R77>ZUBIDE[?^YDQ;:V;Z^+8)J!'^30O.;)) M_ZAH78!,KTS.4LE=\VVAF].MG0O>;D=VG\?;+;GC*(CNES&*\)];FI>1'("; MT+M2DEE4E0FB;7`(!:M"UBR6(T`+%HUC9>,RV%U(LE4<<41MQXNWFDYPGWGS M*YBMU[?3*S">3!:W\\UL_@$L5XLY_GN29T\=2HY4FRA&O<&H&88;&Z^'YI;* MZJYQPV4NUM:R4<;T"[GFIDERJ5S1$/'E3)L7GF7[TTL23\+V0*B;9RA!)+UG M/@<_@(Q,\KI%FM70(!U/I48EL=T^P6-OQD;FI3-RR"Q,Y7TY'9.+N%["L08@ MWNR),8*;`:N"DZZT2F>M"UJ#3$X`7,1)POB"I7 MOPJK%&(BF:H2R082S\RB%&(PISC\NH)W*3N8$0N5*2+90L;Y!%EFE?FCDV-: MX$B<:)"KZ!7OZ&S)Z93R%B6N+U>2U"G2J8%F2D*6?#TY(=]B;W"QF(A2Y*(; M4D8-J)#7('__]>.$F[NR.U`&DND,-^_;8QS#UA7R0IEV#K.JC+V$92>K?>:H M;'E1S$?6T,O'>B&*[B]QK3^"\"0ZF)QCC+ID)QAC?WIN-K&3."=U6-->7R#I M(Y%DVT,GA-131EZ`T]NO'1[R[)":^!A;Z>HCJ.1S'"!'%',UBNM#@3*2K(P\^P[G/TY;Q//+C)9^+`PW M=%3*61`5%>.)$+D3NW,ARO[$TR&*9CPJ69R+`+LC#5_C3`4_CETG--8"!NI> M<C8?SR=D*9BL$L\^C=_?3->#6#C2`$23C!H5QB"C1+M%1B5OSLBXJ$^I M,LXO"23RK\.4,&06PZ;UD3??AX@\/"WO=$Y_0&><1+6'E#]WG08,X2KJN;;Z M@82U<;;`?@<\C*J`J.UA_YH!P1E?=T.$R[$U77^;H,=##!]@E`1/,"O;-8IA M)[Y[#1#;B'<:(W/5(): M$W_67SVX;H-T:>*"<^9M[1F4-/4Z!GMJQ-6+<([F6;LT71I>32?YMJ!MU="@ M1A/VT*K08G;#BUI;J&Y;I973+:G;]FN<)#!-)LR9-KY`M7UI"-AH+VHF=?FO M<)M M]M7>1XZ(:1L$4N@T+<#N"+<'""BMK$30ERVD,LX+Q!-X;%^\#$8Q\?T`<7!;W#7 M0*2:<)DM4BQLG"=29-[FJ%')DS@WI-2`5\ID*9LN0$+%@%_*@1=!E#]U//13 MA`'J4EG-_)`BO7IF2+F'09&,I`%5(EA=4$"N0K`'8F6F^R95S8LNH2K*7#(% M5&;81&I4MX1$[8J1$RC3D9&G:GE0Q%D5>SW M3::V*UU&-2UP:85.@L/F%@L,$H)Q:DS.LHJBC&HM'P/AV]*/%_$Z)1L'/_GA M$2YA3`LLI)U,BGS"2OV.(C\_T5^^<6^7O1QM,L>0/R2/FGQV,0( MXXX`'2,6;PU0=VN7]P8E4+U90-.P5^AF%X<[QK"G1+Y+(-P?U#^KS$2"1G@TE*O$.^"Z/=4DA%3^V!0-2<]5SCEKDM\R-A ML%C=6ZX6R^EJ\RO-8$J2ERY)EC6ZN9Y<$^)OM\?'8W;\90$Z&/_C-X M.\K>.V\$Y$!"^A7>(C17JT%;B767Y'P*R"K+-8JOT/$NW1_#/*%;@_+*@#1IO,:]CR&5[DT_:B@6[-!1-N:;LJH<V#F++.?`\U.,WV0`Z+TM.@F]G<0%XWN&S@=&4VN@F0; MHN08PPW\DKX/VS,Y1C:*S"#=;)AF#.GBM8;JJ'\2>3S>.TY$8H0Y9!$$C?4D7<[6T)MW+XXH.]C).F92@%R:0C%5$]R([ M@W\!J#[M);,M9Q43X&0#_)U8`=2,XYSU[HG"RXWEC"DN>]Q*;I3JH32%?K:# M9O[!M30-&Q$-7SWTI/K>1:V&KC5O-;T9;Z97E\LQF5[=K,;S]7BRF2WFCG-W M=8$.,J[3.MTUC%1)KNW[O/BUUO5U\&L1NKB;RS4`50%5G6'V:^?%-*NK=;1%ZYYJ5S_J&L--4DHTZUS3\V3,\:M_1#>D*.[=_[V'Y76(3_EEAWS M_8!_`PYTT7W$.#EA8"'_LITL&)*T@T^;K.WN7D3CKE:]\2.*T^"WNY)MGV M9;QL:N0W.\394\>[4'@5A)2^:AO\%<$FL%LV[->VM1D$CFW-JJ8S`?3!`(Y/ M=ZMI03NG7M4#:I\X&;PD4NSVREJN+8[='N9TQ9XTX-VX?7B(;9DH6Y7"%Q<" MGI572FBS/X3TU>8U?70$1Z,-',SUTW;`HM8\:J)E*,WE!X1VC+0[(A%&0WD2 ML.G M8`LE(&=(,7!>D[((]8K=OM#>=J$*^*9F!?-DP.J'"=W>D>1BPZ$`JTXY+.!4 M`)\(%04>%UHV'=YXBPN$;3_+-TVHB):WWXI$C2\UY1OO(696<">^Y52B[LWF MGZ;SS6(U&\1F0*5:1OJUT;SLE*]5O_)49KUG,%F\)U?NR`1'],[<7&28NPQL M(XM[CZX=:#D-P^$]Z417\$!FYZ-[>>.LH5$$+RH:IH&,W$K\0#VK.F``W6NO49$)%>N14>JOLZ# M2'NS*NK^+(`1=P*Y)"A%A]D9]`M)WKQ,+YATVU&$V.;]!QC!V`_'T6Z\>PRB M@$PFI<$3;-Q/7_85.DIE=Z&F9,Q/%3=61\(Z'L4<53;DY;(7X#Z3IL-DOR;O MFI]:&$$F-=@DJ8I^G:?J'MTQ]0$W(AL8/Y*X,[]@J<81JTR MC&]?R">>FD??7*;X%0A.[QP31E1Y2/UC-\C`D*Y!GVO-'=!)DC52D,5^XBH,?D#'*&BRNP62\_AEZ0:#@`?4#A#L8)F7=/G[DTDPF6).,+&E.,9]HNP21>Q/02*GOKS6+RMY\7 M-U?3U?J/--G7YE?75)%6+-*M@B9->#IUDH@M#X@BY(RKPFR:KAZ70%P]ZWSB M>.IC?DW3MQ[I1+9J'!PH!65($3)2H1)E!.68$/-5Z/><4+4W\:;KU1I*R21< M1?Z/(-.@60\&.AEW-A#S)N9Z1['+23JR\^5S$)*9B5F48HP%=R',KEN3=T7= ME///JZMLR'0]=SWT3)T*(")^!X/>A\7BZI?9S4TEW\]LOAG//\Q(OA^W3.^( M)F2CCNN4U[-3Y7V7$IP=V-;ZL6ZN[6(:]VB%$IVH/JGE%V<.LUMS`79.!W=. MM#M=CSH>#B&=+_'#8KYD%NU1_)C=$,^9H-#3*@9;JEJF\:N:'ZOS&%HNA9&K MAB5O?;M+]>UJ6DX:SN;7B]5'NJ/!<<"J"1AD5)N-6%7- M0"U2U?'I<"LHN09]XW^!R=(/FHD0.&_+#9^-M\;;\FKVE+FE?A*;[4&\`Z^M MX64/04J>@@-^['J/';N6D-*G;6ZDJPG6]\XQ;-BO3=Z#B?VO>G9#VV\,P1LZ\)T';1*#YNSK(OPVI;/#YIO M\_O>?2K@%J_22^VYW[0.5>Y-]@Q]V[5LK5%B6M:J8I*_@SZ[`/G3KZUZ.4V1 M>OT.IAGB#&V$,JQFR=JPA6G5YB!%Y$`9QHW]"[>K%=E*/5ZOIQO'4V7BFN.! M6CY^8(IS,3Z0L<$O,+A_P!'U^`G&_CV<'\E=58O]51`>\5/9_;X=M?/OIJUM M2!Q-?S8IU]'\ZMP%TAA*S4:YW!FH:JW.Y4AJ&QOE7,]WX2 M;-4X+]85,YZGVP_?V=[.P':AXPY<%]C#3+\C_Q@\SR6PD;-<7IM*'&>;46"X MR+_#A,0)Q'7R,(YV5_`)AH@>W6896Z1AVJI)EM6*!63S0LM>]X%,@<]C''>98&=CU-."F/WZI3 M3./!3"WQQV>R`5E[!&9Q^JB'>2/U":/:3-'P*TDX)<2N)9>30/32'-PNT1MT M3O?ES&'*GI]6EL]_OH*\(42E'FSVJ:K.1+!6L^%=!Y$?;.5+5**D4_SNA&KZ6Z"?R[(`S2`"9S_)V9/),+YE]))&C(++[I M'O8^2IV)*"51]K(+VD(4W6?'+L.3J%LR*50STJV0.GWX.E7>R"SWBB1KH87< M37<0C0H4523(58"%S.\'1YP(Q@:07$8ZI^V&B_T$/9*Q%]V^E-_`-$%)FM!I MCO=^0BYDRB_NY>QKMV0M_\3&U@SY:>B_A^[`3HE$=+?AP5O_/%Y-+]^/U_3` M\L?E=+X>P/Y"6^!$O2"DWJP8&JZV/5;*Z)Y)UKI#2V7IF42X8ZULOT=[4+53 M7*L'J*4+0&U=WA%CY8WL`]JR/TSB<3KT83'/_4X8X188X=X7RYM>NNYV49PC MU=[K4M_D,IS-+?)=+:K;6?C[6*S>@]`V:7E65>?6`Y;&5UNYPEE7M=IUV0!- M_$-`N$LNSUK8Y7?*8?@<8G2`Y%9DLN`)BVSQ%\!/TSBX.Z9DLI'($2F?IJ^D=\\- M8=Y6%36H4]76>2=1K!)1R82TDV_PH264.$"ZWW,,.DXD]$`[F^ M=SV>K<"G\)[>QAS&?WC6"[`9L*@ZDQR/5;#A%0^+ZVZ='Y=5K'?4L6I:)VK%JHTSMBI^ MW.Z\R$;]XDT7/)GJ?HNVC(T%\J95FZ01.9`NBC/UO"PWU!!FC,3UUESX%GUF MQI)W4[RUVLVVYP[HQ=1#OK^8-Z\ME2L`SYI.>31TQ"LA70/A M0F3;V1K'LFIO1QS/NC8$1M7V;OJ5USYOBYMV];L<-D[].,+%298PIFOKO%EJ MB5@Q7\T5,YVYYACN84I/XDHXJ2U2](I;5L=(KSX:T]X+CQ\4GAR@CK0SNN"[U[ M(*J#NZ1VZP.D[X=VL0.+$.*O+;NI07PE@Y7PA6VVQZM"5$(6GA;[\H]Q8W\3 M;@V#A>.E;"7&K=M5;A$[ MY$1F>E+*ELO0K.1(!G?9\UK758R77Y5<'+JUA68N759-ON# MCOW!%[F$X\#3#F)D:9@[0<9E8[J,\P5KVL[3(+>!2X%$ M_A&8$H8L8-BT.4+CFQ=AGZ?EE2^*0=@?OG\].HW$_@)&%Z]?OR;_GV=L`_XQ M?4!Q\!O<_06<'J9@CIX@R3X&WKZ^`*3.Z*;K-^_>7;Q^\T-%[J/_#-Z.OND9/:\0B#C($V94$E@X[SGZP`DX6XJQ?J5 M[:P2F!'OLI+Z/S>B;49F^IZM@CF+XJ@L>%%HO01!!&H@S_*"K+Y=D/-#P3.A M?$C+L+R3%E(YSD*LO1,67,MG6(K5.5DAUI6NI@UK"4VX[UVI1L1K:,SM[A*[ M?>*HM_58K6,4$F6O>`^P0)948D#')^Q!2'$=5A]#3A,YP0,.*`-Z3A3_'4)Z M"5VT&S^B.`U^H\\;R-51*5(R*:F89HM1<&)SK*_A3YCU1=6,5Y6DL9)?$2') M7M@'JAUG<=%!"^I>FXUT+`K:M9PKRMZ<,?7],0DBF"03]'@71%E)I3>&ZRGE MWU!5R9"O:FYZ"*>T'(NHJV'(>W^[GLVGZS6)KM[/Y@-(;*:)#612;GR>G11 M9-SKQ85I8K<>"F6SB>BQ?,(4[Z)`PZ'T`;:?=Z\%9+WM?;KW%W#XN?TNRI>0E1U`QI^`+% M32L,`=.K55HF>QC:. M4Q4(JA&I?OC&_2@MV=J%*!Q+O2##VNB2;UX?%'C4F+T@TXV5CS246*B(#SE"IA$>TVP/S:'0D3#8XBN>]N0

  • . M@QYQ/2*=K]X(/)CRM=!!8+$WB-C+\BQTT0T=HPH\\K<78#*$2VULX(27&-H` M*([;R?@(=Y4+=KA-I5CNU%KRY,S9P+;<3YLI]"4AAD#7RU^7^4XJNQH'.@-I=$)2[?ZPH;2SEO##;VT-`32`-G<9 MHSU,$APM^^$UE#2\$N%ZZ\L5MD,:COG^VF&Q0P4.B0R4/#I4A,`>#J01EE5\ MFTD*U<-D$T>/02FAA]XQ9KMUEK@R@U>EG:Y*`2(VK-;:*M#$[;85I`V@!5_[ M(4SH^APMHK`!%\O6VV^>K!UJL:WWUWH+_2FP2Z!?)X_SJS0-6 M<)P(2*&VD6Z]-'9?ZXEEGL%E+U[8:5NNF.)W.::P:>XN367&4A[;!-) MO'M5+4#)91M,>X9QM)M^V08)2=,A7)13E"Z2KWWT"ZK>11FXE*P MX&7A#9&TCDZ-I MBX:U&M@/Y'B)X*QBSGV*.+(E[AI_QFP_\C&([D][/][#/8IAF90))M,O:>RC M>!=$?OP\2^$CO=P$:^(JPN6[GT4IQ"1AIYGKU5,M55U/GJSD+.NE;+J]ES2) M:/]EE:=/Z\][GH&MR-A^1XWE:=Q)3^IZQ>`4Z_&W M#;M1L)P,L==R.FP13DD97]S0)H'P$)S<5'>'YJW%*8DC&<'6G`'J[0+4_8'" MX?^T+3W@^_?8N+A-I9%LX^!`?L1B/X>?\TUON(3+&$7XSRVDIRSF*/T5IN,= M.J2GF^*+F5@3&V6RC4XVC+-O=/#:Q]2N03G$:3JZVO56T\ETOKGY%NX3+%>+.?Y[,H2[K,VPARQ"H9G+HX.Y>G*/SN5Q10I[T],F)>B% M#V12^Z1+SI%@;7!2!W5]'!*DX!FFH*C8X1PU<4\8WJ2Y,\:X['^O<8`0;7$9 M*_D,>7EQE&3SCRJ1-6PBA-9[Z!]5_(EX+]?WKF?S\7Q"NC?2\\T^C=_?3-PCC-/" MVX/8$`XJ,A+1SF$J/K>HI-,XQBC1L71D3>C%:B(*#8O/OQXMT//S5O+G"^34T#HHR3=\H(8I_#$ZJSCN4I^'.7]M!/@F2Q M7V+RX<+X>5[&=7`?!?M@ZT=I)39%84!2`W&3(5HP5:1(-#)EFJ'.P'D?Z13- MBR-,:6=JWGL_7L_6)&_%;4T*+R6JVF4W&-[4IF<7-C&3CC669M!OI"#^(U8*ZB M5Z[.G4+Y;#O'(*YA%%8GTOGXS65.EGQ]A9)OT1D)%O&]'^5YR"[/,!OQ_2ZZ6SU)GL_))6;>9?V9)-0T9:*85-`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`@O9^9$E],3 MXM[#.(:[%<2Q2#5\YW7FJO+EX6RIO/&94XD'J[VNHC/Q25(5&][5]'JZ6N&. MA@Z%4^H00!UKJ7FZ4Z):/\FIY,==?D1X3[K3%3R@F-XER::93*S( MB,@5,\U3QS%LDTL2'\*\=")5;SW]0.9J,'&6BQ7ME_)5%)*68&A[>:0UC?1J MI9&*CJ-1RT$GM.IP7TR9WO1Y$_LX2-V*=@NHBI<[9F3BQMMGQ`[L[J51\B7> M6*-@PEM-;\:;Z=7E7N1YC MB$=\5S#[[RRBVX'S4W'9"DEKPE1=Y91]44'%/&.:U(DR_]YE_(O@/:D]T<$P M#;>21&9J9CSZ'&SS@XX^?>-Z=E4#$:A[C;5R>4FU&TFY%+V="8@V<_`I.[2! MP2PK'A4!+PKAER"(0(;-XA#N^!O`)C_17"_@=)P7F%5&DJ=.O[O@:8E[C+96 M/UQM^CE?O\'QW(&V3$MY[S'@7H,+##DY1;6F1,^F`06&LGV>#Y5]=R(\GY8` M*>M*3CI#[DTL8U:O3[$$VD'W+)4K7G6[%X:J:A]34^V;TA5G=G=\:/LUHG;3 M7-[AA"BZOTQA_#B<.[`[(4>'T)P:U21UQ8H6LUO>G;&[4A+W[R(8#PMKXH#/WL#TH<8'>\?@+_]YS%(`C*QY)93HHI$ MRE^^SA"&<)4(7%O.\#Y'*4QFN"QMH+->Y;^V_LH0VE5C-C'-L"L"R-JYX]L$F?6&Y-^[CN2J5!7" M;6V'V(VV?O)`-BDF=%DHVI7)%6E6>LY"C+9>B7IE/6-**'JRRQ<]IV(RZ=CR MUK?+Y0W=OCZ^`>O)S].KVYLIV=,S7\PO)^/USX#LUEV7*Z6GL]1D<>?3;.,\ M.Y@^II!A=3?IJFBBSF4MO\Z(OHSS/1/K%&W_<14\!3L8[9(L#TR9+F'V>&AS MO8MJ_F7U5`T9K^.LAPF^#NY%]-[_`X/Z!7/?A/\'8OX*0$(L)0`=TR3UHQVV[[;!,,4?L@J&>BO2T6"U M03$JDV'3DL#M]_?HZ=4.!EFK@O]H-B;XT7^-<9NV(^W:=>C?-XC&?%><(*F_ MZTCE5@ELD)-GE$4WMJQ7/@+DF>/C',Q:0)*/USBP414C$.7HG@ET^;Z.:XQ] M/_P5^O$4DP+WKPUTR,2*)#U<,0-4\HS:`JC$/@^K0C6OV'F4O0;D/<`"@$@X M3IPCJTJD_MD;J7`X&@7*Q1;/!/@KM#T2IN&>($`[-MJ%,L7)(K:,`\`MF[@4!;7&](\3,WCO^PQ`M$"VR="<[3"!?WF7<%!^=M,5IH MOC4`;\.6+=BRS?(`RY+VLH<#2H;/JQ0D_9*-L+@N6&"2J7]6-/X"P_!O$?H< MK:&?H`CNZ(I2S,2F1+:&5*ZL,6XYENVB6.Q$C&F1;H%P(G/Y#R($"BF0B0T! M[[**1IKUP>("1ZW.#*'ML_+D$PJ/4>K'S]=!"./F?C*A3(T7+1EC/C0LVN4! MV[@8_RR=`O?E.Y"]'`+:>=6&%+\R"]T-\3JJF;;.BN8\NB_/<9)IVB,;U&+1 M&K9YHL809QNVBW2A#S'@!:H%[HLA9BD#,J$AX%]2PTBO)EAL8&O522&R?%9N M4%).\-C@'L7/3$HP)6I,:$@8$Z!FSR[N6:;%<&]K%"BG;T#Q:@C89E<54OJV M+"37A.L`9M@Y*VZ7Q[LPV%Z'R&^M5_'>US!;>V^,V(HUNWAM&Q:CM2E?8#5[ M#NB+(2"553U(X8NR4%H1K6.T9>.L"%W!^X"LU43IW&]=4R82J>&T*6(,U;I! MNVAEVA8#EJ%28/;T"I!W0X`MI\*0V@=F@;LZG%\&^HL(& M?LOFF:&_P68Y:*^^:@`\>V4!T\20;1A7;,J06XJ>P$H>#0.=M>^/Q-^-C4$B MU83=2;,#TI[\!%$TC49O7U,LD2=E)MH)#EGN85+-_I=/BS"5\B!7+!(X0BH:+&F,XP,RPI(0)WJJL$,J2[ABY:;_F&G M=;AIE_.G4+#R1L=HF,DWZ$$WICU,V_,>?ZFTM/4B8L!01A-\`B_$'Y`<%GF<*7K MY*Y3M_2&RS=GPN6;,\5QIQ1+ZJ%<6T<>S55U>B+_C72.6_+K M,2IQ\!?#+<(_I?Q*63#8C@5Q''B@TT=8:)_BGU>-"N_@,\I*_S4'AS::"?T0 MT:2=Z"]0K/LY5ZS8]FK>3KRI7?E$[]D`V3T;D\5\?7M#TS--_Y/B+AF;Q#N,=_XW1%\&,!F16C@I5`EGC@)6C0G7SC:_SK!5=1[SZP]@[5/9-(RUQ^5S!;,]3H,:E,$V ME_6BVF\6_J:1K#WX6XUGR3&0("&+2\D*/L'H".>P&;$*9?+/P9$QX2G3I+6X M4F2=2S&^DE=Y!?)W`+]TG!516'-(]4/7(<\4+T$M,-8+&.S&6$(W^K#`<=+X M_CZFEQG@."1#Q>X8%S%/%HP`4EDTA7(!(++P"O/G16R48`,'_(FRXC^15=H8 M9JN\-+KZ,`4_0S],'[9^#!V'*8:XXX0:'8%G&"YP[5H-"(1>]('WIM8@?=5@ MX'2\'<%@N?-,TL6^[:O5?XK%RBZ4)V8&7[95BQVIT($`NP(]C[P%BSU@=*NN MT2RI3*3QX9N09FM44"TRV1=*;/>P8D^=\$+F(U#JA_GNKV*+%_YNC%[U&.U@ M_)5VJQ:PQ^U<#`Z18[G\C M7./$Q6)/+WE<9K==;E#]JIU6?ZRG5O;/JFIF7%#S8K'_UG(HH(B&'>\D75Q5 MFI1WE6(<'>IWJ[DFDR9>D$%=-KFF9J'"/1V7YP*J[1!"S[,5R.9+'D]^>(1M MR&ZII3SF:("7K#I$V;659,DCN[>2+F;LBYLK:]O0G0<99T`[-PCI$>[=KE/C M=#TWP3^/P4YP20%?("VN7&\+F/"Q;<]:%\$US6461\.[F?W'[>QJMOEU0#<7 M"&H**7W;.H;;LB5:>6;L5[O=!I?O0Q,`>2.*?04Q!+OR:C)Z/?GG!QB181G^ M9T`.HR3'.Y*0*B4G6G;H>)<"_PX=\?]&U$#Z_$^F?\Y&>O@A"4/I299[ M1%=O2:W'$35/S@"1U/BTOD M)P\09N=I7CINH#OCE=/H:@/6<+3'-FIUG,=WH0G8-Y4FZRNM=./) M9'$[WZS!>'X%%IN?IRNPFDZFLT_C]S?3]6"XH(,(U*W*ZGQ14"X9I.SH#`#4 MBDMEO;R&3U,DCF10O`#SZ>9;P",GB.P!D%;'Z[-H2\)_>`6+_W*/LC;@W4$S M_S1:FB;DTW!DK1?0]\GEH*XIKU``A<9I^STS38E;,G8!$#*KV3HW-8R4'-5V M?$;\VIWUF9]W&9TCNI=RQXT)._BVQ>8W.$9\)$S]C;8UC:Q$S?QTWPR, M.?-/9X!Q.6-5_=8W^"_\L'B$_^<.6\)/_C]02P,$%`````@`^7XQ0!-M7,OG M'0``D=L!`!4`'`!V87-O+3(P,3$Q,3,P7W!R92YX;6Q55`D``U;@%4]6X!5/ M=7@+``$$)0X```0Y`0``[5W=<^,VDG^_JOL?O+//'H^3N]V;5');_IQRK6.I M;">[^Y2B*4CFA2(4DK*M_>L/X(?$#S30`"D#T,P^[#AB=P/=^*$!-!K`CW][ M6\9'+R3-(IK\].'TXZ__>]__L>/?SH^_D(2 MD@8YF1T];8X>G^DRH\G1/5GG3,#161B2F+$<<^(X2G[_@?_?4Y"1(U9(DOWP MED4_?7C.\]4/)R>OKZ\?7[__2-/%R7>?/IV>_//GVX?PF2R#XRC)\B`)R8;%?GI0Q8M5S&I?WM.R5PL)T[3K1ANG<_<.J=_ MX=;Y\T[RR9#J+3AT'FD>Q./4LY#7KVNOF.&5OAO+M+(JWXUI9=8CR3M8N5', M\$I/21K1V54RVW_%NT6-5?F'/$C?`2K]PH8KL/]::U3U)J*<@EX.+8^&Q205"4<>7.UUF4D"QCW>N)"3=U?T(QQI6Z M21@P0^9-/-Q@/.?L^48&UF6*\(`/-VDJL&C[CEOW0*IN\ MY83)VM:(:S*>FD4MZGK$-&P5'?/(*$V%2_1B>3X/LJ=BC;[.CA=!L#KA]C@A M<9[5OQ06.OYT6H5"_US]_-L6PY-Y-84-XBG-HL+_/&5LT`FW+%;+BCIQ9/I3>2IVV'IK\X2]LV"=*P+H+]V7(6 M_7V!BN)D53C8X_`YBK=^9I[2I:KMJ)G2S?K_<"0LXBBG1TC1-)V1M-I>8I++ M2,)MV22@YH7:<3-D:,,)/K.Y]B-)EWQQFN6MY5GM]"0DM9,3DKB+&(1*2("( M)55X^,X_/,@#`94!NLY5AZ=VMC@>=R%DHC024TC1%L+F@69[U'8F4IK(E0.,N6#!*(0$" MB*I`\1<+SJ8?S>"__+:MXW.0+DC6W#T4NP\\0V4Q#(.[F-!6%PD0C-P*+7_U M=F@J>D'+!"(W(B1H^I`.@;M@4:JCXSTZ_F+UBRF-!40,!29#+353H:_P:)I2E>$^7^^-5M,CF>S06#R#.]U(1]I=W)^:JW_J?!AD\, MY?D68J).@D67R)J30#0,1>K6=A&PX&8R15>@N8-P9/+$%$O79/80Q"0KSB%F M_(X#$#%JVAUP9+3NXP>MJ2:,9'+-(W5NH:EO!#&28+HVBD1T?B!(J:$!>D0R MS:.#CB"GZ!(\=/T61AEY#-ZD8Q>2NLXK55$[CB4];740I93L?=98YT"V/-=# M3-0)+G6)'`^-R@+KJ7X(H^9+2#!B=3-D; M[D:/W7$(#;2'KD/2*\K[\&4UJD]3.B?%=#"(KXEBXJ0@;L^>0&+'8:>EJ\$\ M"A3L?3[:Y9H\TD:\'YR'JPGKP4]"Z#B,T#IJ#8(2H=YGL"F7;\I5C8<+ME%7 M:I(EFJ]);MI!8:%-4=%Z;%%B2Q]"BEQ#J]WFG#I4#=/V^Z6(UI55FC(I`*03 MK]6Q[YDV(':D-.T91T%>%7MN+"GD*)9*EF4*I9'$? ME`:J:Z(05X*_*;M%[I?0"J*T.2EA,W<.('0?46@U-7$DDVL>+G?$:6'P@[&I MMZC9`V#D6#&(<1]"Z$"YJATE>B`JQ=^34X@;RNN[OA!WF5H9:JVYBM:P/ M"*7Y&Y6M[N.&$`%];KC/]F?'L:#01P<(?5'^#JUGLUEQ;B"(IT$TNTDN@E64 M!]TSR@JJ.MX(43D.#9QV.@@!)?H[5-Z3/(@2,JMO]3\+P_5R7403+LD\"J/N MD(EGJ`R,87`<2=HZZX`*(]S?*$Y#FR+0P!]E2,DS2;+HA=PD(5T2_I#$'7H=$OR]X(]^`4J<(V@7!LXCR2E3CI@$0G[ M"H-!Z+6D^7)=5H2_0X3*`G"X5DJ.//#I&CCNB>Y#0\< MFYWQQA_6_9#TX\F])^D.;;&RK6[Z_X]H8*`6GLZ17'])7WGFN: M7M+U4SY?U^^@9;O[EX`3&R:\M1WT>!V^,G2`$;!7BNH5,7(4VJ'+8W0RK;^" MVT9;,1]6=>;URX2R54RJ-P+/EORER/+)0/`J33A\,HK8?EQEH%@7\;D?FRDA M/5JQ'F]:[&S0U'4R[U_@#P,=R]G'LIK3;;AJ:JZ!2+7DD3=`'%X&.GVAE^T> M_.TNKV^9*.'O;+T^20OPSXJ-]"E)6Z^-"Y-35$S"?!68R?$`O)'NYEDM<`'^ M^IJVAH4ZV=DZ?Z9I].]=($J(-8A8B+$^L5?84NAJCJF^8']GGB+-;K)LC<)1 MFU""H9K00_P(=1R*G5JHO]DS(JTFZSS+@V06)0L$>`34$@2UJ#V$$:SM4"RU M)/N[%]K(043.HC0X^CF>WLZ?]+4VS`15SIP\3'EIJ*>8-B$H^Z#R;L*$U](0 M1.!4R2`_QCGP".=)"BH(-)[,D'#:#0)+9V[DX5,'/97@B1&&%(*,3U,B#3T' M@4WXPXV"]^1E)`*]=B3VG)>B,2A* MJ8YO$LOD^5O*+VISP-)7Z*0*&`AH!(@HT7E"SA@U8SPT1)G(T(.7$BV M>]FCH81@7@[2-"]^Y5`S?D"LP()C+*H(UC7YM>^8N57:QU"HTVH2JMVGU!++@>:CD1_YYNE*K6B0CQT/[;@ ML/OH%1H`GI?9"+Y4)FQ]\00?L#8F@&A)\_RL M-V(QHSWE1J]K,)+]39VL]B62Q=7;BF]:0(>#E73U)M)ZF:DAJJW^Q-83A$I0,KW=X5T MSVS!&N.9Z7;))G4Q+0[WB8&&HMU>QB:E=1M6.HIJH$DA]H!RMR1DP7/-;(]*#<6*>P5*"\#`$1#U@=,B\@XX ML(K#@-.2Z^^L%GI]K;H.:$K2B!9/L-V3D"X2P:F6`1(4+^E))?@!Q.'&,4"I M4:$'.%/`SA"P,P-?0(=5U`!:$M&>;VOLUB#7S.+EXSUKIN4N4_R#]C M&TTG]EBY?6PRO7M_9#I7=CLG">EO.2JH6OU`0.43AE5*&N-/(-C@0*U;"Z$[ MDH.!.>&W>NQO?_,#'S*%3,;XMCCS,[-.^)'V]1:7T4LT(\DLZX33;I:K?DC) MA%5XW8B*U0^8#3"'`0KU2C,XENNPPSI[":*8WUW\2!NGD:LSFN=!%H4REX;G M%CD]#+!UFE*&.$U-@A=K/A[O7H1N51^]Y(`3[>V\1YI6H,HK#?D]YI.>2 ME/]"Z4*C"6P^_CY0H'/FO69+K6A1ACQX4VOMU-DX'ZQ2L3/\;JKXFQPF,`_P?B*",%Z8\ MD&Z"M\8^D"TMW7P[SI=YU>@#.C[99(22_;WLKWY6MKZX$)AOJ<@JH\-DSB@H M6FU*:0#5;*\EU&\3KO904HJ`"4;*F\PHE8 M-W.D;.6-G%;BUA"&])'H@0F69WX]J*-=KG`E/'FM!$KYA$R4A3'-UBEX9FB@ M%)ECQTBQ9KU_L*7.,W]WA[5FL"!WZ^4322?SWN6.HJ'.B+>RE":O,RY/%Q=T MF)GD?A)9&>X`-"OA[XH54+0RD>IZ6$-N.:AA[@.$-=)4^P8V7(VO:MY@-HP9 M3RO0Q8UTU[1[=Z=>!-GS=4Q?';@ZM7'C[;96T`VC"-+^J]$"4IM;Q+PZTY3R MO?#9^>87UC`WR?;TSUF81R_EK;[`$1EC`;N-8FT!;NRH^Y@"9-Y:>CE!VN7` M24(>3J9V6QS9(^4)\4D8Q:2EWB,=UN_V643]\.I>BK#6*)A'>SM&UF&IC(9C ML?=,[3YA0XTLUO8<^Z@@]RVXBOGKPBN37U[6K;,,]%L(KR(`:BIOJ,0"^0,3IDEGK&6-\MQ!!'HA=^ M@JP[S3+B!8TCY;6Y$:S;^H*NKV.9WHXPLGQ1EU:4>P#WC'7UO4E>F/%H&B'0 M*J`%T=FB]1Z-L.;CHJ]5CO?QO[Y^Y?.V1,=%PBP@]D0LWD-0:8=QD2@JSOMP M7E]->5P$30]"T9VHR%@XU`EU#`4A%+_0BLP*5?8;2;OP8FPQ7[6U.T"1\JS=@*31>^[6JYBNB&D"@3>1L%3 M%!=11)SW5//+_:B,WWO0ZEEH#[Y55K;!+6;.0IEUUG2MAUZ81>9:>RS>8U1I MA]'=:J\X\YO)W$/B-.4WA>6;.A1;W*-;C2%*3&*8073*F;W'J89MQD6LO.`Z MNO[I$,!;AR[$SSZCZ96!)?L/08\=6,*\##U68*G[5/2IAUGIHFY&5D'$E$O4 M>[,"6HE;;-!ZCS=8\[&=7J.<&F>'M*E3)I[I3QL5?/+%SD%.('$6VBF+!"$):R'@J(\?;9"XREQ7M_8J&I#G_:M?B[O-6B@UL$ M9?VFB(S24U3BM1\#A-+2/'[_'&T,X[F1\9S(6V0:VV8,H.H4OH]GU_U99>'G M\:.LLJ3%'5R396M^]'(RG[:>4F9KQO(' MPCX6OTBPJB]$@%X=(0>`9V.;C8UPG8I\#8.7\:!E/%AYBV=CVXR!89W"O^Y- M!OP$:Y3IK[0X?Q?05_,Y"9DIKM["YR!9D'MFG$E21`N2&?^'QUA?@ICT;^LT M8:T?TM)B=1ZA`RRAATV]@OR]?5.L$>JE<1/69I01S>H\*@=80@^5>@69WY\) MCUK6H7G&QHPTW;#AX=<@[AU5T>*1@K''XRD*Y;J/`;]>">;W8ZX*)+-JI/G! MHN^W[[YF_/6TWR<"#4[KEPB\2JQO[CVL5ZNX,$40UZ:X2>8T799M#KP_IL=5 M7S*,Y;*8<)X3!I1\&D3=/7G1IVW">/.3O0ZDV2A4JE2GP^!DERG`39G>IW&4 MV:[5H5P!*H1?=R<)VE_]PH9,M0'PZ(C=3WZ$@P.7F=/4&[C09?A[.P<_,\(T MV^U>)K-M*.>&&0?#Z+L\CB;$7QFM+D*8X616MG-^7IFJ[30E)O MYXT*:GM18>T6I;K*=R+`V`++.:2B(']WYHH=1KXA0V:GO5[6_[3M2,U/?J%& MHM8`B+2EVMBU`MY[N*"L_FE6O)?2W$Y^I.W-MZYCT62K/0R:S2_0&)ICB,]! ME^CO!L=U$*7%^KM^4@U(HE;25>:6T/D%-ZS"`_`E*<+?O8G&T6.FU'K9']0D M%)5-A11^P4>MY`#@"(7[^_#69<2WDI-9[5_/EOPNSPYJY$3UL\T`D5_80:DZ M`#Z0_)&?R'(P:&"Z:M5,D<"7,M)EBC^>]"Q^RWXHOPD_M5J#O.4,#KNAK=4> M?`K+/$P4!O''D"[+TB?I(DBJ1P!YSE@M"84Z1I59OVXYCDQ[:]8@7Z>DU>2=E2M(4*]?!036_,>X M34P1ZK<]RBCE%ZY'4*YY9(2M?IYH1FZMNIKS((NR(D]UAX9D=I&RZ0^CJR[^ M9IYURHP6\L0_6WVB7Q7`H:@)*Y#("*UU?7%[/$2+))JS%DGR?JT?6:N?Q_T( MQQBB*E,-$V7O@B,U%.BH=NI<7`06SYW)L&(]=SNW$5N+SZ)\8^!/@#C@5B3@ M%\#OVV5Q[_MX0P<7OXUN+^Y7FW@R;U:HNGKU@F9Y5E3Y MB5>YOB<$Z/OC"-O&$8<)LQA*15;\O%EQR,>,)$W7J)`T:[YI)&S1L2W:]F[# M:ED&A@?6SG/_>!6D"7/]&;^-XDY-$BR(HWMD;^.*JBD.N@P M2$8=)C2383M$C\(!'<=$PB"]K`)%0-*L8,_]!T^R2%B/B4S]Q5CGFLIJ;'8V M!MP*@G)[WDE":?$$5Z]6D+?`D,*ZNM#W,8U%M11M=VV)_/)TETRNYSVWON:7 MK;*?HL1N)%)0%VA:@"&M]Z2EI/8V\/O54O=E/2;8`&[U;U1C4D/MVUU=5E2Q MV8XLPO->OTV$'#S1'Z;9"H&>]\\OE,Y>HSBNEP\W3'2RB+B2UOIHHTZ[ZI0G9I33;2/>"@Z:O-9Z M/*J>D`LP8]:QD`M.P@P&=*!YVOY$JP[_D#4-W`%`$T@TI[%]P$OBFI@>J=[7I56<6./*(,S[M]XZ'ES6,:)!E3 MW6JR(50A<'V`(]\N%E3DUCH_5#6U%S#@5)C#+;^`;F,ZQ!;=Y8>\3.X>M,KR MW$\45RT\TY@ID?%K!(TR\T?*62F*AU)QA!_K[)3.1WL)QSUK\JTC1-JQ+E^= M?(SGLY>F(VXY:JYU)UFG);](.L;+];SW\ERZJ'S_NCQ6P'.L26+UP)ZD3LI) MOQ'O]H8>+5Y[]Z!AZ@DY"C-F'0NYX#+,8$`'FJ?M5K3J4-YKI%>VYZZ'QVF3 M/-Z45X,USBRF-&%_AI;3!^_(*U0GWCK%0P;93=*DB5A;K>`=BQ$E;I^U&4&B MQ:!&%J;1JCQ`+U&%C;W_(OG9C*[RWOU7@V1L0Q]&,BR^$S0>CN@X)NS<>C.\ M@F60Q:ABGKO%2QJNN5K\H7"F;+YIW&P[T!EF)/RXH"\G,Q*5O93]T>V<[*?? MRG+!C'_QUWHEU?TZT+WHU?F>+"(.H"2_"Y;=%P5D)*W:=TGLK7P`4U.4,IU5 M3EM6<1)!*,/VC:UZ+7Y!^#'H^(9ULK>_DXVPR0&:5IOW:-QM=+DZR%;O";'] MG""VV2_XQ<))?LUFQ$'\+Q*D5\GL,LA[SXO M-&;SQ2#=7$+Y@`]V"IN*IHI"BA8,.A;O-+U,% MV>H=$>8O@=EH[.GZ*8["ZY@&O:U`Z'NKH5O?W6UF6`UD([<$V'XQ1]/3ES=! M\-VZXBA]-EGG61XD,^:AQ/X>P=#V^E(&=U&AH2AV!)!*'.G"Y+WCIHZN[98^ MU^R7[N1`057'C2$J%V&!4TF)!5!,'37ZY!<"RN=^U1@0T`E1T*)S'P>P6II( M:`FJL>!\"+'6X9&)!9J_^:G3XN4GEQM94'ETNY:\=5,Z'Q8\8W6>%7B,@^[8 M+_Q67P[1_N9B:\JJKVS.#G/=GLX'^&H83NLWA`4Q7BE-I[-V:%QL9XPZZ.[; M$5*W^]#(';P=6GWA_\`L``00E#@`` M!#D!``#M6]V3HS82?T]5_@?.3TE5/+9W=O(!!_`F>R\I&61; MM5CR2C`?]]=?2X"-`1M_[&U-4LS+@-0M=?=/+76WQ8=?GY>A]HBY((SV6[V+ M;DO#U&<'X'`;I]CI_/HQ<-7=&*ZP,-H MN\`78%(M&G3DY8+5IFERO2%*680B6,BJ*6UVMDB^6O%\07(EY%P%N(]X,CN#K`(6,Y*LM%F MXFP(Q/W2**75`(.P%>81@=6W64R=KZ:6=(8CU0(6/PY?M58AFAZK%;#@\/^K MCQS'`PTT^3!QS)T[DQ)HP*A@(0GDK@O/`:8"!S!;;GVR!SJGC&4+T/#*XQ2EC$,^FOZCGHJNDW"G)/L[":CR<<2/9 M;KZT-0/N6^$Y1AR,L<"1'.%H<+>YZY#NG8VT]L/6C`WR!R&_-KFP9_9*!E<@ MST$N7<>Y'_$W!_NVZT'#@V$!VO:M9H\-1_=,(&V\_!RL!T@L;D/V=#34%8S[ MD;X\$>F![MYKMR/[CP;I?4C;?(XH^:^25*?!&+;BO#\FJ-81[4?P?;([#XGP M0R9BCN'%=NYTR_R/).32]3XV1"T9V\5R> M(@Y>,2Z7O?0%!M$GC;9VO'JR.E#>ED!QC3MY.FF.,;8=Y0K*16R(1RVOV?1V MX+6`J!SV,!E.+%<03BB94Y"J^^J0>5=&YEYWC#9L8RJ>>!A#/*'@:-`HH&$@ M3L$;Q(@),<8ZZ6@?]='$T!X,W9TX2<#= M0%&`(HVK!)P;=K3`W,$^)H]H&F)AX2C!I(:F#IR?2^"D09:KSA7;NP=_<8R! M87[4;T:&^Y-F&5X#5`$HDSZ"AHR3'#"%MCH@KDI`F-9'\`K;,1NK[TAE8D$H M%@(.B"FAN2.]JJ/&_KUN.2&9N*9EN*X\+FY,JSG+*T\+L"_UX;2NVIMV==9A M4<[T;\'^UD!&N\U>5(/('6/!$PG#[$`P05TZ)]+V"2K[".J0*:?M=[8]_,,< MC7+'A0G)NW5G2H@:=`KH#/$,#0 MF#11;='N#@Y1\GM0].)Q!%F>GTO4=_;6(5'.SQUC)"O*[;'N>)\TR,@A"QPT M67EE5AXQ__."A0'FPO@2KVM6%>UU.%1DXYX]^.W>'@T-Q]6,WR=-&:OJ!YKE MDD0JBTM*4[)(A>FF[+N/H`Z2,E7X!W;@N=!D[M7'_3, MCZ75P6\,P")Z,>F,\64N2]E+L1^J[E62+J8CY!]A-"T93LN-]P^&YT.G<,,M M:=B^!R=OP9&E+,-KM'0),W^W<8[0:NO"7W*!<\1\-=CV9;Q*Q@X.(Y&UM#=# M73R+(+L'M5>%*'L\60Q#_:"$R'OEP MB@#%BY17R2%`\1RI6RT[9-AB"SG?XFK+<=J]-^W>^_/EB(Z6(3IE_FVC1BM^ M/!(9DWKZ&ECDKX9'V0`$4M9SV;;O[<[O7 M/0Z`TE7W`V?-&.3$[T[3M/HR^R'SYSFMA/%L#RA?QS].DM/%V/^]Q.E!A1IK MCU>DGXTHB3:%I<%"?G\B\F6.@3IYTD*MC&#_.H0XN72N/L>X7C+8)!!_,2.\ ME/$8J!5/!42>L53JCK-XE9$2(&EIE(2AK`'W6Q&7I2\$U!SY4;\U0Z'Z+D01 MK\#F+/#43(D'1EG7-+GDVV\%>$JBD_2V&/6/43U/_S?1WD4A'F$D\!3YGW/E MK$S+.T2D@$*4U\#QK*_%)CY(]U6,4KE`3N+^NYA&57F$_/A-I!7H]2\X2OD= M_=]:O2#F:?9\M'XBLF=E+;94W$7R:K2L+ M5-55MY0^E.75&*$.ZO5U1P\_1S?AMKY5G8EFR>=YUU'6_FUTJU5"3T>KTF'3 MEP<'V@B=?P7QD_=3I-]S(:5"GX.H7YF&)H5E"&?!$&?_=T8/.4V/XGJ5#J<* M:TGH"F__`U!+`0(>`Q0````(`/E^,4#=C&H?=GL``*(Y!P`1`!@```````$` M``"D@0````!V87-O+3(P,3$Q,3,P+GAM;%54!0`#5N`53W5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`/E^,4`)EMN$71$```WG```5`!@```````$```"D M@<%[``!V87-O+3(P,3$Q,3,P7V-A;"YX;6Q55`4``U;@%4]U>`L``00E#@`` M!#D!``!02P$"'@,4````"`#Y?C%`7<&UL550%``-6X!5/=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`^7XQ0!-M7,OG'0``D=L!`!4`&````````0`` M`*2!==$``'9A`Q0````(`/E^,4!:EQ4N10@``#8]```1`!@```````$` M``"D@:OO``!V87-O+3(P,3$Q,3,P+GAS9%54!0`#5N`53W5X"P`!!"4.```$ :.0$``%!+!08`````!0`%`+\!```[^``````` ` end XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
    CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) (USD $)
    		 3 Months Ended 6 Months Ended
    Nov. 30, 2011
    Nov. 30, 2010
    Nov. 30, 2011
    Nov. 30, 2010
    Revenues        
    Equipment sales $ 876,751 $ 1,188,756 $ 1,151,711 $ 1,913,275
    Equipment rentals and services 456,210 600,798 943,198 1,144,690
    Commissions 8,620,367 2,011,188 12,186,855 2,018,624
    Total revenues 9,953,328 3,800,742 14,281,764 5,076,589
    Cost of revenues        
    Cost of sales, equipment 539,297 791,855 700,251 1,191,184
    Cost of equipment rentals and services 222,031 225,016 460,878 461,709
    Cost of commissions 1,799,933 421,963 2,902,041 423,913
    Total cost of revenues 2,561,261 1,438,834 4,063,170 2,076,806
    Gross profit 7,392,067 2,361,908 10,218,594 2,999,783
    Operating expenses        
    Selling, general and administrative 4,791,028 3,408,868 9,165,913 6,513,547
    Research and development 138,426 106,079 273,555 216,468
    Total operating expenses 4,929,454 3,514,947 9,439,468 6,730,015
    Operating income/(loss) 2,462,613 (1,153,039) 779,126 (3,730,232)
    Other income (expenses)        
    Interest and financing costs (4,612) (2,853) (6,872) (6,496)
    Interest and other income, net 21,666 12,612 42,851 16,144
    Amortization of deferred gain on sale-leaseback of building 13,312 13,312 26,623 26,623
    Total other income, net 30,366 23,071 62,602 36,271
    Income/(loss) before income taxes 2,492,979 (1,129,968) 841,728 (3,693,961)
    Income tax benefit/(expense), net (24,329) (1,500) (26,129) (7,330)
    Net income/(loss) 2,468,650 (1,131,468) 815,599 (3,701,291)
    Preferred stock dividends (1,135,869) (124,403) (1,221,362) (152,111)
    Net loss applicable to common stockholders 1,332,781 (1,255,871) (405,763) (3,853,402)
    Other comprehensive income/(loss)        
    Foreign currency adjustments 3,999 0 3,999 0
    Comprehensive income/(loss) $ 1,336,780 $ (1,255,871) $ (401,764) $ (3,853,402)
    Net income/(loss) per common share        
    - basic (in dollars per share) $ 0.01 $ (0.01) $ 0.00 $ (0.03)
    - diluted (in dollars per share) $ 0.01 $ (0.01) $ 0.00 $ (0.03)
    Weighted average common shares outstanding        
    - basic (in shares) 153,310,322 111,123,353 145,387,954 110,775,966
    - diluted (in shares) 160,078,677 111,123,353 145,387,954 110,775,966
    XML 24 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
    FAIR VALUE MEASUREMENTS
    		 6 Months Ended
    Nov. 30, 2011
    FAIR VALUE MEASUREMENTS [Abstract]  
    FAIR VALUE MEASUREMENTS
    NOTE G – FAIR VALUE MEASUREMENTS
     
    The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
     
    The following tables present information about the Company's assets and liabilities measured at fair value as of November 30, 2011 and May 31, 2011:
     

       
    Quoted Prices
    in Active
    Markets for
    Identical Assets
    (Level 1)
    		  
    Significant
    Other
    Observable
    Inputs
    (Level 2)
    		  
    Significant
    Unobservable
    Inputs
    (Level 3)
    		  
    Balance
    as of
    November 30,
    2011
    		 
    Assets
    		            
    Cash equivalents invested in money market funds
       (included in cash and cash equivalents)
    		 $2,811,214  $-  $-  $2,811,214 
    Investment in certificates of deposit
       (included in short-term investments)
    		  110,148   -   -   110,148 
       $2,921,362  $-  $-  $2,921,362 
                      
       
    Quoted Prices
    in Active
    Markets for
    Identical Assets
    (Level 1)
    		  
    Significant
    Other
    Observable
    Inputs
     (Level 2)
    		  
    Significant
    Unobservable
    Inputs
    (Level 3)
    		   
    Balance
    as of
    May 31,
    2011
    		 
    Assets
    		                
    Cash equivalents invested in money market funds
       (included in cash and cash equivalents)
    		 $7,029,886  $-  $-  $7,029,886 
    Investment in certificates of deposit
        (included in short-term investments)
    		  109,709   -   -   109,709 
       $7,139,595  $-  $-  $7,139,595 
                      
     
    The fair values of the Company's cash equivalents invested in money market funds are determined through market, observable and corroborated sources.
     
    XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
    EARNINGS (LOSS) PER COMMON SHARE
    		 6 Months Ended
    Nov. 30, 2011
    EARNINGS (LOSS) PER COMMON SHARE [Abstract]  
    EARNINGS (LOSS) PER COMMON SHARE
    NOTE F – EARNINGS (LOSS) PER COMMON SHARE
     
     Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period.  Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.
     
    Basic and diluted loss per common share was $0.00 and $0.03 for the six months ended November 30, 2011 and 2010, respectively, and earnings of $0.01 and a loss of $0.01 for the three months ended November 30, 2011 and 2010, respectively.
     
    Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares.  A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:
     
       Six months ended November 30,  Three months ended November 30, 
       
    2011
    		  
    2010
    		  
    2011
    		  
    2010
    		 
    Basic weighted average shares outstanding
    		  145,387,954   110,775,966   153,310,322   111,123,353 
    Dilutive effect of share-based compensation and warrants
    		  -   -   4,790,333   - 
    Dilutive effect of contingently issuable shares
    		  -   -   1,978,022   - 
    Dilutive weighted average shares outstanding
    		  145,387,954   110,775,966   160,078,677   111,123,353 
                      
     
    The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the six and three months ended November 30, 2011 and 2010, because the effect of their inclusion would be anti-dilutive.
     
       Six months ended November 30,  Three months ended November 30, 
       
    2011
    		  
    2010
    		  
    2011
    		  
    2010
    		 
    Stock options
    		  1,809,776   1,888,776   259,776   1,888,776 
    Warrants
    		  5,785,714   4,285,714   1,500,000   4,285,714 
    Convertible preferred stock
    		  -   29,156,312   -   29,156,312 
    Common stock grants
    		  2,903,333   4,340,000   375,000   4,340,000 
        10,498,823   39,670,802   2,134,776   39,670,802 
    XML 26 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
    RELATED-PARTY TRANSACTIONS
    		 6 Months Ended
    Nov. 30, 2011
    RELATED-PARTY TRANSACTIONS [Abstract]  
    RELATED-PARTY TRANSACTIONS
    NOTE N – RELATED-PARTY TRANSACTIONS
     
    On June 21, 2007, we entered into a Securities Purchase Agreement with Kerns Manufacturing Corp. (“Kerns”).  Concurrently with our entry into the Securities Purchase Agreement, we also entered into a Distribution Agreement and a Supplier Agreement with Living Data Technology Corporation (“Living Data”), an affiliate of Kerns.  Pursuant to the Distribution Agreement, as amended, we became the exclusive worldwide distributor of the AngioNew EECP® systems manufactured through Living Data. The Distribution Agreement had an initial term extending through May 31, 2012.  Subsequent to August 31, 2011 the Company acquired Life Enhancement Technology (LET) (see Note J), the manufacturer of the AngioNew EECP® system.  Consequently, the Distribution Agreement is no longer effective, and the Company wrote-off the remaining unamortized balance of Deferred Distributor Costs, totaling $93,077, in the quarter ended August 31, 2011.
     
    Pursuant to the Supplier Agreement, Living Data became our exclusive supplier of the external counterpulsation therapy systems that we market under the registered trademark EECP®.  On February 28, 2010, the Supplier Agreement was terminated and, in connection with the termination, the Company purchased Living Data's remaining inventory at cost ($469,450), which was paid in 7,824,167 shares of common stock valued at the closing price on the termination date.  Prior to termination, the Company purchased in fiscal 2010 additional EECP® therapy systems for $40,000 from Living Data.  Payment terms on certain purchases prior to 2010, plus $3,359 in commissions for sales of certain BIOX products, leave a balance of $3,359 and $265,863 in Trade Payable due to Related Party on the accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011, respectively.  The payable balance due Living Data included interest charges of $23,603 at May 31, 2011 and was satisfied through a cash payment in August 2011.
     
    On February 28, 2011, David Lieberman and Edgar Rios were appointed by the Board of Directors as directors of the Company.  Mr. Lieberman, a practicing attorney in the State of New York, was appointed to serve as the Vice Chairman of the Board.  He is currently a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which firm performs certain legal services for the Company.  Fees of approximately $45,000 and $154,000 were billed by the firm through the three and six months ending November 30, 2011, respectively, at which date no amounts were outstanding.
     
    Mr. Rios currently is President of Edgary Consultants, LLC, and was appointed a director in conjunction with the Company's consulting agreement with Edgary Consultants, LLC.  The consulting agreement (the “Agreement”) between the Company and Edgary Consultants, LLC (“Consultant”) commenced on March 1, 2011and runs for a two year term..  The Agreement provides for the engagement of Consultant to assist the Company in seeking broader reimbursement coverage of EECP® therapy.  More specifically, Consultant will be assisting the Company in the following areas:
     
    1.  
    Engaging the adoption of EECP® therapy as a first line option for FDA cleared indications as it relates to CCS Class III/IV angina with a major commercial healthcare third-party payer.
    2.  
    Engaging a major commercial healthcare payer to formally collaborate and co-sponsor a study with Vasomedical for the efficacy, efficiency and/or cost effectiveness of the EECP® therapy for NYHA Class II/III heart failure.
    3.  
    Engaging final approval from the Centers for Medicare and Medicaid Services (“CMS”) of EECP® therapy as a first line treatment for CCS Class III/IV angina.
    4.  
    Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for CCS Class II angina; and
    5.  
    Engaging final approval from CMS to extend coverage and provide for the reimbursement of EECP® therapy for NYHA Class II/III heart failure.
     
    In consideration for the services to be provided by Consultant under the Agreement, the Company has agreed to issue to Consultant or its designees, approximately 10% of the outstanding capital stock of the Company, of which the substantial portion (in excess of 82%) is performance based as referenced above. In conjunction with the Agreement, 3,000,000 shares of restricted common stock valued at $1,020,000 were issued in March 2011.  In connection with the Agreement, Mr. Lieberman received 600,000 of these restricted shares.  The Company has recorded the fair value of the shares issued to Consultant as a prepaid expense and is amortizing the cost ratably over the two year agreement.  The unamortized value is reported as Deferred Related Party Consulting Expense in our accompanying consolidated condensed balance sheets as of November 30, 2011 and May 31, 2011.
     
    During the three and six months ending November 30, 2011, a director performed consulting services for the Company aggregating approximately $30,000 and $60,000 respectively, and the Company accrued dividends of $14,734 on Series E Preferred Stock (see Note O) to directors, management, and other related parties of the Company.
     
    Through the Company's acquisition of FGE in September 2011, it assumed the liability for unsecured notes payable to a family member of the management of LET.  The notes have no stated maturity date, aggregated approximately $285,000 at November 30, 2011, and bear interest at 5.31% per annum.  Approximately $95,000 of such notes were subsequently repaid.  In addition, $10,049 in pre-acquisition earnings were distributed to current BIOX management during the three months ended November 30, 2011.
     
    XML 27 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
    BUSINESS COMBINATION
    		 6 Months Ended
    Nov. 30, 2011
    BUSINESS COMBINATION [Abstract]  
    BUSINESS COMBINATION
    NOTE J– BUSINESS COMBINATION
     
    On August 19, 2011, the Company, through its newly formed subsidiary, Vasomedical Global, signed an agreement to purchase Life Enhancement Technology Limited and Biox Instruments Co., Ltd., both of which are based in the People's Republic of China.
     
    On September 2, 2011, Vasomedical Global successfully completed the purchase of all the outstanding capital stock of privately-held Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company that owns Life Enhancement Technology Limited (“LET”) and Biox Instruments Co. Ltd. (“Biox”), as per the stock purchase agreement signed on August 19, 2011. The consideration of this acquisition includes a cash payment of $1 million as well as the issuance of 5 million restricted shares of the Company's common stock, up to 2.4 million shares of common stock contingently issuable upon the achievement of certain operating performance targets, and warrants covering 1.5 million shares of common stock.
     
    LET, based in Foshan, Guangdong, China, has been Vasomedical's supplier for its proprietary Enhanced External Counterpulsation (EECP®) systems, including certain Lumenair systems and all AngioNew® systems. Biox, a leading developer and manufacturer of ambulatory monitoring devices in China, is located in Wuxi, Jiangsu, China, and has been Vasomedical's partner on the BIOX series ECG Holter recorder and analysis software as well as ambulatory blood pressure monitoring systems. Vasomedical has obtained FDA clearance to market these products in the United States.  The acquisition of LET provides Vasomedical with consolidated technical and manufacturing capability in its EECP business which should significantly increase gross margins and enable the Company to meet anticipated increasing demand for its EECP systems.  The acquisition of Biox greatly enhances Vasomedical's distribution network, technology and product portfolio, and with combined market and sales efforts of the two companies, should help improve performance and profitability of Vasomedical's equipment segment.
     
    The operating results of FGE from September 2, 2011 to November 30, 2011 are included in the accompanying Consolidated Condensed Statement of Operations.  The Consolidated Condensed Balance Sheet as of November 30, 2011 reflects the acquisition of FGE, effective September 2, 2011.  The acquisition date fair value of the total consideration transferred was $3.979 million, which consisted of the following:

    Vasomedical, Inc. common stock
    		 $2,100,000 
    Vasomedical, Inc. warrants to purchase common stock
    		  304,000 
    Contingent issuance of Vasomedical, Inc. common stock
    		  575,400 
    Cash
    		  1,000,000 
    Total purchase price
    		 $3,979,400 

    In accordance with Accounting Standards Codification ("ASC") 805, Business Combinations ("ASC 805"), the total purchase consideration is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of September 2, 2011 (the acquisition date).  The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates.  The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
     

    Cash and cash equivalents
    		 $441,886 
    Accounts receivable and other current assets
    		  591,460 
    Inventories
    		  669,926 
    Property and equipment
    		  32,587 
    Goodwill
    		  3,175,152 
    Accounts payable and other current liabilites
    		  (931,611)
    Net assets acquired
    		 $3,979,400 

    During the three month period ending November 30, 2011, the Company expensed $122,224 of acquisition-related costs.  These costs are included in the line item Selling, General & Administrative costs in the accompanying Consolidated Condensed Statement of Operations and are comprised of accounting and legal fees.
     
    After elimination of intercompany transactions, the amounts of revenue and  net loss  of FGE included in the Company's Consolidated Condensed Statement of Operations for the three months ended November 30, 2011 was $227,200 and $61,290, respectively.  Loss per share was $0.00.  Prior to elimination of the intercompany transactions, the amounts of revenue and net income recognized by FGE from the acquisition date to November 30, 2011 was $453,011 and $114,494, respectively.
     
    The following supplemental pro forma information presents the financial results as if the acquisition of FGE had occurred June 1, 2010 (amounts in thousands, except per share amounts):
     
       Six Months Ended November 30,  Three Months Ended November 30, 
       
    2011
    		  
    2010
    		  
    2011
    		  
    2010
    		 
    Revenue
    		 $14,655  $5,527  $9,953  $3,918 
                      
    Net income (loss)
    		  977   (3,589)  2,591   (1,047)
                      
    Basic and diluted earnings (loss) per share
    		 $(0.00) $(0.03) $0.01  $(0.01)
     
    An adjustment was made to the pro forma financial information to reflect the acquisition-related costs in the six month period ending November 30, 2010.
     
    XML 28 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
    ACCOUNTS AND OTHER RECEIVABLES, NET
    		 6 Months Ended
    Nov. 30, 2011
    ACCOUNTS AND OTHER RECEIVABLES [Abstract]  
    ACCOUNTS AND OTHER RECEIVABLES, NET
    NOTE H – ACCOUNTS AND OTHER RECEIVABLES, NET
     
    The following table presents information regarding the Company's accounts and other receivables as of November 30, 2011 and May 31, 2011:
     
       
    November 30, 2011
    		  
    May 31, 2011
    		 
    Trade receivables
    		 $14,461,811  $5,194,953 
    Due from employees
    		  137,501   120,566 
    Allowance for doubtful accounts and
    		        
    commission adjustments
    		  (1,617,193)  (1,296,947)
       $12,982,119  $4,018,572 
     
    Trade receivables include amounts due for shipped products and services rendered.  Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
     
    Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.  Due from employees primarily reflects commission advances made to sales personnel.
    XML 29 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
    INVENTORIES, NET
    		 6 Months Ended
    Nov. 30, 2011
    INVENTORIES, NET [Abstract]  
    INVENTORIES, NET
    NOTE I – INVENTORIES, NET
     
    Inventories, net of reserves, consist of the following:
       
    November 30, 2011
    		  
    May 31, 2011
    		 
            
    Raw materials
    		 $875,786  $514,387 
    Work in process
    		  814,138   484,798 
    Finished goods
    		  993,341   786,872 
       $2,683,265  $1,786,057 
     
    At November 30, 2011 and May 31, 2011, the Company had reserves for excess and obsolete inventory of $407,154 and $409,490, respectively.
    XML 30 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
    FINANCING RECEIVABLES, NET
    		 6 Months Ended
    Nov. 30, 2011
    FINANCING RECEIVABLES, NET [Abstract]  
    FINANCING RECEIVABLES, NET
    NOTE K – FINANCING RECEIVABLES, NET
     
    At November 30, 2011, the Company had financing receivables of $36,541, net of unearned interest of $3,059.  These financing receivables were generated by a sales-type lease of our EECP® equipment in our Equipment Segment for a term of three years ending September 1, 2013.  At November 30, 2011, there were no past due amounts on these financing receivables and the Company has consequently made no provision for credit loss.  At May 31, 2011, the Company had financing receivables of $45,558, net of unearned interest of $4,842.
     
    XML 31 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
    COMMITMENTS AND CONTINGENCIES
    		 6 Months Ended
    Nov. 30, 2011
    COMMITMENTS AND CONTINGENCIES [Abstract]  
    COMMITMENTS AND CONTINGENCIES
    NOTE P – COMMITMENTS AND CONTINGENCIES
     
    Sales representation agreement
     
    The GEHC Agreement is for an initial term of three years commencing July 1, 2010, subject to extension and also subject to earlier termination under certain circumstances.  These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements.  Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.
     
    Facility Leases
     
    On August 15, 2007, we sold our facility in Westbury, New York under a five-year leaseback agreement, which expires August 31, 2012.  VasoHealthcare also leases facilities in Greensboro, North Carolina pursuant to a lease which expires in May 2013.
     
    Vehicle Lease Agreement
     
    In June 2011, the Company began taking deliveries under a closed-end master lease agreement for the provision of vehicles to the sales team of its Sales Representation segment.  Vehicles obtained under the terms of the agreement are leased generally for a 36 month term, and payments are fixed for each year of the agreement, subject to readjustment at the beginning of the second and third year.
     
     Future rental payments under these operating leases aggregate approximately as follows:
     
    For the years ended May 31:
     
    		 
    Vehicles
    		  
    Facilities
    		  
    Total
    		 
    2012
    		 $131,000  $106,000  $237,000 
    2013
    		  262,000   89,000   351,000 
    2014
    		  242,000   -   242,000 
    2015
    		  28,000   -   28,000 
    Total
    		 $663,000  $195,000  $858,000 
                  
    XML 32 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
    CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $)
    		 6 Months Ended
    Nov. 30, 2011
    Nov. 30, 2010
    Cash flows from operating activities    
    Net loss $ 815,599 $ (3,701,291)
    Adjustments to reconcile net loss to net cash used in operating activities    
    Depreciation and amortization of property and equipment 83,949 72,707
    Amortization of deferred gain on sale-leaseback of building (26,623) (26,623)
    Losses (gains) on disposal of fixed assets (3,673) 0
    Provision for doubtful accounts 320,426 623,535
    Amortization of deferred distributor costs 124,474 62,792
    Share-based compensation 185,114 208,615
    Amortization of deferred consulting expense 317,079 0
    Changes in operating assets and liabilities:    
    Accounts and other receivables (9,204,258) (7,010,909)
    Inventories, net (254,716) 490,885
    Finance receivables 9,017 (54,200)
    Deferred commission expense (291,408) (894,833)
    Other current assets 69,358 (18,869)
    Other assets (85,892) (93,696)
    Accounts payable (94,174) 203,947
    Accrued commissions 681,255 1,078,125
    Accrued expenses and other liabilities 785,865 612,702
    Sales tax payable 70,522 4,924
    Deferred revenue 2,780,351 5,570,045
    Accrued rent expense (3,001) (1,327)
    Accrued professional fees (31,550) (57,822)
    Trade payable due to related party (62,356) 1,590
    Other long-term liabilities (18,568) 49,320
    Net cash used in operating activities (3,833,210) (2,880,383)
    Cash flows from investing activities    
    Purchases of property and equipment (57,852) (132,270)
    Acquisition of Fast Growth Enterprises (1,000,000) 0
    Cash acquired through purchase of Fast Growth Enterprises 441,886 0
    Net cash used in investing activities (615,966) (132,270)
    Cash flows from financing activities    
    Issuance of note payable 0 250,000
    Proceeds from preferred stock 0 3,333,608
    Net cash provided by financing activities 0 3,583,608
    Effect of exchange rate differences on cash 3,999 0
    NET DECREASE IN CASH AND CASH EQUIVALENTS (4,445,177) 570,955
    Cash and cash equivalents - beginning of period 8,130,031 481,679
    Cash and cash equivalents - end of period 3,684,854 1,052,634
    SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION    
    Interest paid 6,026 722
    Income taxes paid 16,287 2,200
    SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
    Inventories transferred to property and equipment, attributable to operating leases, net 27,433 30,477
    Issuance of note payable for purchase of insurance policy 0 58,360
    Conversion of notes payable to preferred stock 0 1,250,000
    Fair value of assets acquired 4,469,125 0
    Liabilities assumed through acquisition (931,611) 0
    Accrued preferred stock dividends $ (1,221,362) $ (152,111)
    XML 33 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
    SHARE-BASED COMPENSATION
    		 6 Months Ended
    Nov. 30, 2011
    SHARE-BASED COMPENSATION [Abstract]  
    SHARE-BASED COMPENSATION
    NOTE E – SHARE-BASED COMPENSATION
     
    The Company complies with ASC Topic 718 “Compensation – Stock Compensation” (“ASC 718”), which requires all share-based awards to employees, including grants of employee stock options, to be recognized in the consolidated condensed financial statements based on their estimated fair values.
     
    During the six-month period ended November 30, 2011, the Company's Board of Directors granted 525,000 restricted shares of common stock, valued at $189,750 to an officer and an outside director. During the six-month period ended November 30, 2010, the Company's Board of Directors granted, under the 2010 Stock Plan (see Note O), 3,750,000 restricted shares of common stock valued at $712,500 to non-officer employees and consultants.  Shares valued at $65,550 vested immediately with the remainder vesting over three years.  During the six-month period ended November 30, 2010, 1,200,000 shares of common stock valued at $252,000 were issued to officers and outside directors, of which 650,000 shares valued at $136,500 will vest over three years.
     
    During the six-month period ended November 30, 2011 and 2010, the Company's Board of Directors did not grant any stock options.
     
    Share-based compensation expense recognized for the six months ended November 30, 2011 and 2010 was $185,114 and $208,615, respectively, and was $103,776 and $116,109 for the three months ended November 30, 2011 and 2010, respectively.  These expenses are included in cost of revenues; selling, general, and administrative expenses; and research and development expenses in the consolidated condensed statements of operations.  Expense for share-based arrangements was $317,079 and $5,225 for the six months ended November 30, 2011 and 2010, respectively, and was $158,539 and $950 for the three months ended November 31, 2011 and 2010, respectively.  Unrecognized expense related to existing share-based arrangements is approximately $1.2 million at November 30, 2011 and will be recognized ratably through July 2013.
     
    XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 10 148 1 false 0 0 false 3 false false R1.htm 000990 - Document - Document And Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnaudited CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) false false R3.htm 001010 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://vasomedical.com/role/ConsolidatedCondensedBalanceSheetsUnauditedParenthetical CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) false false R4.htm 002000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfOperationsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) false false R5.htm 003000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://vasomedical.com/role/ConsolidatedCondensedStatementsOfCashFlowsUnaudited CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) false false R6.htm 006010 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS false false R7.htm 006020 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES false false R8.htm 006030 - Disclosure - LIQUIDITY Sheet http://vasomedical.com/role/Liquidity LIQUIDITY false false R9.htm 006040 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS false false R10.htm 006050 - Disclosure - SHARE-BASED COMPENSATION Sheet http://vasomedical.com/role/ShareBasedCompensation SHARE-BASED COMPENSATION false false R11.htm 006060 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE Sheet http://vasomedical.com/role/EarningsLossPerCommonShare EARNINGS (LOSS) PER COMMON SHARE false false R12.htm 006070 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS false false R13.htm 006080 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET false false R14.htm 006090 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET false false R15.htm 006100 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION false false R16.htm 006110 - Disclosure - FINANCING RECEIVABLES, NET Sheet http://vasomedical.com/role/FinancingReceivablesNet FINANCING RECEIVABLES, NET false false R17.htm 006120 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES false false R18.htm 006130 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE false false R19.htm 006140 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedPartyTransactions RELATED-PARTY TRANSACTIONS false false R20.htm 006150 - Disclosure - STOCKHOLDERS EQUITY Sheet http://vasomedical.com/role/StockholdersEquity STOCKHOLDERS EQUITY false false R21.htm 006160 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R22.htm 006170 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS false false All Reports Book All Reports Process Flow-Through: 001000 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) Process Flow-Through: Removing column 'Nov. 30, 2010' Process Flow-Through: Removing column 'May 31, 2010' Process Flow-Through: 001010 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (unaudited) (Parenthetical) Process Flow-Through: 002000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (unaudited) Process Flow-Through: 003000 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (unaudited) vaso-20111130.xml vaso-20111130.xsd vaso-20111130_cal.xml vaso-20111130_lab.xml vaso-20111130_pre.xml true true XML 35 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
    STOCKHOLDERS EQUITY
    		 6 Months Ended
    Nov. 30, 2011
    STOCKHOLDERS EQUITY [Abstract]  
    STOCKHOLDERS EQUITY
    NOTE O – STOCKHOLDERS' EQUITY
     
    Common Stock
     
    On June 17, 2010 the Board of Directors approved the 2010 Stock Plan (the “2010 Plan”) for officers, directors, employees and consultants of the Company.  The stock issuable under the 2010 Plan shall be shares of the Company's authorized but unissued or reacquired common stock.  The maximum number of shares of common stock which may be issued under the 2010 Plan is 5,000,000 shares.
    The 2010 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company.
     
    The 2010 Plan provides that the Board of Directors, or a committee of the Board of Directors, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares.  Options granted under the 2010 Plan may be either incentive stock options or non-qualified stock options.  The option price shall be 100% of the fair market value of the common stock on the date of the grant ( or in the case of incentive stock options granted to any individual stockholder possessing more than 10% of the total combined voting power of all voting stock of the Company, 110% of such fair market value).  The term of any option may be fixed by the Board of Directors, or its authorized committee, but in no event shall it exceed five years from the date of grant.  Options are exercisable upon payment in full of the exercise price, either in cash or in common stock valued at fair market value on the date of exercise of the option.
    As of November 30, 2011, 3,790,000 restricted shares of common stock were granted under the 2010 Plan to non-officer employees and consultants of the Company. As of November 30, 2011, 465,000 shares have been forfeited.  In September 2010, 650,000 restricted shares of common stock were granted under the 2010 Plan to officers of the Company.  In September 2011, 475,000 restricted shares of common stock were granted under the 2010 Plan to an officer, of which 100,000 vested immediately with the remainder vesting over a three year period.
     
    No options were issued under the 2010 Plan during the six months ended November 30, 2011 and 2010.
     
    In September 2011, the Company issued 5,000,000 shares of restricted common stock and a two year common stock purchase warrant for 1,500,000 shares at an exercise price of $0.50 per share as partial consideration for the acquisition of FGE (see Note J).  In addition, up to 2,400,000 shares of common stock are contingently issuable should FGE attain certain operating targets for the twelve months ending December 31, 2011.
     
    Preferred Stock
     
    On June 24, 2010, the Company filed a Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (“Certificate of Designations”), as authorized by the Board of Directors, designating 350,000 shares of its 1,000,000 shares of preferred stock as Series E Convertible Preferred Stock (“Series E Preferred”). The conversion rights of the Series E Preferred are that each share will be convertible at any time on or after January 1, 2011, at the holder's option into 100 shares of common stock (an exercise price of $.16 per share of common stock, the “Conversion Price”), subject to anti-dilution adjustment as set forth below.  Each share of outstanding Series E Preferred Stock shall automatically be converted into shares of common stock on or after July 1, 2011, at the then effective applicable conversion ratio, if, at any time following the Issuance Date, the price of the common stock for any 30 consecutive trading days equals or exceeds three times the Conversion Price and the average daily trading volume for the Company's common stock for the 30 consecutive trading days exceeds 250,000 shares.  Notwithstanding the foregoing, the Series E Preferred shall be automatically converted into common stock on June 1, 2015.
     
    For the three months ended November 30, 2011 and 2010, the Company recorded dividends totaling $1,135,869 and $124,403, respectively, and for the six months ended November 30, 2011 and 2010 the Company recorded dividends totaling $1,221,362 and $152,111, respectively.  Included in these amounts is the recognition of the value of the embedded beneficial conversion feature of the Series E Preferred, which reflects the difference between the conversion price and the market price at time of investment. The amounts included in the dividends reported attributable to this beneficial conversion feature are $1,135,869 and $70,709 for the three months ended November 30, 2011 and 2010, respectively, and $1,201,428 and $70,709 for the six months ended November 30, 2011 and 2010, respectively. These are noncash dividends requiring no payment and ceased on conversion of the Series E Preferred to common stock.
     
    Pursuant to its conversion terms, the Series E Preferred was deemed automatically converted to common stock effective July 1, 2011.  As of November 30, 2011, 29,956,100 shares of common stock had been issued for 299,561 shares of Series E Preferred, with 712,350 shares of common stock yet to be issued.